US20160102291A1 - Dendritic Cell Compositions and Methods - Google Patents
Dendritic Cell Compositions and Methods Download PDFInfo
- Publication number
- US20160102291A1 US20160102291A1 US14/879,336 US201514879336A US2016102291A1 US 20160102291 A1 US20160102291 A1 US 20160102291A1 US 201514879336 A US201514879336 A US 201514879336A US 2016102291 A1 US2016102291 A1 US 2016102291A1
- Authority
- US
- United States
- Prior art keywords
- monocytes
- cells
- dendritic cells
- cell
- dcs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 373
- 238000000034 method Methods 0.000 title claims abstract description 128
- 239000000203 mixture Substances 0.000 title claims description 46
- 210000001616 monocyte Anatomy 0.000 claims abstract description 234
- 238000011534 incubation Methods 0.000 claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 claims abstract description 36
- 239000000427 antigen Substances 0.000 claims description 120
- 108091007433 antigens Proteins 0.000 claims description 120
- 102000036639 antigens Human genes 0.000 claims description 120
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 113
- 108020004999 messenger RNA Proteins 0.000 claims description 55
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 49
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 49
- 108090000978 Interleukin-4 Proteins 0.000 claims description 45
- 102000004388 Interleukin-4 Human genes 0.000 claims description 45
- 102100032937 CD40 ligand Human genes 0.000 claims description 37
- 108010029697 CD40 Ligand Proteins 0.000 claims description 33
- 230000004069 differentiation Effects 0.000 claims description 26
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 24
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 19
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 19
- 108010074328 Interferon-gamma Proteins 0.000 claims description 16
- 229920001917 Ficoll Polymers 0.000 claims description 14
- 238000011068 loading method Methods 0.000 claims description 14
- 102100037850 Interferon gamma Human genes 0.000 claims description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims description 13
- 239000004033 plastic Substances 0.000 claims description 11
- 229920003023 plastic Polymers 0.000 claims description 11
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 10
- 238000005119 centrifugation Methods 0.000 claims description 9
- 102000003816 Interleukin-13 Human genes 0.000 claims description 8
- 108090000176 Interleukin-13 Proteins 0.000 claims description 8
- 102000003812 Interleukin-15 Human genes 0.000 claims description 7
- 108090000172 Interleukin-15 Proteins 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 30
- 229960005486 vaccine Drugs 0.000 abstract description 27
- -1 CD86 Proteins 0.000 abstract description 20
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract description 19
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract description 19
- 238000002360 preparation method Methods 0.000 abstract description 16
- 108091054438 MHC class II family Proteins 0.000 abstract description 7
- 108091054437 MHC class I family Proteins 0.000 abstract description 5
- 230000000638 stimulation Effects 0.000 abstract description 5
- 102000043131 MHC class II family Human genes 0.000 abstract description 2
- 102100035793 CD83 antigen Human genes 0.000 abstract 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 abstract 1
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 246
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 107
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 79
- 108090000623 proteins and genes Proteins 0.000 description 68
- 230000014509 gene expression Effects 0.000 description 50
- 206010028980 Neoplasm Diseases 0.000 description 46
- 229940028885 interleukin-4 Drugs 0.000 description 44
- 230000007423 decrease Effects 0.000 description 40
- 229940029030 dendritic cell vaccine Drugs 0.000 description 39
- 239000000047 product Substances 0.000 description 38
- 238000004520 electroporation Methods 0.000 description 37
- 201000011510 cancer Diseases 0.000 description 36
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 36
- 239000002609 medium Substances 0.000 description 33
- 230000035800 maturation Effects 0.000 description 26
- 102000004127 Cytokines Human genes 0.000 description 25
- 108090000695 Cytokines Proteins 0.000 description 25
- 150000007523 nucleic acids Chemical group 0.000 description 24
- 238000000338 in vitro Methods 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 23
- 238000001890 transfection Methods 0.000 description 23
- 244000052769 pathogen Species 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000035899 viability Effects 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 19
- 230000001717 pathogenic effect Effects 0.000 description 19
- 239000000872 buffer Substances 0.000 description 18
- 230000008014 freezing Effects 0.000 description 18
- 238000007710 freezing Methods 0.000 description 18
- 238000010257 thawing Methods 0.000 description 17
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 16
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 16
- 102000040430 polynucleotide Human genes 0.000 description 16
- 108091033319 polynucleotide Proteins 0.000 description 16
- 239000002157 polynucleotide Substances 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 230000001464 adherent effect Effects 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 15
- 238000000684 flow cytometry Methods 0.000 description 15
- 108010085238 Actins Proteins 0.000 description 14
- 102000000588 Interleukin-2 Human genes 0.000 description 14
- 108010002350 Interleukin-2 Proteins 0.000 description 14
- 206010022000 influenza Diseases 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 238000013518 transcription Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 230000027455 binding Effects 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- 102000007469 Actins Human genes 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 12
- 239000006285 cell suspension Substances 0.000 description 12
- 229940100601 interleukin-6 Drugs 0.000 description 12
- 230000019491 signal transduction Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 11
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 11
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 11
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 210000005087 mononuclear cell Anatomy 0.000 description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 10
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 10
- 101001064853 Homo sapiens Polyunsaturated fatty acid lipoxygenase ALOX15 Proteins 0.000 description 10
- 241000725303 Human immunodeficiency virus Species 0.000 description 10
- 239000008121 dextrose Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 239000005090 green fluorescent protein Substances 0.000 description 10
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 9
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 9
- 102000006354 HLA-DR Antigens Human genes 0.000 description 9
- 108010058597 HLA-DR Antigens Proteins 0.000 description 9
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 9
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 9
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 9
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 108010065524 CD52 Antigen Proteins 0.000 description 8
- 102000013135 CD52 Antigen Human genes 0.000 description 8
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 8
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 8
- 102100031950 Polyunsaturated fatty acid lipoxygenase ALOX15 Human genes 0.000 description 8
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 8
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102100033511 Keratin, type I cytoskeletal 17 Human genes 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 238000002493 microarray Methods 0.000 description 7
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 6
- 102000013462 Interleukin-12 Human genes 0.000 description 6
- 108010065805 Interleukin-12 Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002617 apheresis Methods 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 230000000139 costimulatory effect Effects 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 108091008048 CMVpp65 Proteins 0.000 description 5
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002577 cryoprotective agent Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 238000013394 immunophenotyping Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229940117681 interleukin-12 Drugs 0.000 description 5
- 230000004073 interleukin-2 production Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000003071 memory t lymphocyte Anatomy 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100028742 CAP-Gly domain-containing linker protein 4 Human genes 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000767061 Homo sapiens CAP-Gly domain-containing linker protein 4 Proteins 0.000 description 4
- 101000998027 Homo sapiens Keratin, type I cytoskeletal 17 Proteins 0.000 description 4
- 101000772560 Homo sapiens Zinc finger transcription factor Trps1 Proteins 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 102100030619 Zinc finger transcription factor Trps1 Human genes 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 230000009822 protein phosphorylation Effects 0.000 description 4
- 238000010079 rubber tapping Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100040517 Golgi-associated kinase 1B Human genes 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 101000924629 Homo sapiens Apoptotic protease-activating factor 1 Proteins 0.000 description 3
- 101000893979 Homo sapiens Golgi-associated kinase 1B Proteins 0.000 description 3
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 3
- 101001117517 Homo sapiens Prostaglandin E2 receptor EP3 subtype Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 102100039685 Polypeptide N-acetylgalactosaminyltransferase 3 Human genes 0.000 description 3
- 102100024447 Prostaglandin E2 receptor EP3 subtype Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 238000003633 gene expression assay Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000006882 induction of apoptosis Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 230000031146 intracellular signal transduction Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000007898 magnetic cell sorting Methods 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102100040685 14-3-3 protein zeta/delta Human genes 0.000 description 2
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 102100030835 AT-rich interactive domain-containing protein 5B Human genes 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 2
- 102100035388 Beta-enolase Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
- 108010092574 CD69 antigen Proteins 0.000 description 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 2
- 102100025579 Calmodulin-2 Human genes 0.000 description 2
- 102100033561 Calmodulin-binding transcription activator 1 Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102100038196 Chitinase-3-like protein 1 Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 2
- 102100039223 Cytoplasmic polyadenylation element-binding protein 1 Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102100031149 Deoxyribonuclease gamma Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100035372 DmX-like protein 1 Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 238000012424 Freeze-thaw process Methods 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000792947 Homo sapiens AT-rich interactive domain-containing protein 5B Proteins 0.000 description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 2
- 101000877537 Homo sapiens Beta-enolase Proteins 0.000 description 2
- 101000984150 Homo sapiens Calmodulin-2 Proteins 0.000 description 2
- 101000945309 Homo sapiens Calmodulin-binding transcription activator 1 Proteins 0.000 description 2
- 101000745747 Homo sapiens Cytoplasmic polyadenylation element-binding protein 1 Proteins 0.000 description 2
- 101000845618 Homo sapiens Deoxyribonuclease gamma Proteins 0.000 description 2
- 101000804531 Homo sapiens DmX-like protein 1 Proteins 0.000 description 2
- 101000944277 Homo sapiens Inward rectifier potassium channel 2 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101001109465 Homo sapiens NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 description 2
- 101001134134 Homo sapiens Oxidation resistance protein 1 Proteins 0.000 description 2
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 description 2
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 2
- 101000596119 Homo sapiens Plastin-3 Proteins 0.000 description 2
- 101000886179 Homo sapiens Polypeptide N-acetylgalactosaminyltransferase 3 Proteins 0.000 description 2
- 101000914035 Homo sapiens Pre-mRNA-splicing regulator WTAP Proteins 0.000 description 2
- 101000620365 Homo sapiens Protein TMEPAI Proteins 0.000 description 2
- 101001134896 Homo sapiens Protein-L-isoaspartate O-methyltransferase domain-containing protein 1 Proteins 0.000 description 2
- 101001130279 Homo sapiens Rab9 effector protein with kelch motifs Proteins 0.000 description 2
- 101000641015 Homo sapiens Sterile alpha motif domain-containing protein 9 Proteins 0.000 description 2
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 description 2
- 101000795107 Homo sapiens Triggering receptor expressed on myeloid cells 1 Proteins 0.000 description 2
- 101000680652 Homo sapiens Tripartite motif-containing protein 14 Proteins 0.000 description 2
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 2
- 101000978006 Homo sapiens cAMP-dependent protein kinase inhibitor beta Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102100033114 Inward rectifier potassium channel 2 Human genes 0.000 description 2
- 101710183401 Keratin, type I cytoskeletal 17 Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 2
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- 108010040897 Microfilament Proteins Proteins 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102100034219 Oxidation resistance protein 1 Human genes 0.000 description 2
- 108010015181 PPAR delta Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 2
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 2
- 102100026123 Pirin Human genes 0.000 description 2
- 102100035220 Plastin-3 Human genes 0.000 description 2
- 102100026431 Pre-mRNA-splicing regulator WTAP Human genes 0.000 description 2
- 102100026651 Pro-adrenomedullin Human genes 0.000 description 2
- 102100025726 Probable UDP-sugar transporter protein SLC35A5 Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100022429 Protein TMEPAI Human genes 0.000 description 2
- 102100033431 Protein-L-isoaspartate O-methyltransferase domain-containing protein 1 Human genes 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 102100031543 Rab9 effector protein with kelch motifs Human genes 0.000 description 2
- 108091006543 SLC35A5 Proteins 0.000 description 2
- 102000005039 SLC6A6 Human genes 0.000 description 2
- 108060007765 SLC6A6 Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102100034291 Sterile alpha motif domain-containing protein 9 Human genes 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 101000987219 Sus scrofa Pregnancy-associated glycoprotein 1 Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102100024547 Tensin-1 Human genes 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102100029681 Triggering receptor expressed on myeloid cells 1 Human genes 0.000 description 2
- 102100022350 Tripartite motif-containing protein 14 Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102100023516 cAMP-dependent protein kinase inhibitor beta Human genes 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000023549 cell-cell signaling Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 238000013501 data transformation Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940074383 interleukin-11 Drugs 0.000 description 2
- 229940076264 interleukin-3 Drugs 0.000 description 2
- 230000037427 ion transport Effects 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 244000052613 viral pathogen Species 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108010062544 Apoptotic Protease-Activating Factor 1 Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000012454 Cdc42 effector protein 2 Human genes 0.000 description 1
- 108050002003 Cdc42 effector protein 2 Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100024478 Cell division cycle-associated protein 2 Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108010066813 Chitinase-3-Like Protein 1 Proteins 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 102100029305 Chondroitin sulfate synthase 3 Human genes 0.000 description 1
- 101710111970 Chondroitin sulfate synthase 3 Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102100037373 DNA-(apurinic or apyrimidinic site) endonuclease Human genes 0.000 description 1
- 101710109420 DNA-(apurinic or apyrimidinic site) endonuclease Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101710116650 FAD-dependent monooxygenase Proteins 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000028953 G1 phase of mitotic cell cycle Effects 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 description 1
- 101100059511 Homo sapiens CD40LG gene Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000980905 Homo sapiens Cell division cycle-associated protein 2 Proteins 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101100341519 Homo sapiens ITGAX gene Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000986786 Homo sapiens Orexin/Hypocretin receptor type 1 Proteins 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 101001057750 Human cytomegalovirus (strain AD169) Uncharacterized protein IRL2 Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 108010066325 Keratin-17 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000589929 Leptospira interrogans Species 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 101000792948 Mus musculus AT-rich interactive domain-containing protein 5B Proteins 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 230000019048 NLS-bearing substrate import into nucleus Effects 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 101710128228 O-methyltransferase Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 description 1
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 108010066816 Polypeptide N-acetylgalactosaminyltransferase Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 102000028677 Rab9 Human genes 0.000 description 1
- 108050007276 Rab9 Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102000018779 Replication Protein C Human genes 0.000 description 1
- 108010027647 Replication Protein C Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 108010060889 Toll-like receptor 1 Proteins 0.000 description 1
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 230000010632 Transcription Factor Activity Effects 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 102000004271 Tryptophan 5-monooxygenases Human genes 0.000 description 1
- 108090000885 Tryptophan 5-monooxygenases Proteins 0.000 description 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 101710097146 Uncharacterized protein HKLF1 Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 102000006757 Wnt Receptors Human genes 0.000 description 1
- 108010047118 Wnt Receptors Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000011552 cellular defense response Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000024690 epidermis development Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 102000050820 human ALOX15 Human genes 0.000 description 1
- 102000043738 human CD52 Human genes 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 102000056142 human TLR1 Human genes 0.000 description 1
- 102000045718 human TLR2 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000029225 intracellular protein transport Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000034701 macropinocytosis Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 244000079416 protozoan pathogen Species 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000019908 regulation of T cell activation Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Definitions
- the present invention relates to methods for the production of dendritic cells and related compositions useful in the treatment of disease.
- a common method for preparing dendritic cells is to collect peripheral blood mononuclear cells (PBMCs) from a subject, and then differentiate the monocytes, which are a small proportion of the PBMCs, into DCs. It was widely believed in order to act as suitable precursors for the in vitro manufacture of dendritic cells, monocytes must be either frozen or cultured soon after isolation from a subject. Accordingly, in previous clinical trials where dendritic cell vaccines were made from monocytes, the PBMCs or monocytes were either cultured at approximately 37° C. or frozen within a few hours of the collection of PBMCs from a patient.
- PBMCs peripheral blood mononuclear cells
- a commercially viable model for manufacturing DC vaccines is to provide one or a relatively small number of facilities that can manufacture DC vaccines from patient PBMCs or monocytes collected at a clinical site and then shipped to a manufacturing site.
- PBMCs or monocytes collected at a clinical site and then shipped to a manufacturing site.
- Freezing fresh monocytes requires additional manipulations at the collection site following leukapheresis, and therefore is not a desirable alternative. Accordingly, there is a need to develop methods for manufacturing DC vaccines using PBMCs or monocytes that have been stored during shipment to a manufacturing facility.
- the present invention satisfies this need and provides additional advantages as well.
- the inventors have discovered methods which allow the preparation of dendritic cells and dendritic cell vaccines from monocytes which have be stored at 1-34° C. for time periods of 6-96 hours following isolation from a subject.
- the ability to manufacture DCs from stored monocytes allows greater flexibility and shipment of the monocytes from the site of collection to a manufacturing facility.
- the inventors have found that the dendritic cell vaccines manufactured from stored monocytes are phenotypically superior to dendritic cells manufactured from fresh monocytes.
- the dendritic cell vaccines manufactured from stored monocytes have increased levels of costimulatory molecules, such as CD80, CD83 and CD86, as well as higher levels of MHC class I and MHC class II molecules as compared to dendritic cells manufactured from fresh monocytes.
- the invention provides a method for producing dendritic cells from monocytes, comprising:
- the monocytes are obtained by leukapheresis to collect peripheral blood mononuclear cells (PBMCs) that comprise monocytes.
- PBMCs peripheral blood mononuclear cells
- differentiation is induced by contacting the monocytes with a culture medium comprising an effective amount of a composition that induces the differentiation of monocytes into immature dendritic cells, such as, but not limited to, GM-CSF; GM-CSF and IL-4: GM-CSF and IL-13; GM-CSF and IL-15; and IFN ⁇ .
- immature dendritic cells such as, but not limited to, GM-CSF; GM-CSF and IL-4: GM-CSF and IL-13; GM-CSF and IL-15; and IFN ⁇ .
- immature dendritic cells can then be matured to produce mature dendritic cells.
- the mature dendritic cells manufactured by the methods of the invention are phenotypically different than prior art mature dendritic cells.
- the invention provides mature monocyte derived dendritic cell, wherein the steady state ratio of ALOX15 RNA to actin RNA or GAPDH RNA in the cell is less than 1.0. This is a decreased ratio as compared to the ratio of ALOX15 to Actin or GAPDH RNA in mature dendritic cells prepared from fresh monocytes.
- the invention provides a mature monocyte derived dendritic cell, wherein the steady state ratio of CD52 RNA to actin RNA or GAPDH in the cell is greater than 1.0.
- the invention provides a mature monocyte derived dendritic cell, wherein the steady state ratio of TLR1 RNA, TLR2 RNA, IL-1 ⁇ RNA or CD69 RNA to actin RNA or GAPDH RNA in the cell is less than 1.0.
- the invention provides a composition comprising mature monocyte derived dendritic cells, wherein the mature dendritic cells have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from fresh monocytes.
- the invention provides mature monocyte derived dendritic cells having altered steady state levels of ALOX15 RNA, CD52 RNA, TLR1 RNA, TLR2 RNA, IL-1 ⁇ RNA or CD69 RNA.
- the dendritic cells prepared by the methods of the invention are particularly useful for preparing vaccines.
- related dendritic cell compositions and vaccines are provided as well.
- the vaccine is autologous to the subject.
- the dendritic cell vaccine is loaded with antigen from a cancer cell or pathogen present in the subject.
- the invention provides the use of an antigen-loaded dendritic cell for the preparation of a frozen medicament for the treatment or prevention of cancer or pathogen infection, wherein the medicament comprises at least 2% DMSO and is ready for administration upon thawing.
- the invention provides a method of vaccinating a subject, comprising:
- the invention provides an antigen-loaded dendritic cell, wherein said cell is differentiated in vitro from a monocyte and is capable of surviving in vitro for at least 24 hours following freezing in the presence of ⁇ 5% DMSO and thawing.
- the antigen loaded dendritic cell is capable of surviving in vitro for at least 24 hours following freezing in the presence of ⁇ 10% DMSO and thawing.
- the invention provides a dendritic cell vaccine, comprising approximately 5-15% DMSO, wherein said vaccine is ready for administration to a subject.
- FIG. 1 Diagram of a preferred shipping container and packaging materials for the temperature controlled shipping of monocytes (e.g, leukapheresis product).
- monocytes e.g, leukapheresis product
- FIG. 2 RNA-transfected DCs provide functional costimulatory support.
- DCs were tested for the ability to stimulate INF- ⁇ production from PBMC in a mixed lymphocyte (MLR) assay.
- MLR mixed lymphocyte
- Thawed DCs manufactured from 3 different donors were paired with previously frozen PBMCs from each donor. All pair wise combinations were tested using ELISPOT (INF- ⁇ ) as the readout.
- Columns 1, 4, and 7 represent DCs paired with autologous PBMCs.
- Columns 2, 3, 5, 6, 8 and 9 represent DCs paired with non-autologous PBMCs.
- Columns 10-12 represent DC only controls.
- Columns 13-14 represent PBMC only controls.
- FIG. 3 Cytokine cocktail matured DCs were compared to immature DCs from the same donor in their ability to stimulate Th1 cytokine production from autologous T cells. Both populations of DCs were transfected with RNA encoding Flu matrix protein and used to stimulate Flu-specific memory CTL from autologous PBMCs. The results of the ELISPOT analyses (# spots/well as a function of input PBMC) are shown.
- Each set of four columns is arranged in the following order: IFN ⁇ production elicited from Flu-specific T memory cells by immature DCs, IFN ⁇ production elicited from Flu-specific T memory cells by mature DCs; IL-2 production elicited from Flu-specific T memory cells by immature DCs; and IL-2 production elicited from Flu-specific T memory cells by mature DCs.
- FIG. 4 Two vials each of two RNA-loaded dendritic cells preparations made from day-old PBMCs obtained from 2 different healthy donors were thawed. One vial from each donor was immediately tested in an allo MLR assay while the second vial from each preparation was allowed remain at room temperature for 40 minutes before being assayed by the same method.
- the PBMCs used in this experiment included autologous cells from each donor as well as a third sample of PBMCs from a donor unrelated to either. The readout for this assay was ELISPOT (INF- ⁇ ).
- FIG. 5 The functionality of DCs pre-freeze versus post-thaw was assessed by the ability of the DCs to stimulate a memory Flu-specific response from autologous PBMC as a function of decreasing Flu mRNA concentration used for transfection.
- the assay readout was ELISPOT (INF- ⁇ ).
- FIG. 6 Flow cytometry assessment of GFP expression by DCs following electroporation with RNA encoding GFP. Untransfected (dashed line).
- FIG. 7 Intracellular cytokine staining: IL-2/IFN- ⁇ on CD4 and CD8 T cells following stimulation with DC transfected with RNA encoding GFP (negative control, left panels) or CMV pp65 (right panels).
- FIG. 8 CSFE dilution in CD4 and CD8 T cells following stimulation with DCs transfected with RNA encoding GFP (negative control, left panels) or CMV pp65 (right panels).
- FIG. 9 Phenotypes of day 6 immature dendritic cells (iDCs) prepared from day old leukapheresis product.
- FIG. 10 Phenotypes of day 7 mature dendritic cells (mDCs) prepared from day old leukapheresis product.
- a cell includes a plurality of cells, including mixtures thereof.
- antigen is well understood in the art and includes substances which are immunogenic, i.e., immunogens, as well as antigenic epitopes. It will be appreciated that the use of any antigen is envisioned for use in the present invention and thus includes, but is not limited to, a self-antigen (whether normal or disease-related), an infectious antigen (e.g., a microbial antigen, viral antigen, etc.), or some other foreign antigen (e.g., a food component, pollen, etc.).
- infectious antigen e.g., a microbial antigen, viral antigen, etc.
- foreign antigen e.g., a food component, pollen, etc.
- immunogen or alternatively, “immunogen” applies to collections of more than one immunogen, so that immune responses to multiple immunogens may be modulated simultaneously.
- the term includes any of a variety of different formulations of immunogen or antigen.
- the antigen is from a cancer cell or a pathogen.
- the cancer cell is a renal cancer cell, a multiple myeloma cell or a melanoma cell.
- Preferred pathogens are HIV and HCV.
- the antigen is delivered to the antigen presenting cell (APC) in the form of RNA isolated or derived from a cancer cell or a pathogen. “Derived from” includes, but is not limited recombinant variants of naturally occurring sequences, including fusions to unrelated or related sequences.
- RNA extracted from any cell e.g., a cancer cell or pathogen cell
- in vitro transcription Methods for RT-PCR of RNA extracted from any cell (e.g., a cancer cell or pathogen cell), and in vitro transcription are disclosed in copending U.S. provisional patent application No. 60/525,076, and PCT/US05/053271, the contents of which are incorporated by reference.
- cancer is meant the abnormal presence of cells which exhibit relatively autonomous growth, so that a cancer cell exhibits an aberrant growth phenotype characterized by a significant loss of cell proliferation control.
- Cancerous cells can be benign or malignant.
- the cancer affects cells of the bladder, blood, brain, breast, colon, digestive tract, lung, ovaries, pancreas, prostate gland, or skin.
- the definition of a cancer cell, as used herein, includes not only a primary cancer cell, but also any cell derived from a cancer cell. This includes metastasized cancer cells, and in vitro cultures and cell lines derived from cancer cells.
- Cancer includes, but is not limited to, solid tumors, liquid tumors, hematologic malignancies, renal cell cancer, melanoma, breast cancer, prostate cancer, testicular cancer, bladder cancer, ovarian cancer, cervical cancer, stomach cancer, esophageal cancer, pancreatic cancer, lung cancer, neuroblastoma, glioblastoma, retinoblastoma, leukemias, myelomas, lymphomas, hepatoma, adenomas, sarcomas, carcinomas, blastomas, etc.
- compositions and methods include the recited elements, but not excluding others.
- Consisting essentially of when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like.
- Consisting of shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention.
- cytokine refers to any one of the numerous factors that exert a variety of effects on cells, for example, inducing growth or proliferation.
- Non-limiting examples of cytokines which may be used alone or in combination in the practice of the present invention include, interleukin-2 (IL-2), stem cell factor (SCF), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-11 (IL-11), interleukin-12 (IL-12), interleukin-13 (IL-13), interleukin-15 (IL-15), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin-1 beta (IL-1 ⁇ ), interferon- ⁇ (IFN ⁇ ), tumor necrosis factor- ⁇ (TNF ⁇ ), prostaglandin E 2 (PGE 2 ), MIP-11, leukemia inhibitory factor (LIF), c-kit ligand, thrombopoie
- LIF le
- Cytokines are commercially available from several vendors such as, for example, Genzyme (Framingham, Mass.), Genentech (South San Francisco, Calif.), Amgen (Thousand Oaks, Calif.), R&D Systems (Minneapolis, Minn.) and Immunex (Seattle, Wash.). It is intended, although not always explicitly stated, that molecules having similar biological activity as wild-type or purified cytokines (e.g., recombinantly produced or muteins thereof) are intended to be used within the spirit and scope of the invention.
- dendritic cells refers to a diverse population of morphologically similar cell types found in a variety of lymphoid and non-lymphoid tissues, Steinman (1991) Ann. Rev. Immunol. 9:271-296. Dendritic cells constitute the most potent and preferred APCs in the organism. Dendritic cells can be differentiated from monocytes, and possess a distinct phenotype from monocytes. For example, a particular differentiating marker, CD14 antigen, is not found in dendritic cells but is possessed by monocytes. It has been shown that mature DCs can provide all the signals necessary for T cell activation and proliferation.
- Immature DCs are capable of capturing antigens by endocytosis, phagocytosis, macropinocytosis or adsorptive pinocytosis and receptor mediated antigen uptake, and are phenotypically CD80 ⁇ or CD80 low , CD83 ⁇ or CD83 low , CD86 low , and have high intracellular concentrations of MHC class II molecules.
- Mature DCs have a veiled morphology, a lower capacity for endocytosis and are phenotypically CD80 high , CD83 high , CD86 high in comparison to immature DCs.
- the mature DCs secrete IL-12 p70 polypeptide or protein, and/or secrete significantly reduced levels (0 to 500 pg/ml per million DCs) of IL-10.
- IL-10 and IL-12 levels can be determined by ELISA of culture supernatants collected at up to 36 hrs post induction of DC maturation from immature DCs. Wierda W. G. et al (2000) Blood 96: 2917. Ajdary S et al (2000) Infection and Immunity 68: 1760. See Banchereau and Steinman (1998) Nature 392:245 for a review.
- an “effective amount” is an amount sufficient to effect beneficial or desired results.
- An effective amount can be administered in one or more administrations, applications or dosages.
- expression refers to the processes by which polynucleotides are transcribed into mRNA and/or mRNA is translated into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA of an appropriate eukaryotic host, expression may include splicing of the mRNA. Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome binding.
- a bacterial expression vector or cassette includes a promoter (e.g., lac promoter) and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG (Sambrook et al. (1989) supra).
- a eukaryotic expression vector or cassette typically includes a heterologous or homologous promoter for RNA polymerase II, a Kozak sequence, the start codon AUG, a termination codon for detachment of the ribosome and a downstream polyadenylation signal.
- a heterologous or homologous promoter for RNA polymerase II typically includes a heterologous or homologous promoter for RNA polymerase II, a Kozak sequence, the start codon AUG, a termination codon for detachment of the ribosome and a downstream polyadenylation signal.
- Such vectors can be obtained commercially or assembled by the sequences described in methods known in the art.
- genetically modified means containing and/or expressing a foreign gene or nucleic acid sequence which in turn, modifies the genotype or phenotype of the cell or its progeny. In other words, it refers to any addition, deletion or disruption to a cell's endogenous nucleotides.
- isolated means separated from constituents, cellular and otherwise, in which the polynucleotide, peptide, polypeptide, protein, antibody, or fragments thereof, are normally associated with in nature.
- an isolated polynucleotide is one that is separated from the 5′ and 3′ sequences with which it is normally associated in the chromosome.
- a non-naturally occurring polynucleotide, peptide, polypeptide, protein, antibody, or fragment(s) thereof does not require “isolation” to distinguish it from its naturally occurring counterpart.
- a “concentrated”, “separated” or “diluted” polynucleotide, peptide, polypeptide, protein, antibody, or fragment(s) thereof is distinguishable from its naturally occurring counterpart in that the concentration or number of molecules per volume is greater than “concentrated” or less than “separated” than that of its naturally occurring counterpart.
- a non-naturally occurring polynucleotide is provided as a separate embodiment from the isolated naturally occurring polynucleotide.
- a protein produced in a bacterial cell is provided as a separate embodiment from the naturally occurring protein isolated from a eukaryotic cell in which it is produced in nature.
- An isolated mammalian cell is separated from where it is normally found in the body, or is removed from the body. For example, leukocytes collected by leukophereis are “isolated”, and dendritic cells differentiated from monocytes in vitro are “isolated”.
- MHC major histocompatibility complex
- HLA human leukocyte antigen
- the proteins encoded by the MHC are known as “MHC molecules” and are classified into Class I and Class II MHC molecules.
- Class I MHC molecules include membrane heterodimeric proteins made up of an a chain encoded in the MHC noncovalently linked with the ⁇ 2-microglobulin.
- Class I MHC molecules are expressed by nearly all nucleated cells and have been shown to function in antigen presentation to CD8 + T cells.
- Class I molecules include HLA-A, B, and C in humans.
- Class II MHC molecules also include membrane heterodimeric proteins consisting of noncovalently associated ⁇ and ⁇ chains.
- Class II MHC molecules are known to function in CD4 + T cells and, in humans, include HLA-DP, DQ, and DR.
- monocytes By monocytes is meant CD14 + peripheral blood mononuclear cells capable of differentiating into immature dendritic cells in response to GM-CSF and IL-4.
- Phathogen refers to any disease causing organism or virus, and also to attenuated derivatives thereof.
- a “pharmaceutical composition” is intended to include the combination of an active agent (such as an antigen-loaded DC) with a carrier, inert or active, making the composition suitable for diagnostic or therapeutic use in vitro, in vivo or ex vivo.
- an active agent such as an antigen-loaded DC
- the term “pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutical carriers, such as heat-inactivated serum plus 10% DMSO plus 5% dextrose, phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents.
- the compositions also can include adjuvants, stabilizers and preservatives.
- carriers, stabilizers and adjuvants see Remington's Pharm. Sci. 18 th Ed. (Mack Publ. Co., Easton (1990)).
- polynucleotide and “nucleic acid molecule” are used interchangeably to refer to polymeric forms of nucleotides of any length.
- the polynucleotides may contain deoxyribonucleotides, ribonucleotides, and/or their analogs.
- Nucleotides may have any three-dimensional structure, and may perform any function, known or unknown.
- polynucleotide includes, for example, single-stranded, double-stranded and triple helical molecules, a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.
- a nucleic acid molecule of the present invention may also comprise modified nucleic acid molecules.
- peptide is used in its broadest sense to refer to a compound of two or more subunit amino acids, amino acid analogs, or peptidomimetics.
- the subunits may be linked by peptide bonds. In another embodiment, the subunit may be linked by other bonds, e.g., ester, ether, etc.
- amino acid refers to either natural and/or unnatural or synthetic amino acids, including glycine and both the D and L optical isomers, amino acid analogs and peptidomimetics.
- a peptide of three or more amino acids is commonly called an oligopeptide if the peptide chain is short. If the peptide chain is long, the peptide is commonly called a polypeptide or a protein.
- subject refers to a mammal, including, but not limited to, humans and other primates, rodents, dogs and cats. Preferably, the subject is a human.
- the inventors have discovered that immature dendritic cells, mature dendritic cells and antigen loaded dendritic cells can be produced from monocytes stored at 1° C.-34° C. for approximately 6 to 96 hours following collection of the monocytes from a patient. These results are surprising, as it was commonly believed critical to prepare dendritic cells from freshly isolated monocytes, rather than from monocytes that had been stored at ambient temperatures for a significant length of time. Moreover, monocyte-derived DC vaccines used in clinical trials performed prior to the instant invention have been prepared by culturing monocytes within less than 6 hours following collection from a patient, or by freezing PBMCs shortly after collection, and storing the PBMCs for subsequent thawing and culturing of monocytes.
- dendritic cells and dendritic cell vaccines are phenotypically superior to the dendritic cells made from fresh monocytes.
- the method of manufacture and the characteristics of dendritic cell vaccines produced by these methods are particularly relevant to vaccine potency, successful commercialization over a widespread area, and ease of administration.
- the mature dendritic cells manufactured using the methods of the invention when compared to DCs produced by prior art methods, express increased levels CD80, CD83 and CD86 costimulatory molecules, as well as increased levels of MHC class I and MHC class II molecules, all of which are indicative of DC maturity and potency.
- mature DCs of the invention are able to induce IL-2 production from memory T cells in an antigen specific fashion.
- antigen-loaded dendritic cells are typically frozen in DMSO and stored until thawing, washing and resuspending in a DMSO-free pharmaceutically acceptable carrier prior to administration to a patient.
- the washing step was included in prior DC vaccine clinical trials because it was thought that DMSO has detrimental effects on unfrozen or thawed DCs.
- the inventors have discovered that DMSO has no noticeable detrimental effect on dendritic cells.
- there is no need to wash and resuspend the thawed DC vaccine prior to administration. Omitting this step increases the ease of administration and decreases both the risk of contamination and of adverse effects to the DCs due to additional manipulations.
- the invention provides a method for producing dendritic cells from monocytes, comprising:
- monocyte refers to a CD14 + leukocyte having the capacity to differentiate into a dendritic cell.
- the monocyte may be from any mammal, and preferably is a human monocyte.
- the monocytes can be provided and incubated in compositions such as, but not limited to, blood, blood fractions (e.g., white blood cells (WBCs), buffy coats, peripheral blood mononuclear cells (PBMCs), etc, and as well as in compositions further enriched for monocytes.
- WBCs white blood cells
- PBMCs peripheral blood mononuclear cells
- the monocytes are provided together with other peripheral blood mononuclear cells (PBMCs), for example, as a leukapheresis product.
- PBMCs peripheral blood mononuclear cells
- the monocytes are enriched from PBMCs, or isolated directly from peripheral blood. Methods of isolating monocytes or PBMCs containing monocytes are known to those of skill in the art.
- the monocytes are collected together with other PBMCs by leukapheresis. Methods of leukapheresis are known in the art.
- PBMCs comprising monocytes are collected from a subject by leukapheresis at a hospital, clinic, doctor's office, etc. Leukapheresis is a procedure by which the white blood cells are removed from a subject's blood, the remainder of which is then transfused back into the subject.
- the leukapheresis product is typically a blood fraction enriched for PBMCs, with low levels of contaminating red blood cells, granulocytes and platelets.
- Methods and equipment for performing leukapheresis are well known in the art. See, for example gambrobct.com/Products_&_Services/ for detailed information on leukapheresis.
- Examples of leukapheresis apparatuses include the COBESpectraTM manufactured by GAMBRO BCT, and the CS3000 Plus Blood Cell Separator manufactured by Baxter Fenwal.
- Monocytes can be enriched from blood or blood fractions (e.g., PBMCs), during or after the 1° C.-34° C. incubation period.
- PBMCs blood or blood fractions
- enriching monocytes means a method which increases the proportion of monocytes with respect to other cell types that were present at the start of the method.
- Methods for enriching monocytes from PBMCs, blood or other blood fractions are known to those of skill in the art and include, but are not limited to elutriation, FACS, panning, magnetic sorting, low density Ficoll gradient centrifugation, and the like.
- monocytes are enriched from PBMCs by elutriation.
- monocytes are enriched from PBMCs following the 6-96 hour incubation period by selection for monocytes which adhere to plastic during cell culture.
- monocytes are enriched by immunomagnetic selection. The immunomagnetic selection may be positive selection to bind monocytes, or may be negative selection, to bind cells which are not monocytes (e.g., T cells, B cells, etc.)
- monocytes e.g., purified monocytes, enriched monocytes, PBMCs comprising monocytes, etc.
- monocytes are incubated at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject.
- the time at which monocytes or PBMCs containing monocytes are isolated from a subject refers to the time at the completion of the process of removing the cells from the subject. For example, where PBMCs are isolated from a patient over the course of a four hour leukapheresis procedure, the time of isolation would be the time at which collection of PBMCs by leukapheresis ends.
- the monocytes are incubated for 6 to 96 hours at a temperature of 3° C.-34° C., or 4° C.-32° C. or 5° C.-30° C., more preferably at a temperature of 6° C.-28° C., even more preferably at a temperature of 6° C.-27° C., 8° C.-26° C. or about 14° C.-24° C.
- Preferred lower temperature ranges are 6° C., 7° C., 8° C., 9° C., 10° C., 11° C., 12° C., 13° C. and 14° C.
- Preferred upper temperature ranges are 20° C., 21° C., 22° C., 23° C., 24° C., 25° C., 26° C., 27° C., 28° C., 29° C., 30° C., 31° C., 32° C., 33° C. and 34° C.
- the period of incubation is 8 to 72 hours, more preferably 10 to 48 hours, even more preferably 12 to 24 hours, and most preferably, 15 to 22 hours.
- Other preferred ranges of incubation times include 8 to 48 hours, 10 to 30 hours, 26 to 72 hours and 48 to 80 hours.
- Preferred lower limits of incubation times can be selected from 6, 7, 8, 10, 12, 14, 16, 20, 22, 24, 26, 28, 30, 36 and 48 hours.
- Preferred upper limits of incubation times can be selected from 24, 26, 28, 30, 36, 48, 60, 72, 84 and 96 hours.
- Monocytes in any form may be shipped from a clinical site to a dendritic cell manufacturing site during the 1° C.-34° C. incubation period.
- the monocytes are shipped in a temperature controlled container.
- Methods of maintaining the temperature of the monocytes between 1° C.-34° C. during the incubation period are known to those of skill in the art.
- the monocytes can be incubated in an incubator or a room at 1° C.-34° C.
- the monocytes are subjected to some motion (either occasional or continuous) during the incubation period.
- the motion can be the motion associated with shipping.
- the cells can be gently rocked or rotated during incubation. While not wishing to be bound by theory, it is thought that the motion may prevent cell damage associated with compaction during settling.
- the monocytes are incubated without culturing.
- “without culturing”, is meant that during the 6 to 96 hour incubation period, the monocytes are not cultured in a mammalian cell culture medium (including, but not limited to, physiologically appropriate concentrations (e.g., about 1 ⁇ ) of culture mediums such as RPMI, DMEM, X-VIVO 15, AIM-V, StemSpan H2000, and the like) at a temperature of about 36-38° C.
- monocytes processed by the methods of the invention are incubated at 1° C.-34° C., preferably in blood or blood fractions (e.g., serum, plasma, leukapheresis product (e.g., PBMCs), buffy coat, etc.) saline or biological buffers such as phosphate buffer saline (PBS).
- blood or blood fractions e.g., serum, plasma, leukapheresis product (e.g., PBMCs), buffy coat, etc.
- saline or biological buffers such as phosphate buffer saline (PBS).
- PBS phosphate buffer saline
- the leukapheresis product containing monocytes is incubated at 1° C.-34° C. in the leukapheresis collection container (e.g., a blood collection bag). While the leukapheresis product may be transferred to another container at the beginning or during the incubation period, it is preferable to
- the monocytes can be enriched prior to differentiation step. Manipulations may be performed on the monocytes or PBMCs, etc., during the period of incubation, so long as the manipulations are performed at 1° C.-34° C.
- PBMCs may be further purified, or monocytes may be enriched from PBMCs during this period of incubation.
- monocytes can be enriched from PBMCs after the incubation period by culture in a container (preferably a plastic container) and selection for adherent monocytes.
- the monocytes are induced to differentiate into dendritic cells.
- monocytes are differentiated into immature dendritic cells and then the immature dendritic cells then can be matured into mature dendritic cells.
- a variety of methods for differentiating monocytes into dendritic cells, and for maturing the dendritic cells are known to those of skill in the art.
- monocytes are cultured in a medium comprising a composition that induces the differentiation of monocytes into immature or mature dendritic cells.
- compositions which induce the differentiation of monocytes into immature dendritic cells are known to those of skill in the art. Such compositions include, but are not limited to, GM-CSF+IL-4; GM-CSF+IL-13; GM-CSF+IL-15; IFN ⁇ ; and GM-CSF+TNF ⁇ .
- the composition which induces differentiation is GM-CSF+IL-4.
- the concentrations of GM-CSF and IL-4 may range from about 400 to 2000 U/ml of each cytokine Preferably, the concentration of GM-CSF and IL-4 is 500 to 1000 units/ml of each cytokine.
- the monocytes are contacted with GM-CSF and IL-4 for about 4-7 days, most preferably for about 5-6 days, during which time the monocytes differentiate into immature dendritic cells.
- the immature dendritic cells can be matured into mature dendritic cells.
- Methods for maturing dendritic cells are known to those of skill in the art.
- the immature dendritic cell are matured by contact with a medium comprising GM-CSF, IL-4 and a maturation cocktail (PGE 2 , TNF ⁇ , IL-6 and IL-1 ⁇ ). See for example, Jonuliet et al. (1997) Eur J Immunol 27:3135-3142, the contents of which are incorporated by reference.
- immature dendritic cells are signaled with a first signal, comprising IFN- ⁇ , followed by a second signal comprising CD40L.
- immature dendritic cells are contacted with PGE 2 , IFN- ⁇ and CD40L, preferably in the presence of GM-CSF and IL-4.
- the contacting with CD40L is effected upon translation of a recombinant CD40L mRNA within the dendritic cells.
- the dendritic cell is transiently transfected with an mRNA encoding CD40L or an active fragment thereof.
- immature dendritic cells are contacted with PGE 2 , TNF ⁇ , and IFN ⁇ , preferably in the presence of GM-CSF and IL-4, to produce mature dendritic cells.
- the maturity of the dendritic cells can be further increased by transfection, preferably transient transfection, with an RNA encoding CD40L.
- the dendritic cells are transfected with an RNA encoding CD40L and/or RNA encoding one or more antigens or epitopes of interest.
- the dendritic cells are loaded with one or more antigens.
- Antigen loaded dendritic cells are useful as vaccines and for the in vitro stimulation of T cells.
- Antigens can be loaded into immature or mature dendritic cells. If antigens are loaded into immature dendritic cells, the immature dendritic cells can then be matured by the process of loading itself, or by other maturation methods described herein or alternative maturation methods known to those of skill in the art.
- the antigen(s) can be loaded as the antigen itself (e.g., proteins, peptides, epitopes, cell lysates, viral particles, etc.) or can be loaded as a nucleic acid(s) encoding antigen(s).
- the antigen is loaded as a nucleic acid encoding the antigen. More preferably, the nucleic acid is an RNA, most preferably an mRNA. In a preferred embodiment mRNA encoding one or more antigens is cotransfected with mRNA encoding CD40L.
- the antigen is autologous to the subject, and is used to prepare an antigen loaded autologous DC vaccine for administration to the subject. Methods for loading dendritic cells with peptide and protein antigens, cells, cell or tissue lysates, viruses or viral particles, nucleic acids and the like are known to those of skill in the art.
- the antigen is loaded by electroporation of a dendritic cell (mature or immature) with a nucleic acid, preferably an mRNA.
- the dendritic cells are transfected with approximately 0.25 to 4 micrograms RNA per 10 6 dendritic cells, most preferably with about 2 ⁇ g RNA per 10 6 dendritic cells.
- 1 microgram tumor RNA per million DC is used per transfection.
- 0.25 to 1.0 ⁇ g each of four RNAs encoding four separate antigens from a pathogen (e.g., HIV) is used per 10 6 dendritic cells.
- the antigen can be from any source. However, in preferred embodiments, the antigen or antigen(s) are autologous to the subject. By autologous to the subject is meant that the antigen is obtained or derived from the subject.
- the antigens may be from cancer cells or tumor tissue obtained from a subject.
- the cancer antigens could be loaded into dendritic cells as cancer cells, cancer cell or tissue lysates, extracts from cancer cells or tissues, purified or cloned components of cancer cells or tissues, total RNA or total mRNA, or selected RNA or mRNA from such cells or tissues, whether present in extracts, purified, amplified, in vitro translated and the like.
- the antigen may be obtained or derived from a pathogen or pathogen-infected cells present in a subject.
- the methods of the invention are particularly useful for the treatment or prevention of cancer and pathogen infection.
- the cancer is renal cell carcinoma, melanoma, breast cancer, chronic lymphocytic leukemia, multiple myeloma, lung cancer, colon cancer, pancreatic cancer, stomach cancer or prostate cancer.
- pathogen refers to any virus or organism which is involved in the etiology of a disease and also to attenuated derivatives thereof.
- pathogens include, but are not limited to, bacterial, protozoan, fungal and viral pathogens such as Helicobacter, such as Helicobacter pylori, Salmonella, Shigella, Enterobacter, Campylobacter, various mycobacteria, such as Mycobacterium leprae, Bacillus anthracis, Yersinia pestis, Francisella tularensis, Brucella species, Leptospira interrogans, Staphyloccus, (e.g., S.
- the pathogen is a viral pathogen, more preferably a retroviral pathogen, and most preferably HIV or HCV.
- Dendritic cells whether mature or immature, antigen loaded or not, can be frozen in a composition comprising a cryoprotectant.
- cryoprotectants include, but are not limited to, dimethylsulfoxide (DMSO), glycerol, ethanol, methanol, acetamide, glycerol monoacetate, propane-diol, polyethylene glycol, ethylene glycol, i-erythritol, D-ribitol, D-mannitol, D-sorbitol, D-lactose, i-inositol, choline chloride, amino acids, albumin (preferably human serum albumin), polyvinyl pyrrolidone, dextran, sucrose, Ficoll, inorganic salts, and hydroxyethyl starch.
- DMSO dimethylsulfoxide
- glycerol glycerol
- ethanol ethanol
- methanol acetamide
- glycerol monoacetate propane
- the cryoprotectant is DMSO.
- the concentration of DMSO is 2-20%, more preferably 5-15%, and most preferably approximately 10%.
- the freezing medium may contain one or more polyol compounds derived from carbohydrates, such as glucose, dextrose, sucrose, etc., preferably in a concentration of from 2-30%, more preferably from 5-10%, most preferably 5% dextrose. Methods for freezing dendritic cells are known to those of skill in the art. See, for example U.S. patent application 20040253574, the contents of which are incorporated by reference.
- the cryoprotectant is dimethylsulfoxide (DMSO).
- the concentration of DMSO is 5% to 20%. Most preferably, the concentration of DMSO in the composition is approximately 10%.
- dendritic cells and dendritic cell vaccines made by the methods of the invention are capable of surviving in vitro for at least 24 hours post-thaw following freezing in the presence of 5%-20% DMSO and thawing. Because the antigen-loaded dendritic cells of the invention are resistant to DMSO, it is not necessary to wash the cell prior to administering the dendritic cell vaccine. Accordingly, the thawed dendritic cell vaccines of the invention are ready for administration to a subject at any time after thawing. Eliminating the washing step reduces the risk of contamination and avoids further manipulations that may damage the dendritic cells.
- the invention provides a method for the administration of an antigen loaded dendritic cell vaccine, comprising thawing a frozen dendritic cell vaccine comprising at least 2% to 20% DMSO, and administering the vaccine to a subject without altering the ratio of dendritic cells to DMSO prior to administration.
- concentration of DMSO in the vaccine is approximately 5-20%, and more preferably 10%.
- the invention provides the use of an antigen-loaded dendritic cell for the preparation of a frozen medicament for the treatment or prevention of cancer or pathogen infection, wherein the medicament comprises at least 2% DMSO and is ready for administration upon thawing.
- the methods of the invention allow the production of novel dendritic cells with increased functionality and increased levels of maturity markers.
- the invention provides mature monocyte derived dendritic cells, wherein the mature dendritic cells have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from fresh monocytes.
- the invention provides a mature monocyte derived dendritic cell, wherein the dendritic cell can elicit antigen-specific IL-2 production from a memory T cell.
- Methods for measuring IL-2 are known in the art. Cell surface markers and expression of other molecules which are characteristic of memory T cells, and which distinguish them from other types of T cells, are disclosed in FIG. 10.35 of Immunobiology, 6 th Edition, Eds. Janeway et al., Garland Science Publishing, New York, N.Y., 2005; the content of which is incorporated by reference.
- memory T cells express high levels of CD44, CD45RO, CD45RA, Bcl-2, IFN ⁇ , CD127 and Ly6C; moderate levels of CD122, and CXCR4; low levels of FasL, and are CD69 and CD25 negative.
- the invention provides a mature monocyte-derived dendritic cell, wherein the steady state ratio of ALOX15 RNA to either ⁇ -actin RNA or GAPDH RNA in the cell is less that 1.0.
- the ratio is between 0.2 to 0.7, more preferably between 0.4 to 0.5, and most preferably about 0.45.
- the invention provides a mature monocyte derived dendritic cell, wherein the steady state ratio of CD52 RNA to ⁇ -actin RNA or GAPDH in the cell is greater than 1.0.
- the ratio is between 1.2 to 5.0, more preferably between 1.5 to 2.2, or between 1.8 to 1.9, and most preferably the ratio is 1.86.
- the invention provides a mature monocyte derived dendritic cell, wherein the steady state ratio of TLR1 RNA, TLR2 RNA, IL-1 ⁇ RNA or CD69 RNA to ⁇ -actin RNA or GAPDH RNA in the cell is less than 1.0. Preferably the ratio is between 0.2 to 0.9, and more preferably between 0.5 to 0.8.
- the human ALOX15 mRNA (SEQ ID NO:1) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:2-12.
- the human IL-1 ⁇ mRNA (SEQ ID NO:13) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:14-24.
- the human TLR1 mRNA (SEQ ID NO:25) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:26-36.
- the human TLR2 mRNA (SEQ ID NO:37) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:38-48.
- the human CD69 mRNA (SEQ ID NO:49) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:50-60.
- the human CD52 mRNA (SEQ ID NO:61) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:62-77.
- the human GAPDH mRNA (SEQ ID NO:78) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:79-98.
- the human ⁇ -actin mRNA (SEQ ID NO: 99) and allelic variants thereof can be detected using Affymetrix probes of SEQ ID NOs:100-119.
- RNA steady state expression levels can be detected by microarray, preferably using the Affymetrix Human Genome U133 Plus 2.0 Array.
- hybridization can be performed using the gene specific probes listed in the paragraph above.
- RNA samples extracted from dendritic cells can be applied to the Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, Calif.) according to the manufacture's instruction (Genechip® Expression Analysis Technical Manual, 2004). Briefly, three micrograms of total RNA spiked with Genechip® Poly-A RNA Control Kit (Affymetrix, Santa Clara, Calif.) are converted to first-strand cDNA using SuperScriptTM II reverse transcriptase.
- Second-strand cDNA synthesis is followed by in vitro transcription for linear amplification of each transcript and incorporation of biotinylated CTP and UTP.
- the cRNA products are fragmented to around 100 nucleotides, and hybridized for 16 hours to the microarrays.
- the microarrays are then washed at low (6 ⁇ SSPE) and high (100 mM MES, 0.1M NaCl) stringency and stained with streptavidin-phycoerythrin.
- Fluorescence is amplified by adding biotinylated anti-streptavidin and an additional aliquot of streptavidin-phycoerythrin stain.
- the GeneChip® Scanner 3000 (Affymetrix, Santa Clara, Calif.) is used to collect fluorescence signal at 3 ⁇ m resolution after excitation at 570 nm. The average signal from two sequential scans is calculated for each microarray feature of interest. Scanned images were analyzed with Genechip® Operating Software v1.1 (Affymetrix, Santa Clara, Calif.). Preferably, high linear correlation (R 2 >0.95) of 4 control RNAs included in Poly-A RNA Control Kit (Affymetrix, Santa Clara, Calif.) is confirmed as a control for the success of the labeling process.
- Profile data for all genes, or just the genes of interest are imported into the computer program GeneSpringTM and normalized. Three steps are performed in the normalization step according to the standard method suggested by GeneSpringTM for Affymetrix arrays.
- the ratio of steady state mRNA of interest (ALOX15, IL-1 ⁇ , TLR1, TLR2, CD69 or CD52 mRNA) to steady state GAPDH or ⁇ -Actin mRNA can then be determined by dividing the normalized expression of the mRNA of interest by the normalized expression of GAPDH or ⁇ -actin mRNA.
- the antigen-loaded dendritic cells of the invention are useful as vaccines in the treatment or prevention of disease or for the activation of T cells, which can then be used in therapy.
- antigen loaded dendritic cells can be used to elicit an immune response against an antigen. They may be used as vaccines to prevent future infection or disease, or to activate the immune system to treat ongoing disease, such as, but not limited to pathogen infection or cancer.
- the antigen loaded dendritic cells may be formulated for use as vaccines or pharmaceutical compositions with suitable carriers such as physiological buffers or other injectable liquids. The vaccines or pharmaceutical compositions would be administered in therapeutically effective amounts sufficient to elicit an immune response.
- the dendritic cells are loaded with an antigen autologous to the subject from which the dendritic cell is derived, and administered to the same subject.
- an antigen autologous to the subject from which the dendritic cell is derived, and administered to the same subject.
- the dendritic cell may be loaded with an antigen that is not autologous to the intended recipient of the DC therapy.
- antigens include, but are not limited to antigens that are known therapeutic targets, such as telomerase, prostate specific antigen, and other tumor markers, or known antigens from a pathogen.
- a variety of methods for collecting monocytes and PBMCs comprising monocytes from a subject are known to those of ordinary skill in the art. See for example, gambrobct.com/Products_&_Services/ for detailed information on leukapheresis for the collection PBMCs and elutriation for the purification of monocytes.
- a leukapheresis product and plasma are collected in separate sterile, disposable, single-use cytopheresis bags is collected using the AutoPBSC (Automated Peripheral Blood Stem Cell) procedure on a Gambro BCT COBE Spectra (Gambro BCT, Lakewood, Colo.).
- AutoPBSC Automated Peripheral Blood Stem Cell
- PBMCs are obtained by collecting blood in a heparinized syringe, dilution in PBS, layering over Histopaque 1077 (Sigma), centrifugation and recovery of PBMCs at the interface. See Woodhead et al. (2000) International Immunol 12:1051-1061. Additional methods of collecting, purifying or fractionating PBMCs are known to those of ordinary skill in the art.
- the leukapheresis product is collected in a bag and then transported to the vaccine manufacturing facility in a temperature-monitored shipping container maintained at 1-34° C., preferably at about 6-28° C., and most preferably at 8-26° C.
- Gel packs such as those disclosed in U.S. Pat. No. 4,102807, which aid in the prevention of temperature changes, can be included in the shipping container.
- the monocytes can be shipped in an insulated container (e.g., ThermoSafeTM model E65 polyurethane foam insulated container), and packed with ThermoSafeTM U-tek gel packs and gel mats as shown in FIG. 1 .
- an insulated container e.g., ThermoSafeTM model E65 polyurethane foam insulated container
- ThermoSafeTM U-tek gel packs and gel mats as shown in FIG. 1 .
- a 16 oz U-tek gel mat adjusted to a temperature of ⁇ 1° C. is laid flat in the bottom of the E65 container.
- Two 16 oz U-tek gel mats ( ⁇ 1° C.) are folded and placed between the first gel mat and the short wall of the E65 container.
- Two 16 oz U-tek gel (adjusted to +18° C.) are then placed vertically next to the previous gel mats.
- a ThermoSafeTM INF3000 transplant container is placed between the gels.
- the leukapheresis bags are placed in a sealed inner bag (STP711).
- a device which records the temperature of the inner bag can be used to monitor the temperature during shipment.
- One such device is the ThermoSafeTM DataLogger.
- the inner bag is placed in a sealed outer bag (STP710) and then the bags are placed in the INF3000 container.
- a 16 oz U-tek gel (+18° C.) is placed on top of the closed INF300 container, topped with Kraft paper and then a 4′′ foam plug. The box is then sealed with tape and ready for shipment.
- the leukapheresis product can be further processed or purified, for example by Ficoll density gradient centrifugation at room temperature in 50 ml conical tubes to separate and concentrate the mononuclear cell fraction that includes dendritic cell precursors (monocytes).
- the cell concentration and cell viability can be determined.
- Methods of enriching for monocytes include, but are not limited to, density gradient centrifugation (e.g, dilute Ficoll density gradient centrifugation, dilute Percoll density gradient centrifugation, etc.), elutriation, adherence to plastic, tangential flow filtration, fluorescence activated cell sorting (FACS), immunological cell separation techniques (antibody panning to select monocytes or to remove non-monocytes (e.g., leukocytes, macrophages, granulocytes, etc), differential lysis, magnetic cell sorting, etc.), culture in plastic culture bags coated with plastic microcarrier beads, etc. See, for example, O'Doherty et al.
- magnetic cell sorting can be used to enrich form monocytes by positive selection (CD14+ cells) or by negative selection (i.e., removal of cells that are not monocytes; e.g., CD3+, CD19+ and CD2+ cells).
- monocytes are enriched from the leukapheresis product by elutriation, an automated method to isolate monocytes from the subject leukapheresis.
- Methods of leukapheresis are known in the art.
- elutriation can be performed on the Gambro BCT ElutraTM Cell Separation System (Gambro BCT, Lakewood, Colo.).
- Elutriation buffer can be prepared by adding 1000 mL of 5% Human Albumin Serum (HSA) to a 4 L bag of Hank's Balanced Salt Solution (HBSS).
- HSA Human Albumin Serum
- HBSS Hank's Balanced Salt Solution
- the cells can be fractionated by elutriation according to the manufacturer's protocol.
- a modified version of the manufacturer's (Gambro) protocol is used for elutriation, where the final rotor off fraction is the fourth fraction instead of the fifth fraction.
- CBC with differential analysis can performed on the monocyte fraction to verify purity and recovery. Alternatively, monocyte purity can be assessed by immunophenotyping with CD14.
- the enriched monocytes can then be differentiated into dendritic cells, or can be frozen and stored for later use. In one embodiment, the cells are frozen in 25 ml or 50 mL freezing bags. Examples of freezing bags include CryocyteTM freezing bags, OrigenTM freezing bags (Cryostore) and PallTM freezing bags.
- each freezing bag contains 15 mL of up to 3 ⁇ 10 9 cells in culture medium (e.g., AIM V, X-VIVO, RPMI, etc.) with approximately 10-12% DMSO and 10-20% heat inactivated, filtered plasma, about 107 to 507 mg/L final concentration of CaCl 2 and about 44 to 241 mg/L final concentration of MgSO 4 .
- culture medium e.g., AIM V, X-VIVO, RPMI, etc.
- the cells can be frozen using a controlled rate freezer, then stored cryogenically.
- the PBMCs are resuspended in AIM-V® medium and seeded in T150 cm 2 flasks at 2.0 ⁇ 10 8 cells per flask.
- the PBMCs may be frozen and combined with a second leukapheresis.
- Monocytes are selected from the mononuclear cell population of PBMCs by adhesion to sterile tissue culture plastic flasks for one to two hours at 37° C., 5% CO 2 , ⁇ 75% humidity. Non-adherent and semi adherent cells are removed. PBS is added to the flasks to remove the remaining non-adherent cells, semi-adherent cells and residual medium. The remaining adherent cells are predominantly monocytes, and represent a population of enriched monocytes.
- Examples of alternative methods for differentiating monocytes into dendritic cells include, but are not limited to exposure to physical perturbation (e.g., shearing), irradiation in the presence of a photo-activatable agent capable of forming photoadducts with cellular DNA components, and/or treatment with a DNA binding agent, followed by incubation with disease effector agents, such as microbes, fungi, viruses, and malignant cells. See U.S. Pat. No. 6,607,722, the contents of which are incorporated by reference.
- monocytes are differentiated into dendritic cells by culture in medium comprising a composition that induces differentiation of monocytes into dendritic cells.
- Suitable media for the culture of monocytes, immature and mature dendritic cells includes, but is not limited to, AIM-V, X-VIVO-15, RPMI, DMEM, and the like.
- Compositions that induce the differentiation of monocytes into dendritic cells are known in the art, and include, but are not limited to, GM-CSF plus IL-4; GM-CSF plus IL-13; and IFN ⁇ .
- enriched monocytes are differentiated into dendritic cells by culture in the presence of GM-CSF and IL-4 (see, e.g., WO 97/29182; Sallusto and Lanzavecchia (1994) J. Exp. Med. 179:1109; and Romani et al. (1994) J. Exp. Med. 180:83-93).
- enriched monocytes preferably at a concentration of 1 ⁇ 10 6 cells/ml are cultured in AIM V medium, X-VIVO 15 medium, or other suitable medium in the presence 800 U/ml GM-CSF and 500 U/ml IL-4 for approximately 4-7 days, preferably 6 days at 37° C., 5% CO 2 , ⁇ 75% humidity to allow the differentiation of monocytes into immature dendritic cells.
- Cytokine concentrations can be varied.
- preferred concentrations of GM-CSF are 500 to 1500 U/ml, more preferably 700 to 1000 U/ml, most preferably 800 U/ml.
- Preferred concentrations of IL-4 are 400-1500 U/ml, more preferably 450 to 1000 U/ml, most preferably 500 U/ml.
- IL-13 or IL-15 can be used in place of or in addition to IL-4.
- IFN ⁇ can be used in place of GM-CSF plus IL-4, IL-13 or IL-15.
- compositions that induce maturation of immature dendritic cells include, but are not limited to, monocyte conditioned medium; PBMC conditioned medium; fixed Staphylococcus aureus (PansorbinTM); lipopolysacharrides (LPS); other bacterial cell products, such as monophosphoryllipid A (MPL), lipoteichoic acid, etc.; phosphorylcholine; calcium ionophores; phorbol esters such as PMA; heat-shock proteins; nucleotides, such as ATP, etc.; lipopeptides; Toll-like receptor 4; artificial ligands for Toll-like receptors; double stranded RNA, such as poly-I:C, etc.; immunostimulant DNA sequences; maturation cocktail (TNF- ⁇
- a maturation cocktail containing TNF ⁇ , IL-6, IL-1 ⁇ and PGE 2 is added to a culture of immature dendritic cells. The cells are then cultured overnight (approximately 12 hours or more) to produce mature dendritic cells.
- immature dendritic cells are transfected, preferably by electroporation, with mRNA encoding CD40L, and optionally with mRNA encoding one or more antigens, and then cultured overnight (approximately 12 hours or more) in the presence of IFN ⁇ and optionally PGE 2 to produce mature dendritic cells.
- a human CD40L cDNA and protein are shown in SEQ ID NO:120 and SEQ ID NO:121, respectively.
- Other CD40L mRNAs are known to those of skill in the art.
- a maturation formulation in AIM V medium is added directly to the immature DC to give a final concentration of TNF- ⁇ (10 ng/ml), IFN- ⁇ (1000 U/ml), and PGE 2 (1 ⁇ g/ml).
- the cells can then cultured overnight (approximately 12 hours or more) to produce mature dendritic cells. Maturation can optionally be further increased by exposure of the cells to CD40 Ligand (CD40L), either added to the culture media, or more preferably expressed within the cell.
- CD40L can be expressed constitutively or transiently.
- the mature dendritic cells are transfected with an mRNA encoding CD40L, and optionally with mRNA encoding one or more antigens of interest.
- antigens can be loaded into immature or mature dendritic cells.
- the antigen will then be processed and presented by the mature DCs.
- antigens include, but are not limited to, viral particles, bacteria, or other pathogens, proteins, and fragments thereof, polypeptides, pathogen lysates, pathogen extracts, pathogen nucleic acids, cancer cells, cancer cell proteins and fragments thereof, cancer cell lysates, cancer cell extracts and cancer cell nucleic acids.
- Antigens can be naturally occurring, chemically processed or recombinantly produced.
- the antigens can be delivered to the cells as polypeptides, proteins or as nucleic acids using methods known in the art.
- an antigen may be delivered in its “natural” form in that no human intervention was involved in preparing the antigen or inducing it to enter the environment in which it encounters the dendritic cell.
- the antigen may comprise a crude preparation, for example of the type that is commonly administered in a conventional allergy shot or in a tumor lysate.
- the antigen may alternatively be substantially purified, e.g., at least about 90% pure.
- the antigen is a peptide
- it may be generated, for example, by proteolytic cleavage of isolated proteins. Any of a variety of cleavage agents may be utilized including, but not limited to, pepsin, cyanogen bromide, trypsin, chymotrypsin, etc.
- cleavage agents including, but not limited to, pepsin, cyanogen bromide, trypsin, chymotrypsin, etc.
- peptides may be chemically synthesized, preferably on an automated synthesizer such as is available in the art, or recombinantly expressed.
- recombinant techniques may be employed to create a nucleic acid encoding the peptide of interest, and to express that peptide under desired conditions.
- antigen encoding nucleic acids may be purified or derived from a cell, tissue or virus.
- the antigen can have a structure that is distinct from any naturally-occurring compound.
- the antigen is a “modified antigen” in that the antigen has a structure that is substantially identical to that of a naturally-occurring antigen but that includes one or more deviations from the precise structure of the naturally-occurring compound.
- a modified antigen as compared with that protein or polypeptide antigen would have an amino acid sequence that differs from that of the naturally-occurring antigen in the addition, substitution, or deletion of one or more amino acids, and/or would include one or more amino acids that differ from the corresponding amino acid in the naturally-occurring antigen by the addition, substitution, or deletion of one or more chemical moieties covalently linked to the amino acid.
- the naturally-occurring and modified antigens share at least one region of at least 5 amino acids that are at least 75% identical.
- Naturally-occurring and modified protein or polypeptide antigens can show at least approximately 80% identity, more alternatively 85%, 90%, 95%, or greater than 99% identity in amino acid sequence for at least one region of at least 5 amino acids. Often, it may be useful for a much longer region (e.g., 10, 20, 50, or 100 or more amino acids) of amino acid sequence to show the designated degree of identity.
- the antigen is delivered as a polynucleotide or gene encoding the antigen, so that expression of the gene results in antigen production either in the individual being treated (when delivered in vivo) or the cell culture system (when delivered in vitro).
- Techniques for generating nucleic acids including an expressible gene or mRNA, and for introducing such nucleic acids into an expression system in which any protein encoded by the expressible gene will be produced are known in the art and briefly described infra.
- the antigen is delivered as an mRNA.
- RNA or mRNA obtained from a cell for example a cancer cell, pathogen cell or pathogen-infected cell
- RNA or mRNA can be amplified prior to loading.
- total or targeted mRNA is amplified by RT-PCR using a primer containing a sense promoter to make a cDNA expression construct.
- RNA transcribed in vitro from the expression construct can then be used to load the cells.
- Methods for isolating, amplifying, in vitro transcribing the RNA and loading RNA or other nucleic acids into dendritic cells are known to those of skill in the art. See, for example, PCT/US04/39539 and U.S. provisional application 60/522,310, the contents of which are incorporated by reference.
- the antigen is one or more HIV proteins or fragments thereof.
- plasma from an HIV infected patient can serve as a source for isolation of HIV RNA.
- a portion of the plasma is centrifuged, and the supernatant is collected and filtered using 0.22 ⁇ m filters and stored at ⁇ 20° C. until use in formulation of the dendritic cell vaccine.
- the HIV RNA present in plasma is amplified by RT-PCR and in vitro transcription reactions to provide a sufficient quantity of amplified HIV RNA for loading into dendritic cells.
- viral RNA is reverse transcribed in to single-stranded (ss) DNA using a reverse transcriptase, appropriate reaction buffers and random hexamers or targeted reverse primers.
- the single-stranded cDNA is then amplified by PCR into double-stranded DNA in a primary PCR reaction using multiplex primers.
- the identity of region(s) amplified in the primary PCR reaction is determined by the selection of specific primers complimentary to target sequences which flank those regions.
- the product of the primary PCR reaction is purified using a QIAquick® PCR Purification Kit and then serves as the template in a second round or nested PCR amplification.
- the 5′ primers(s) contains an overhang with an RNA polymerase binding site (e.g., a T7 promoter), and the 3′ primer contains an overhang with poly T stretches.
- the modifications introduced by the overhanging regions in a nested round of PCR enable transcription of the PCR product in vitro and successful translation upon delivery into dendritic cells. Purification of the in vitro transcribed RNA is performed using the Qiagen RNeasy® Kit, and the RNA is eluted in nuclease-free water. If necessary, ethanol precipitation is performed to concentrate the RNA.
- RNA is re-suspended in nuclease-free water and passed through a 0.8/0.2 ⁇ m polyethersulfone (PES) filter, then dispensed into 0.5 ml safe-lock polypropylene tubes and loaded into DC or cryopreserved at ⁇ 150° C. for until thawing prior to transfection.
- PES polyethersulfone
- RNA or mRNA is extracted from one or more cancer cells.
- the RNA or mRNA can be loaded directly into dendritic cells, or it can first be amplified by RT-PCR and in vitro transcription using the methods described in PCT/US04/39539.
- Dendritic cells may be loaded with one or more antigens as immature dendritic cells, mature dendritic cells, or during differentiation from immature to mature dendritic cells.
- Dendritic cells are capable of ingesting antigens, such as proteins, peptides, viruses, cells, cell lysates, and the like. Accordingly, antigen loading can be performed simply by contacting the dendritic cell with the antigen or nucleic acid encoding the antigen.
- Other methods for loading dendritic cells are known to those of skill in the art, including, but not limited to nucleic acid transfection, exosomes, viral vectors, microparticle delivery, etc. See for example, Mitchell et al.
- One or more antigens may be loaded directly into the dendritic cells, or nucleic acids encoding one or more antigens may be loaded (transfected) into the dendritic cells.
- the dendritic cells are loaded with nucleic acids encoding one or more antigens.
- the nucleic acid is an mRNA.
- dendritic cells with proteins, polypeptides, peptides, cell or tissue extracts and other types of antigens are known to those of ordinary skill in the art.
- immature dendritic cells are loaded with one or more antigens.
- peptides, polypeptides and/or cell or tissue extracts are loaded simply by incubation with immature dendritic cells in culture medium.
- immature dendritic cells are harvested by tapping the culture flask to dislodge the cells. Cells in suspension are then transferred to conical tubes. PBS is added to the culture flask to remove the remaining floating cells and residual medium, which is added to the conical flask. Some immature dendritic cells may remain adherent to the flask. Detachment of these cells is promoted by adding PBS and incubating the flasks at anywhere from 2° C. up to room temperature. At the end of the incubation period, the flasks are tapped and the dislodged cells are added to the conical tubes.
- the total cell suspension is then pelleted, washed in PBS and re-suspended in chilled ViaSpan® at 4 ⁇ 10 7 /ml in 0.5 ml and placed on ice.
- DCs are mixed with mRNA at 2 ⁇ g/10 6 cells for mRNA encoding antigen(s) and placed in a 4 mm gap electroporation cuvette and electroporated at a pulse of 275-350V, 100-300 ⁇ and 150 ⁇ F, and preferably at 325V, 200 ⁇ .
- DCs are washed in X-VIVO 15 medium and re-suspended at 1 ⁇ 10 6 /ml in X-VIVO 15 supplemented with GM-CSF (800 U/ml), IL-4 (500 U/ml) and PGE 2 (1 ⁇ g/ml), TNF- ⁇ (10 ng/ml), IL-1 ⁇ (10 ng/ml) and IL-6 (100 ng/ml).
- the immature dendritic cells are then incubated overnight at 37° C., 5% CO 2 , ⁇ 75% humidity to produce stably mature dendritic cells. Mature dendritic cells are then washed in PBS.
- immature dendritic cells are matured using CD40L and IFN- ⁇ .
- immature DCs are transfected with 4 ⁇ g CD40L mRNA per 10 6 and mRNA (2 ⁇ g/10 6 cells) encoding one or more antigens by electroporation as described above, and then are cultured overnight in X-VIVO 15 supplemented with GM-CSF (800-1000 U/ml), IL-4 (500-1000 U/ml), IFN- ⁇ (500-1000 U/ml) or TNF- ⁇ (10 ng/ml) and PGE 2 (1 ⁇ g/ml) to generate stable mature dendritic cells.
- Dendritic cells matured by this process secrete higher levels of IL-12 (a T cell growth factor), and minimal IL-10, as compared to dendritic cell matured by the cytokine cocktail process described above.
- Mature Dendritic cells can be loaded with antigen by methods known to those of skill in the art.
- a maturation formulation in AIM V medium is added directly to the immature DC to give a final concentration of TNF- ⁇ (10 ng/ml), IFN- ⁇ (1000 U/ml), and PGE 2 (1 ⁇ g/ml).
- the cells are then cultured overnight to produce mature dendritic cells.
- the DC are then harvested and co-electroporated with 1 ⁇ g of antigen encoding RNA and optionally with 4 ⁇ g of CD40L RNA per 10 6 cells.
- the cells are cultured for 4 hours at 1 ⁇ 10 6 cells AIM V medium supplemented with GM-CSF (800 U/mL), and IL-4 (500 U/mL).
- the cells can then be formulated for administration to a subject without freezing, or formulated for freezing.
- the cells are preferably formulated in heat inactivated autologous plasma, 10% DMSO, and 5% dextrose at 2 ⁇ 10 7 cells/mL.
- Cryogenic vials are filled with 0.7 mL for a total number of 1.4 ⁇ 10 7 cells per vial.
- Vials are then frozen in alcohol boxes at ⁇ 85° C. for a minimum of 4 hours and transferred to the cryogenic freezer for storage.
- the frozen dendritic cell vaccine can then be thawed and administered to a subject without washing or reformulation.
- DCs are harvested and re-suspended in chilled PBS/1% FCS.
- Phycoerythrin (PE) or FITC conjugated antibodies specific for MHC molecules (HLA-ABC, HLA-DR), co-stimulatory molecules (CD80, CD86), maturation markers (CD83) and monocyte markers (CD14) are mixed with 1 ⁇ 10 5 DCs per well in a 96 well plates (BD Biosciences) and incubated at 4° C. for a minimum of 15 minutes. Isotype matched antibodies were used as controls. After thorough washing, fluorescence analysis was performed with a FACScalibur flow cytometer (BD Biosciences) using CellQuest software (BD Biosciences).
- the mature dendritic cells are washed and resuspended in heat-inactivated plasma (preferably autologous plasma) and 10% dextrose at a concentration of 4 ⁇ 10 7 cells/ml.
- the cells can then be diluted 1:1 with a mixture of heat-inactivated plasma and 20% DMSO to give a final concentration of 5% dextrose, 10% DMSO in heat-inactivated plasma.
- the target final filled formulation is 1.4 ⁇ 10 7 cells/0.7 ml in a container suitable for cyropreservation.
- the dendritic cells can then be administered to a patient or frozen, preferably at ⁇ 85° C., and stored in cryogenic freezer (preferably in a dry liquid nitrogen freezer designed to prevent contamination), preferably at a temperature of ⁇ 150° C.
- cryogenic freezer preferably in a dry liquid nitrogen freezer designed to prevent contamination
- the frozen vaccine can then be shipped to a clinical site for patient administration (preferably by intradermal injection). Upon thawing, the vaccine can be administered directly to the patient without further processing.
- Suitable formulations for administration can include aqueous isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, preservatives, immunostimulants, cytokines and adjuvants.
- aqueous isotonic sterile injection solutions which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient
- aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, preservatives, immunostimulants, cytokines and adjuvants.
- mature dendritic cells are suspended in heat-inactivated autologous plasma and 10% dextrose, at a final concentration of 4 ⁇ 10 7 cells/ml. These cells are then diluted 1:1 with a mixture of heat-inactivated autologous plasma and 20% DMSO to give a final concentration of 2 ⁇ 10 7 cells/ml in heat inactivated autologous plasma which contains 5% dextrose and 10% DMSO. The final filled formulation is 1.4 ⁇ 10 7 cells/0.7 ml in a container suitable for cyropreservation. The vaccine is then frozen and stored at ⁇ 150° C. in a dry liquid nitrogen freezer. The vaccine is ready for administration after thawing, without the need for washing and resuspending.
- the dendritic cell vaccine can be administered by a variety of methods, such as, but not limited to, injection (e.g., subcutaneous, intradermal, intravenous, intralymphatic, intraarticular, intramuscular, intraperitoneal), by continuous infusion, sustained release from implants, etc.
- DC vaccines have typically been administered at two to four week intervals.
- the dendritic cell vaccine can be administered with physiologically acceptable carriers, buffers, dilutents, adjuvants, immunomodulaters, etc.
- the dendritic cell vaccine is autologous to the patient it is administered to, or is HLA matched.
- the dose of cells (e.g., activated T cells, or dendritic cells) administered to a subject is in an effective amount, effective to achieve the desired beneficial therapeutic response in the subject over time, or to inhibit growth of cancer cells, or to inhibit infection.
- a preferred dose is approximately 10 7 cells.
- Biological response modifiers are optionally added for treatment by the DCs or activated T cells of the invention.
- the cells are optionally administered with an adjuvant, or cytokine such as GM-CSF, IL-12 or IL-2.
- the immunogenicity of the antigen-loaded dendritic cells or educated T cells produced by the methods of the invention can be determined by well known methodologies including, but not limited to the following:
- 51 Cr-release lysis assay Lysis of peptide-pulsed 51 Cr-labeled targets by antigen-specific T cells can be compared. “More active” compositions will show greater lysis of targets as a function of time. The kinetics of lysis as well as overall target lysis at a fixed timepoint (e.g., 4 hours) may be used to evaluate performance. Ware, C. F. et al. (1983) J. Immunol. 131:1312.
- Cytokine-release assay Analysis of the types and quantities of cytokines secreted by T cells upon contacting modified APCs can be a measure of functional activity. Cytokines can be measured by ELISA or ELISPOT assays to determine the rate and total amount of cytokine production. Fujihashi, K. et al. (1993) J. Immunol. Meth. 160:181; Tanquay, S. and Killion, J. J. (1994) Lymphokine Cytokine Res. 13:259.
- compositions of the invention can be assayed for the ability to elicit reactive T cell populations from normal donor or patient-derived PBMC.
- elicited T cells can be tested for lytic activity, cytokine-release, polyclonality, and cross-reactivity to the antigenic epitope. Parkhurst, M. R. et al. (1996) J. Immunol. 157:2539.
- T cells will proliferate in response to reactive compositions. Proliferation can be monitored quantitatively by measuring, for example, 3H-thymidine uptake. Caruso, A. et al. (1997) Cytometry 27:71.
- Transgenic animal models Immunogenicity can be assessed in vivo by vaccinating HLA transgenic mice with the compositions of the invention and determining the nature and magnitude of the induced immune response.
- the hu-PBL-SCID mouse model allows reconstitution of a human immune system in a mouse by adoptive transfer of human PBL.
- These animals may be vaccinated with the compositions and analyzed for immune response as previously mentioned in Shirai, M. et al. (1995) J. Immunol. 154:2733; Mosier, D. E. et al. (1993) Proc. Natl. Acad. Sci. USA 90:2443.
- a non-human primate (chimpanzee) model system can be utilized to monitor in vivo immunogenicities of HLA-restricted ligands. It has been demonstrated that chimpanzees share overlapping MHC-ligand specificities with human MHC molecules thus allowing one to test HLA-restricted ligands for relative in vivo immunogenicity. Bertoni, R. et al. (1998) J. Immunol. 161:4447.
- TCR Signal Transduction Events Several intracellular signal transduction events (e.g., phosphorylation) are associated with successful TCR engagement by MHC-ligand complexes. The qualitative and quantitative analysis of these events have been correlated with the relative abilities of compositions to activate effector cells through TCR engagement. Salazar, E. et al. (2000) Int. J. Cancer 85:829; Isakov, N. et al. (1995) J. Exp. Med. 181:375).
- phosphorylation e.g., phosphorylation
- Cell isolation or immunoassays for detection of cells during cell purification can be performed in any of several configurations, e.g., those reviewed in Maggio (ed.) (1980) Enzyme Immunoassay CRC Press, Boca Raton, Fla.; Tijan (1985) “Practice and Theory of Enzyme Immunoassays,” Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers B.V., Amsterdam; Harlow and Lane, supra; Chan (ed.) (1987) Immunoassay: A Practical Guide Academic Press, Orlando, Fla.; Price and Newman (eds.) (1991) Principles and Practice of Immunoassays Stockton Press, NY; and Ngo (ed.) (1988) Non-isotopic Immunoassays Plenum Press, NY.
- Cells can be isolated and characterized by flow cytometry methods such a FACS analysis.
- flow cytometry methods such a FACS analysis.
- a wide variety of flow-cytometry methods are known.
- fluorescence activated flow cytometry see, for example, Abbas et al. (1991) Cellular and Molecular immunology W.B. Saunders Company, particularly chapter 3, and Kuby (1992) Immunology W.H. Freeman and Company, particularly chapter 6.
- FACS machines are available, e.g., from Becton Dickinson.
- Labeling agents which can be used to label cell antigen include, but are not limited to monoclonal antibodies, polyclonal antibodies, proteins, or other polymers such as affinity matrices, carbohydrates or lipids. Detection proceeds by any known method, such as immunoblotting, western blot analysis, tracking of radioactive or bioluminescent markers, capillary electrophoresis, or other methods which track a molecule based upon size, charge or affinity.
- PBMCs Peripheral blood mononuclear cells
- mononuclear cells were resuspended in StemSpanTM H2000 medium (StemCell Technologies, Inc.) and seeded in T150 cm 2 flasks at 2.0 ⁇ 10 8 cells per flask. Monocytes were then selected from the mononuclear cell population by adhesion to the sterile tissue culture plastic flask for 1-2 hours at 37° C., 5% CO 2 , ⁇ 75% humidity. Non-adherent and semi-adherent cells (primarily lymphocytes) were discarded.
- the remaining adherent cells which were predominantly monocytes, were cultured in StemSpanTM H2000 medium containing GM-CSF (800 U/ml) and IL-4 (500 U/ml). These cells were incubated for 6 days at 37° C., 5% CO 2 , ⁇ 75% humidity to allow the differentiation of monocytes into immature dendritic cells.
- the immature dendritic cell-rich population was harvested by gently tapping the flasks to dislodge the cells.
- Cells in suspension were transferred to conical tubes.
- Additional PBS was added to the flasks to remove the remaining floating cells and residual media and added to the cell suspension in the conical tubes.
- Detachment of the remaining adherent cells was completed by adding PBS and incubating the flasks at 2-8° C. for approximately 10 minutes. While these cells were incubating, the cell suspension in the conical tubes was centrifuged, and the cell pellet was resuspended in PBS. At the end of the incubation period, the flasks were gently tapped and the contents added to the cell suspension in the conical tubes.
- the total cell suspension was pelleted and resuspended in PBS, and a sample was removed for cell concentration, cell viability and immunophenotyping.
- the following four sets of cell markers were examined by flow cytometry: monocyte lineage markers (CD3, CD14, CD19, and CD56), indication of presence of dendritic cells (CD11c), an antigen presenting cell marker (HLA-DR), and a mature dendritic cell marker (CD83).
- the immature dendritic cell-enriched preparation expressed insignificant levels of lineage markers and CD83, and high levels of CD11c and HLA-DR.
- Immature dendritic cells were washed once with OPTI-MEM® I reduced serum medium (GIBCOTM) with HEPES buffer, L-glutamine, without phenol red.
- the dendritic cells were then transfected with amplified tumor RNA by electroporation at a ratio of approximately 2 ⁇ g of RNA per 10 6 dendritic cells. Electroporation was performed in 4 mm gap cuvettes containing 600 ⁇ L of a cell suspension containing 5 ⁇ 10 7 cells/ml, at a pulse of 500 V for 500 ⁇ s.
- transfected cells were transferred into T150 flasks (one cuvette per flask) containing StemSpan H2000TM medium (serum free culture medium), supplemented with IL-4 (500 U/ml) and GM-CSF (800 U/ml). Transfected cells were incubated at for 2-3 hours at 37° C., 5% CO 2 , ⁇ 75% humidity to allow the cells to recover from electroporation.
- StemSpan H2000TM medium serum free culture medium
- IL-4 500 U/ml
- GM-CSF 800 U/ml
- the immature electroporated dendritic cells were matured in StemSpan H2000TM medium, supplemented with IL-4 (500 U/ml) and GM-CSF (800 U/ml) and a maturation cocktail (IL-1 ⁇ at 5 ng/ml, IL-6 at 150 ng/ml, TNF- ⁇ at 5 ng/ml and PGE 2 at 1 ⁇ g/ml) at 37° C., 5% CO 2 , ⁇ 75% humidity for 20-24 hours. All cytokines, as well as PGE 2 , were reconstituted or diluted (in the case of PGE 2 ) in PBS with 1% HSA. Prior to the dilution step, PGE 2 was reconstituted in ethanol.
- Transfected mature dendritic cells were suspended in autologous plasma at a final concentration of 2 ⁇ 10 7 cells/ml. The cells were then diluted 1:1 with a mixture of 80% plasma and 20% DMSO to give a final concentrations of 3 ⁇ 10 6 or 1 ⁇ 10 7 cells/ml in 90% plasma with 10% DMSO, then frozen in cryovials using controlled-rate freezing, and stored at ⁇ 150° C.
- Dendritic Cell Vaccines Prepared from Day-Old Leukapheresis Product Remain Viable for at Least 2 Hours Post Thaw in 10% DMSO
- a frozen dendritic cell vaccine prepared as described in Example 1 was thawed at 37° C., and kept at 20-25° C. or at 2-8° C. for 2 hours. Viability was determined immediately post-thaw and at 30 minute intervals for up to two hours. Viability immediately post-thaw at 37° C. was 92%. The results are shown in Table 2, and confirm that the vaccine can be thawed and stored in 10% DMSO for at least two hours.
- Peripheral blood mononuclear cells and plasma were collected from a patient or volunteer by leukapheresis at room temperature at a clinical site.
- the leukapheresis product (PBMCs) and serum were shipped overnight in a temperature controlled container maintained in a temperature range of 6-28° C.
- the day following leukapheresis the PBMCs were purified by Ficoll density gradient centrifugation in 50 ml conical tubes at room temperature to separate and concentrate the mononuclear cell fraction that includes monocytes (the dendritic cell precursors) and leukocytes.
- the mononuclear cells were washed several times in phosphate buffered saline (PBS), and the cell concentration was determined.
- PBS phosphate buffered saline
- mononuclear cells were resuspended in AIM-V medium and seeded in T150 cm 2 flasks at 2.0 ⁇ 10 8 cells per flask.
- Monocytes were then selected from the mononuclear cell population by adhesion to sterile tissue culture flasks for one to two hours at 37° C., 5% CO 2 , ⁇ 75% humidity.
- Nonadherent and semi-adherent cells were removed by gentle washing with PBS.
- the remaining adherent cells which were predominantly monocytes, were cultured in X-VIVO 15 culture medium containing 1000 U/ml GM-CSF and 1000 U/ml IL-4. The cells were incubated for 6 days at 37° C., 5% CO 2 , ⁇ 75% humidity to allow differentiation of monocytes into immature dendritic cells.
- the immature dendritic cell-rich population was harvested by tapping the flasks to dislodge the cells. Cells in suspension were transferred to conical tubes. PBS was added to the flasks to remove the remaining floating cells and residual medium, and then added to the cell suspension in the same conical tubes. Detachment of remaining adherent immature dendritic cells was promoted by incubation in PBS at 2-8° C. At the end of the incubation period, the flasks were tapped and the contents added to the cell suspension in the same conical tubes. The total cell suspension was then pelleted and resuspended in PBS, and a sample was removed to determine the cell concentration.
- Immature dendritic cells were washed and resuspended in ViaSpan and transfected with 2 ⁇ g antigen-encoding mRNA per 10 6 dendritic cells. Electroporation was performed in 4 mm gap cuvettes containing 0.4 ml of the cell suspension (4 ⁇ 10 7 cells/ml) at a pulse of 300V, 100 ⁇ and 150 ⁇ F.
- transfected cells were diluted with X-VIVO 15 medium, centrifuged and resuspended in X-VIVO 15 medium (serum free) supplemented with GM-CSF (800 U/ml), IL-4 (500 U/ml), IL-1 ⁇ (10 ng/ml), IL-6 (150 ng/ml), TNF- ⁇ (10 ng/ml) and PGE 2 (1 ⁇ g/ml).
- the cells were incubated at 37° C., 5% CO 2 , ⁇ 75% humidity overnight to mature.
- Transfected mature dendritic cells were suspended in heat-inactivated autologous plasma and 10% dextrose, at a final concentration of 4 ⁇ 10 7 cells/ml. The cells were then diluted 1:1 with a mixture of 20% DMSO to give a final concentration of 2 ⁇ 10 7 cells/ml in heat-inactivated autologous plasma which contains 10% DMSO and 5% dextrose, and then frozen in sterile cryovials at ⁇ 150° C.
- the data in this example supports the functionality and feasibility of producing RNA transfected dendritic cells from day-old apheresis product.
- Dendritic cells were prepared by the method described in Example 3. The data below shows that dendritic cells can be reproducibly manufactured at the appropriate yield from a single day-old apheresis product and that the resulting cells (1) exhibit a classical mature phenotype, (2) can be efficiently transfected with RNA, and (3) can be cryopreserved with high post-thaw viability.
- CMV-infected subjects were identified by stimulating PBMCs from several blood donors with well-defined immunodominant peptides derived from the pp65 protein and measuring IL-2/IFN- ⁇ secretion as well as cell proliferation in both CD4 and CD8 T cells. Individuals in which positive CMV-specific T cell responses were detected and who agreed to undergo leukapheresis after informed consent were selected for further studies.
- DCs from these individuals were prepared as described above. Mature DCs transfected with RNA encoding the CMV pp65 protein were then incubated for 16 hours (ICS) or 6 days (proliferation) with autologous PBMCs at a 1/40 ratio. After stimulation, IL-2 and IFN- ⁇ secretion ( FIG. 7 ) and proliferation ( FIG. 8 ) of CMV-specific CD4 and CD8 T cells was assessed by flow cytometry. DCs electroporated with CMV pp65 RNA selectively induced high IFN- ⁇ and IL-2 expression as well as proliferation of CD8 T cells from CMV-infected subjects. However, this protocol induces minimal CD4 T cell activation, as shown by the low level of cytokine secretion and proliferation detected in CD4 T cells ( FIGS. 7 and 8 , lower panels).
- the cells were resuspended in fresh X-VIVO 15 medium supplemented with 1000 U/ml GM-CSF and 500 U/ml IL-4; the media and cells added back into flasks still containing the adherent cells; and the flasks were incubated @ 37° C. for a further three days.
- DCs were transfected with 2 ⁇ g GFP mRNA per 10 6 cells (20 ⁇ g GFP mRNA per 5 ⁇ 10 6 cells), resuspended in X-VIVO 15 and seeded at 1 ⁇ 10 6 /ml; supplemented with 800 U/ml GM-CSF and 500 U/ml IL-4 and matured with cytokine cocktail (TNF ⁇ —10 ng/ml; IL-1 ⁇ —10 ng/ml; IL-6—100 ng/ml; PGE 2 —1 ⁇ g/ml). The DC's were incubated overnight @ 37° C.; 5% CO 2 .
- Phenotyping was undertaken on immature DC's on day 6 (immature DC; FIG. 9 ) and 24 hours post transfection (mature DC; FIG. 10 ).
- the yield (% Rec) and viability (% V) for each culture condition immediately post transfection and at 24 hour post transfection is shown in Tables 6A-C.
- Elutriation also known as counter-flow centrifugation, was performed on the ElutraTM Cell Separation System (Gambro BCT, Lakewood, Colo.) as an automated method to isolate monocytes from a day old leukapheresis, which had been shipped to the manufacturing facility from a collection site by overnight delivery in a temperature controlled (6-28° C.) container.
- Elutriation buffer was prepared by adding 1000 mL of 5% Human Albumin Serum (HSA, Baxter Healthcare, Westlake, Calif.) to a 4 L bag of Hank's Balanced Salts Solution (HBSS, Cambrex Bio Science, Walkersville, Md.).
- HSA Human Albumin Serum
- HBSS Hank's Balanced Salts Solution
- This elutriation buffer was added to the day old pheresis product in a volume equal to that of the pheresis.
- the ElutraTM Cell Separation System (Gambro BCT, Lakewood, Colo.) was primed with elutriation buffer and the pheresis product was loaded. After the elutriation procedure was performed, monocytes were collected from the rotor off fraction. The monocytes were stored frozen.
- iDC immature dendritic cells
- mDC mature dendritic cells
- Peripheral blood was collected from 3 healthy human donors on three separate days by leukapheresis and transported to the University of Montreal within 30 minutes post collection. Twenty mL of the leukapheresis was removed and autologous plasma was prepared by centrifugation. The leukapheresis volume was divided into two equal parts. One part was processed immediately to generate “fresh” monocytes while the second part was stored as 20 mL aliquots in five 50 mL conical tubes to generate cells from a “day old pheresis”. The tubes were placed in a plastic container within a box that was stored tilted on a rocking platform between 16-20° C. for 24 hours. Following the incubation period, the PBMCs were separated using Ficoll density gradient.
- a mononuclear cell fraction that includes the dendritic cell precursors (monocytes) was separated from both fresh and day old pheresis using a Ficoll density gradient.
- the Leukapheresis was layered onto Ficoll in 50 mL conical tubes and tubes were centrifuged (800 ⁇ g) for 20 minutes at room temperature. Cells were washed four times with phosphate buffered saline (PBS), and counted to determine cell concentration and cell viability.
- PBS phosphate buffered saline
- the mononuclear fraction was further purified using CD14 microbeads (Miltenyi).
- 1 ⁇ 10 9 cells were resuspended in 8 mL of buffer containing PBS, 0.5% BSA, and 2 mM EDTA (Miltenyi buffer). 2 mL of CD14 microbeads were added to each 50 mL tube containing the 1 ⁇ 10 9 cells and incubated at 4° C. for 15 minutes. The cells were washed in 100 mL of the same buffer, centrifuged at 300 ⁇ g and resuspended in 20 mL of Miltenyi buffer. The cell suspension was applied to four LS columns situated under magnetic field (Miltenyi QuadromaxTM). Following application of the cells using gravity flow, the columns were washed three times with 3 mL of Miltenyi buffer.
- the monocytes were eluted twice in the absence of a magnetic field with 5 mL of Miltenyi buffer and centrifuged at 300 ⁇ g for 10 minutes. Purity of both the eluate and flow through fractions were determined with flow cytometry using antibodies specific for CD3, CD19, CD16, CD56, CD14, and CD209. The eluate fraction contained 88-98% monocytes and less than 2% small cells. The nonadherent fractions contained only a small percentage (2%) of monocytes. Total RNA was extracted from a portion of the purified monocytes (50 million) at this time.
- TIP cytokine cocktail
- PBS phosphate buffered saline
- monocyte lineage markers CD3, CD14, CD19, CD16, and CD56
- indication of presence of dendritic cells CD11c, CD1a, and CD209
- an antigen presenting cell marker HLA-II
- markers of migration CD38 and CCR7
- markers for mature dendritic cells CD83 and CD86.
- PME-CD40L DCs were frozen in 90% autologous plasma with 10% DMSO, in cryovials using controlled-rate freezing, and stored at ⁇ 85° C.
- a frozen dendritic cell vaccine prepared as described above was thawed at 37° C., and kept at 20-25° C. for 30 minutes. Viability was determined immediately post-thaw and at 10 minute intervals up to 30 minutes.
- Post Thaw PME-CD40L DCs were analyzed by flow cytometry using antibodies specific for monocyte lineage markers (CD14), dendritic cell markers (CD11c, CD1a, and CD209), an antigen presenting cell marker (HLA-II), markers of migration (CD38 and CCR7) and markers for mature dendritic cells (CD80, CD83 and CD86).
- the data from the three donors demonstrates that positive selection using CD14 bead results in 88-98% pure population of monocytes (Table 7).
- the maximum amount of small cell contamination is 2% (Table 7).
- the nonadherent (flow through) fraction contained up to 2% of monocytes (large cells) in all three donors (data not shown). Therefore, there is no significant loss of monocytes in the nonadherent fraction.
- the small cell population contamination present in the eluate is composed primarily of T cells as evident from high CD3 expression and lower CD19, 16 or 56 markers expression (data not shown). There were no visible differences in expression of CD83, CD86, CD11C, HLA-I, or HLA-II markers in the eluate fraction between fresh and day old leukapheresis.
- the percentage of positive cells refers to the number of cells positive for a marker under investigation.
- the percentage of DCs expressing the surface maturation marker CD83 was lower in TIP-DCs from all 3 donors prepared from fresh leukapheresis than those prepared from day old leukapheresis (Table 8). There were no other differences in any other markers from the TIP-DCs generated from fresh and day old leukapheresis.
- PME-CD40L DCs The DCs post-transfection (PME-CD40L DCs) were analyzed for expression of CD154 (CD40L) four hours after transfection.
- PME-CD40L DCs from day old leukapheresis expressed more CD40L in donors 1 and 2 four hours after transfection than PME-CD40L DCs generated from fresh leukapheresis (Table 9).
- MFI mean fluorescence intensity
- PME-CD40L DCs were analyzed for expression of a variety of DC markers after thawing. There were differences in the phenotype of the post thaw PME-CD40L DCs generated from fresh versus day old leukapheresis. The mean fluorescence intensity of CD40L expression in PME-CD40L DCs prepared from fresh leukapheresis was lower than DCs prepared from day old Leukapheresis (Table 9).
- Percent positive cells measured by flow cytometry revealed that, in two out of three cases, more cells are stained positive with CD83 antibodies in dendritic cells generated from the day old portion of the leukapheresis (Table 10).
- RNA samples from fresh monocytes and day old monocytes (monocytes which had been incubated at 16-20° C. for 24 hours following leukapheresis), and RNA from DCs prepared from fresh and day old monocytes, as described in Example 8, were applied to the Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, Calif.) according to the manufacture's instruction (Genechip® Expression Analysis Technical Manual, 2004). Briefly, three micrograms of total RNA spiked with Genechip® Poly-A RNA Control Kit (Affymetrix, Santa Clara, Calif.) was converted to first-strand cDNA using SuperScriptTM II reverse transcriptase.
- Second-strand cDNA synthesis was followed by in vitro transcription for linear amplification of each transcript and incorporation of biotinylated CTP and UTP.
- the cRNA products were fragmented to around 100 nucleotides, and hybridized for 16 hours to the microarrays.
- the microarrays were then washed at low (6 ⁇ SSPE) and high (100 mM MES, 0.1M NaCl) stringency and stained with streptavidin-phycoerythrin.
- the GeneChip® Scanner 3000 (Affymetrix, Santa Clara, Calif.) was used to collect fluorescence signal at 3 um resolution after excitation at 570 nm. The average signal from two sequential scans was calculated for each microarray feature. Scanned images were analyzed with Genechip® Operating Software v1.1 (Affymetrix, Santa Clara, Calif.). High linear correlation (R 2 >0.95) of 4 control RNAs included in Poly-A RNA Control Kit (Affymetrix, Santa Clara, Calif.) was confirmed to guarantee the success of the labeling process.
- the data was first filtered for flags with missing spots.
- the data was then analyzed with a one way anova without random prediction models with a confidence level ranging from p.05 or p.1.
- the list of filtered genes generated was then analyzed for either fold changes, level of expression, or confidence. This was performed using the samples as averages or as individual samples.
- Level of expression between fresh and day monocytes or dendritic cells were compared prior to or after an anova.
- the lists of genes were compared to one another and those overlapping in several lists were chosen for their reliability. Genes with altered steady state RNA levels in dendritic cells prepared from day old monocytes versus dendritic cell prepared from fresh monocytes are listed in Table 12A. Descriptions of these genes are listed in Table 12B.
- the dendritic cell genes were further normalized to expression of two housekeeping genes shown to remain constant between DCs produced from fresh and day old monocytes.
- the average expression of each gene (normalized) was divided by the average expression (normalized) of GAPDH (glyceraldehyde-3-phosphate dehydrogenase) or ⁇ -actin to produce a ratio of expression relative to the housekeeping gene.
- GAPDH glycosylase dehydrogenase
- ⁇ -actin ⁇ -actin
- RNAs to GAPDH or ⁇ -Actin in DCs prepared from Day Old or Fresh Monocytes GAPDH Gene: GAPDH Gene: Actin Gene: Actin Gene DC do DC f DC do DC f ALOX15 0.45 1.5 0.45 1.52 IL1 ⁇ 0.58 1.38 0.57 1.37 TLR1 0.68 1.49 0.68 1.48 TLR2 0.67 1.34 0.66 1.33 CD69 0.66 1.61 0.65 1.60 CD52 1.86 0.74 1.85 0.74
- TaqMan® Gene Expression Assays or Custom TaqMan® Gene Expression Assays were used as TaqMan® probes. PCR reactions were performed in triplicate using ABsoluteTM QPCR ROX Mix (ABgene, Surrey, UK). Quantitation of relative cDNA concentrations was done using the relative standard curve method as described in ABI Prism® 7700 Sequence Detection System User Bulletin #2 (Applied Biosystems, Foster City, Calif.). One cDNA with the most expression of each gene in the GeneChip analysis was used for generating the relative standard curve. All data are shown as expression relative to internal GAPDH expression. APAF-1 and CDCA2 effector protein 2 were demonstrated to decrease, relative to GAPDH, at least 2.5 fold and 3 fold, respectively between fresh and day old monocytes.
- PBMCs leukopheresis product
- PBMCs were prepared by ficoll-histopaque density centrifugation, and washed four times in PBS at room temperature. 2 ⁇ 10 8 PBMCs were re-suspended in 30 ml AIM-V medium (Invitrogen) and allowed to adhere to 150 cm 3 plastic flasks for 2 hours at 37° C. Non-adherent cells were removed and remaining cells cultured in X-VIVO 15 medium, supplemented with 1000 U/ml GM-CSF (Leukine) and 1000 U/ml IL-4 (R&D systems), for 5 days at 37° C., 5% CO 2 .
- AIM-V medium Invitrogen
- Immature DCs were initially matured by addition of TNF- ⁇ (10 ng/ml), IFN- ⁇ (1000 U/ml) and PGE 2 (1 ⁇ g/ml). After overnight culture, the TIP-DC intermediate products were harvested by removal of media, and a cold PBS wash. TIP-DC were phenotyped to confirm the generation of a mature population of cells. To generate antigen-loaded, fully mature DC, the TIP-DC were electroporated: Cells were re-suspended in chilled Viaspan at 4 ⁇ 10 7 /ml in 0.5 ml and placed on ice.
- DCs were mixed with amplified total tumor renal cell carcinoma mRNA at 1 ⁇ g/10 6 cells, as a model antigen-encoding payload, plus 4 ⁇ g/10 6 CD40L mRNA, and placed in a 4 mm gap electroporation cuvette, followed by electroporation using a Biorad GenePulsar Xcell system. Immediately after electroporation, DCs were washed in X-VIVO 15 medium and finally re-suspended in 20 ml of X-VIVO 15 supplemented with GM-CSF (800 U/ml) and IL-4 (500 U/ml) at 1 ⁇ 10 6 /ml, and cultured for 4 hours at 37° C. in low adherence T75 flasks.
- GM-CSF 800 U/ml
- IL-4 500 U/ml
- PBMCs 3 ⁇ 10 5 cells were each stained with CD19-PE, CD14-PE and CD3-PE, or matched isotype conjugated controls by incubation in antibody for 30 minutes at 4 C. After incubation, the stained cells were washed 3 times in cold 1% FBS/PBS and resuspended in PBS for fluorescence analysis using a FACScalibur flow cytometer (BD Biosciences) using CellQuest software (BD Biosciences). 3 minutes prior to acquisition, propidium iodide (1 ug/ml) was added to each sample as a viability dye for gating purposes.
- DCs 1 ⁇ 10 6 cells (TIP-DC and PME-CD40L DC) were re-suspended in chilled PBS/1% FBS.
- Intracellular CD40L was determined as follows: 2 ⁇ 10 5 PME-CD40L DCs re-suspended in 250 ⁇ L of Cytofix/Cytoperm solution (BD Biosciences) for a minimum of 10 minutes up to 2 hours at 4° C. Cells were washed twice with 2 ml staining buffer (PBS, BSA, NaN 3 , and EDTA), re-suspended in 0.5 ml staining buffer and stored over night at 4° C. Cells were re-suspended in 2.0 ml Perm/Wash solution (BD Biosciences) for 15 minutes, centrifuged and re-suspended in 100 ⁇ l Perm/Wash solution.
- 2 ml staining buffer PBS, BSA, NaN 3 , and EDTA
- mice anti-human CD40L APC or mouse IgG1 APC was added to each DC preparation and incubated at 4° C. for 30 minutes in the dark. Cells were washed twice with 1 ml Perm/Wash solution and re-suspended in staining buffer prior to flow cytometric analysis. The results are shown in Table 18.
- compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
- Tables 17 and 18 show that TIP-DCs generated from the various starting products are equally amenable to electroporation, and recovery, with full maturation into the final product, PME-CD40L DC.
- PME-CD40L DC generated from this study can be formulated as ‘vaccine’ and frozen and thawed without any deterioration of the DC preparations.
- apheresis products held for up to 72 hrs post collection are a viable raw material for centralized manufacturing of DC vaccines for application in the clinic.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced to differentiate into dendritic cells. Mature dendritic cells made by the methods of the invention have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from monocytes that have not been held at 1° C.-34° C. for at least 6 hours from the time they were isolated from a subject. Dendritic cells made by the methods of the invention are useful for the preparation of vaccines and for the stimulation of T cells.
Description
- This application is a continuation of U.S. application Ser. No. 14/307,991, filed Jun. 18, 2014, which is a continuation of U.S. application Ser. No. 13/929,889, filed Jun. 28, 2013, which is a continuation of U.S. application Ser. No. 13/351,510, filed Jan. 17, 2012, now U.S. Pat. No. 8,501,470, which is a divisional of U.S. application Ser. No. 11/918,076, filed Oct. 9, 2007, now U.S. Pat. No. 8,153,425, which is the U.S. national stage application of International Application No. PCT/US2006/013159, filed Apr. 7, 2006, which claims the priority benefit of U.S. Provisional Application No. 60/669,468, filed Apr. 8, 2005, each of which are herein incorporated by reference.
- The content of the electronically submitted sequence listing (Name: 3424_0030005_SL.txt; Size: (49,417 bytes; and Date of Creation: Oct. 6, 2015) filed herewith is incorporated herein by reference in its entirety.
- The present invention relates to methods for the production of dendritic cells and related compositions useful in the treatment of disease.
- Numerous clinical trials have demonstrated the safety of dendritic cells vaccines, and more that 1000 patients have received dendritic cell vaccines with no serious adverse events associated with the therapy and clinical responses in one half of patients (Ridgeway (2003) Cancer Invest 21:873-876). For example, a recent study showed that vaccination using dendritic cells loaded with four melanoma peptides (gp100, melan-A/MART-1, tyrosine melanoma antigen (MAGE-3), KLH and flu matrix resulted in regression of metastatic melanoma after four bimonthly vaccinations (Banchereau et al. (2001) Cancer Res 61:6451-6458).
- A common method for preparing dendritic cells (DCs) is to collect peripheral blood mononuclear cells (PBMCs) from a subject, and then differentiate the monocytes, which are a small proportion of the PBMCs, into DCs. It was widely believed in order to act as suitable precursors for the in vitro manufacture of dendritic cells, monocytes must be either frozen or cultured soon after isolation from a subject. Accordingly, in previous clinical trials where dendritic cell vaccines were made from monocytes, the PBMCs or monocytes were either cultured at approximately 37° C. or frozen within a few hours of the collection of PBMCs from a patient. However, practical manufacturing considerations can limit the widespread use of vaccines processed by a method that requires culturing or freezing freshly isolated PBMCs or monocytes. The differentiation of PBMCs into DCs takes about one week, requires a GMP facility, and skilled technicians. Accordingly, providing facilities and personnel for manufacturing DC vaccines at or near each clinical site where PBMCs are obtained from a patient would likely be cost prohibitive.
- A commercially viable model for manufacturing DC vaccines is to provide one or a relatively small number of facilities that can manufacture DC vaccines from patient PBMCs or monocytes collected at a clinical site and then shipped to a manufacturing site. However, such a model cannot be applied to current DC production methods that require fresh PBMCs or monocytes. Freezing fresh monocytes requires additional manipulations at the collection site following leukapheresis, and therefore is not a desirable alternative. Accordingly, there is a need to develop methods for manufacturing DC vaccines using PBMCs or monocytes that have been stored during shipment to a manufacturing facility. The present invention satisfies this need and provides additional advantages as well.
- The inventors have discovered methods which allow the preparation of dendritic cells and dendritic cell vaccines from monocytes which have be stored at 1-34° C. for time periods of 6-96 hours following isolation from a subject. The ability to manufacture DCs from stored monocytes allows greater flexibility and shipment of the monocytes from the site of collection to a manufacturing facility. In addition, the inventors have found that the dendritic cell vaccines manufactured from stored monocytes are phenotypically superior to dendritic cells manufactured from fresh monocytes. For example, the dendritic cell vaccines manufactured from stored monocytes have increased levels of costimulatory molecules, such as CD80, CD83 and CD86, as well as higher levels of MHC class I and MHC class II molecules as compared to dendritic cells manufactured from fresh monocytes.
- Thus, in one aspect, the invention provides a method for producing dendritic cells from monocytes, comprising:
-
- a. providing monocytes that have been incubated at a temperature of 1° C.-34° C. for a period of 6 to 96 hours from the time they are isolated from a subject; and
- b. inducing the differentiation of said monocytes into dendritic cells.
- In a preferred embodiment, the monocytes are obtained by leukapheresis to collect peripheral blood mononuclear cells (PBMCs) that comprise monocytes.
- Preferably, differentiation is induced by contacting the monocytes with a culture medium comprising an effective amount of a composition that induces the differentiation of monocytes into immature dendritic cells, such as, but not limited to, GM-CSF; GM-CSF and IL-4: GM-CSF and IL-13; GM-CSF and IL-15; and IFNα. The immature dendritic cells can then be matured to produce mature dendritic cells.
- The mature dendritic cells manufactured by the methods of the invention are phenotypically different than prior art mature dendritic cells. For example, the invention provides mature monocyte derived dendritic cell, wherein the steady state ratio of ALOX15 RNA to actin RNA or GAPDH RNA in the cell is less than 1.0. This is a decreased ratio as compared to the ratio of ALOX15 to Actin or GAPDH RNA in mature dendritic cells prepared from fresh monocytes. In another embodiment, the invention provides a mature monocyte derived dendritic cell, wherein the steady state ratio of CD52 RNA to actin RNA or GAPDH in the cell is greater than 1.0. In yet another embodiment, the invention provides a mature monocyte derived dendritic cell, wherein the steady state ratio of TLR1 RNA, TLR2 RNA, IL-1β RNA or CD69 RNA to actin RNA or GAPDH RNA in the cell is less than 1.0.
- In still another embodiment, the invention provides a composition comprising mature monocyte derived dendritic cells, wherein the mature dendritic cells have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from fresh monocytes. In addition, the invention provides mature monocyte derived dendritic cells having altered steady state levels of ALOX15 RNA, CD52 RNA, TLR1 RNA, TLR2 RNA, IL-1β RNA or CD69 RNA.
- The dendritic cells prepared by the methods of the invention are particularly useful for preparing vaccines. Thus, related dendritic cell compositions and vaccines are provided as well. In a preferred embodiment, the vaccine is autologous to the subject. Preferably, the dendritic cell vaccine is loaded with antigen from a cancer cell or pathogen present in the subject.
- Surprisingly, the inventors have found that dendritic cell vaccines frozen with DMSO are stable in the presence of DMSO for at least two hours after thawing. Accordingly, the invention provides the use of an antigen-loaded dendritic cell for the preparation of a frozen medicament for the treatment or prevention of cancer or pathogen infection, wherein the medicament comprises at least 2% DMSO and is ready for administration upon thawing. In another embodiment, the invention provides a method of vaccinating a subject, comprising:
-
- a. thawing a frozen dendritic cell vaccine comprising at least 2% DMSO, and
- b. administering the thawed vaccine to the subject without altering the ratio of cells to DMSO prior to administration.
Preferably the concentration of DMSO is approximately 10%.
- In another embodiment, the invention provides an antigen-loaded dendritic cell, wherein said cell is differentiated in vitro from a monocyte and is capable of surviving in vitro for at least 24 hours following freezing in the presence of ≧5% DMSO and thawing. In a preferred embodiment, the antigen loaded dendritic cell is capable of surviving in vitro for at least 24 hours following freezing in the presence of ≧10% DMSO and thawing.
- In another embodiment, the invention provides a dendritic cell vaccine, comprising approximately 5-15% DMSO, wherein said vaccine is ready for administration to a subject.
-
FIG. 1 : Diagram of a preferred shipping container and packaging materials for the temperature controlled shipping of monocytes (e.g, leukapheresis product). -
FIG. 2 : RNA-transfected DCs provide functional costimulatory support. DCs were tested for the ability to stimulate INF-γ production from PBMC in a mixed lymphocyte (MLR) assay. Thawed DCs manufactured from 3 different donors were paired with previously frozen PBMCs from each donor. All pair wise combinations were tested using ELISPOT (INF-γ) as the readout.Columns Columns -
FIG. 3 : Cytokine cocktail matured DCs were compared to immature DCs from the same donor in their ability to stimulate Th1 cytokine production from autologous T cells. Both populations of DCs were transfected with RNA encoding Flu matrix protein and used to stimulate Flu-specific memory CTL from autologous PBMCs. The results of the ELISPOT analyses (# spots/well as a function of input PBMC) are shown. Each set of four columns is arranged in the following order: IFNγ production elicited from Flu-specific T memory cells by immature DCs, IFNγ production elicited from Flu-specific T memory cells by mature DCs; IL-2 production elicited from Flu-specific T memory cells by immature DCs; and IL-2 production elicited from Flu-specific T memory cells by mature DCs. -
FIG. 4 : Two vials each of two RNA-loaded dendritic cells preparations made from day-old PBMCs obtained from 2 different healthy donors were thawed. One vial from each donor was immediately tested in an allo MLR assay while the second vial from each preparation was allowed remain at room temperature for 40 minutes before being assayed by the same method. The PBMCs used in this experiment included autologous cells from each donor as well as a third sample of PBMCs from a donor unrelated to either. The readout for this assay was ELISPOT (INF-γ). -
FIG. 5 : The functionality of DCs pre-freeze versus post-thaw was assessed by the ability of the DCs to stimulate a memory Flu-specific response from autologous PBMC as a function of decreasing Flu mRNA concentration used for transfection. The assay readout was ELISPOT (INF-γ). -
FIG. 6 : Flow cytometry assessment of GFP expression by DCs following electroporation with RNA encoding GFP. Untransfected (dashed line). -
FIG. 7 : Intracellular cytokine staining: IL-2/IFN-γ on CD4 and CD8 T cells following stimulation with DC transfected with RNA encoding GFP (negative control, left panels) or CMV pp65 (right panels). -
FIG. 8 : CSFE dilution in CD4 and CD8 T cells following stimulation with DCs transfected with RNA encoding GFP (negative control, left panels) or CMV pp65 (right panels). -
FIG. 9 : Phenotypes ofday 6 immature dendritic cells (iDCs) prepared from day old leukapheresis product. -
FIG. 10 : Phenotypes ofday 7 mature dendritic cells (mDCs) prepared from day old leukapheresis product. - Throughout this disclosure, various publications, patents and published patent specifications are referenced by an identifying citation. The disclosures of these publications, patents and published patent specifications are hereby incorporated by reference into the present disclosure to more fully describe the state of the art to which this invention pertains.
- The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook et al. Molecular Cloning: A Laboratory Manual, 2nd edition (1989); Current Protocols in Molecular Biology (F. M. Ausubel et al. eds. (1987)); the series Methods in Enzymology (Academic Press, Inc.); PCR: A Practical Approach (M. MacPherson et al. IRL Press at Oxford University Press (1991)); PCR 2: A Practical Approach (M. J. MacPherson, B. D. Hames and G. R. Taylor eds. (1995)); Antibodies, A Laboratory Manual (Harlow and Lane eds. (1988)); Using Antibodies, A Laboratory Manual (Harlow and Lane eds. (1999)); and Animal Cell Culture (R. I. Freshney ed. (1987)).
- Definitions
- As used herein, certain terms may have the following defined meanings.
- As used in the specification and claims, the singular form “a,” “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a cell” includes a plurality of cells, including mixtures thereof.
- The term “antigen” is well understood in the art and includes substances which are immunogenic, i.e., immunogens, as well as antigenic epitopes. It will be appreciated that the use of any antigen is envisioned for use in the present invention and thus includes, but is not limited to, a self-antigen (whether normal or disease-related), an infectious antigen (e.g., a microbial antigen, viral antigen, etc.), or some other foreign antigen (e.g., a food component, pollen, etc.). The term “antigen” or alternatively, “immunogen” applies to collections of more than one immunogen, so that immune responses to multiple immunogens may be modulated simultaneously. Moreover, the term includes any of a variety of different formulations of immunogen or antigen. In preferred embodiments, the antigen is from a cancer cell or a pathogen. Preferably, the cancer cell is a renal cancer cell, a multiple myeloma cell or a melanoma cell. Preferred pathogens are HIV and HCV. In preferred embodiments, the antigen is delivered to the antigen presenting cell (APC) in the form of RNA isolated or derived from a cancer cell or a pathogen. “Derived from” includes, but is not limited recombinant variants of naturally occurring sequences, including fusions to unrelated or related sequences. Methods for RT-PCR of RNA extracted from any cell (e.g., a cancer cell or pathogen cell), and in vitro transcription are disclosed in copending U.S. provisional patent application No. 60/525,076, and PCT/US05/053271, the contents of which are incorporated by reference.
- By “cancer” is meant the abnormal presence of cells which exhibit relatively autonomous growth, so that a cancer cell exhibits an aberrant growth phenotype characterized by a significant loss of cell proliferation control. Cancerous cells can be benign or malignant. In various embodiments, the cancer affects cells of the bladder, blood, brain, breast, colon, digestive tract, lung, ovaries, pancreas, prostate gland, or skin. The definition of a cancer cell, as used herein, includes not only a primary cancer cell, but also any cell derived from a cancer cell. This includes metastasized cancer cells, and in vitro cultures and cell lines derived from cancer cells. Cancer includes, but is not limited to, solid tumors, liquid tumors, hematologic malignancies, renal cell cancer, melanoma, breast cancer, prostate cancer, testicular cancer, bladder cancer, ovarian cancer, cervical cancer, stomach cancer, esophageal cancer, pancreatic cancer, lung cancer, neuroblastoma, glioblastoma, retinoblastoma, leukemias, myelomas, lymphomas, hepatoma, adenomas, sarcomas, carcinomas, blastomas, etc.
- As used herein, the term “comprising” is intended to mean that the compositions and methods include the recited elements, but not excluding others. “Consisting essentially of” when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. “Consisting of” shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention.
- As used herein, the term “cytokine” refers to any one of the numerous factors that exert a variety of effects on cells, for example, inducing growth or proliferation. Non-limiting examples of cytokines which may be used alone or in combination in the practice of the present invention include, interleukin-2 (IL-2), stem cell factor (SCF), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-11 (IL-11), interleukin-12 (IL-12), interleukin-13 (IL-13), interleukin-15 (IL-15), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin-1 beta (IL-1β), interferon-γ (IFNγ), tumor necrosis factor-α (TNFα), prostaglandin E2 (PGE2), MIP-11, leukemia inhibitory factor (LIF), c-kit ligand, thrombopoietin (TPO) and flt3 ligand. Cytokines are commercially available from several vendors such as, for example, Genzyme (Framingham, Mass.), Genentech (South San Francisco, Calif.), Amgen (Thousand Oaks, Calif.), R&D Systems (Minneapolis, Minn.) and Immunex (Seattle, Wash.). It is intended, although not always explicitly stated, that molecules having similar biological activity as wild-type or purified cytokines (e.g., recombinantly produced or muteins thereof) are intended to be used within the spirit and scope of the invention.
- The term “dendritic cells (DCs)” refers to a diverse population of morphologically similar cell types found in a variety of lymphoid and non-lymphoid tissues, Steinman (1991) Ann. Rev. Immunol. 9:271-296. Dendritic cells constitute the most potent and preferred APCs in the organism. Dendritic cells can be differentiated from monocytes, and possess a distinct phenotype from monocytes. For example, a particular differentiating marker, CD14 antigen, is not found in dendritic cells but is possessed by monocytes. It has been shown that mature DCs can provide all the signals necessary for T cell activation and proliferation. Also, mature dendritic cells are not phagocytic, whereas the monocytes and immature dendritic cells are strongly phagocytosing cells. Immature DCs are capable of capturing antigens by endocytosis, phagocytosis, macropinocytosis or adsorptive pinocytosis and receptor mediated antigen uptake, and are phenotypically CD80− or CD80low, CD83− or CD83low, CD86low, and have high intracellular concentrations of MHC class II molecules. Mature DCs have a veiled morphology, a lower capacity for endocytosis and are phenotypically CD80high, CD83high, CD86high in comparison to immature DCs. Preferably, the mature DCs secrete IL-12 p70 polypeptide or protein, and/or secrete significantly reduced levels (0 to 500 pg/ml per million DCs) of IL-10. IL-10 and IL-12 levels can be determined by ELISA of culture supernatants collected at up to 36 hrs post induction of DC maturation from immature DCs. Wierda W. G. et al (2000) Blood 96: 2917. Ajdary S et al (2000) Infection and Immunity 68: 1760. See Banchereau and Steinman (1998) Nature 392:245 for a review.
- An “effective amount” is an amount sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages.
- As used herein, “expression” refers to the processes by which polynucleotides are transcribed into mRNA and/or mRNA is translated into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA of an appropriate eukaryotic host, expression may include splicing of the mRNA. Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector or cassette includes a promoter (e.g., lac promoter) and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG (Sambrook et al. (1989) supra). Similarly, a eukaryotic expression vector or cassette typically includes a heterologous or homologous promoter for RNA polymerase II, a Kozak sequence, the start codon AUG, a termination codon for detachment of the ribosome and a downstream polyadenylation signal. Such vectors can be obtained commercially or assembled by the sequences described in methods known in the art.
- The term “genetically modified” means containing and/or expressing a foreign gene or nucleic acid sequence which in turn, modifies the genotype or phenotype of the cell or its progeny. In other words, it refers to any addition, deletion or disruption to a cell's endogenous nucleotides.
- The term “isolated” means separated from constituents, cellular and otherwise, in which the polynucleotide, peptide, polypeptide, protein, antibody, or fragments thereof, are normally associated with in nature. For example, with respect to a polynucleotide, an isolated polynucleotide is one that is separated from the 5′ and 3′ sequences with which it is normally associated in the chromosome. As is apparent to those of skill in the art, a non-naturally occurring polynucleotide, peptide, polypeptide, protein, antibody, or fragment(s) thereof, does not require “isolation” to distinguish it from its naturally occurring counterpart. In addition, a “concentrated”, “separated” or “diluted” polynucleotide, peptide, polypeptide, protein, antibody, or fragment(s) thereof, is distinguishable from its naturally occurring counterpart in that the concentration or number of molecules per volume is greater than “concentrated” or less than “separated” than that of its naturally occurring counterpart. A polynucleotide, peptide, polypeptide, protein, antibody, or fragment(s) thereof, which differs from the naturally occurring counterpart in its primary sequence or for example, by its glycosylation pattern, need not be present in its isolated form since it is distinguishable from its naturally occurring counterpart by its primary sequence, or alternatively, by another characteristic such as its glycosylation pattern. Although not explicitly stated for each of the inventions disclosed herein, it is to be understood that all of the above embodiments for each of the compositions disclosed below and under the appropriate conditions, are provided by this invention. Thus, a non-naturally occurring polynucleotide is provided as a separate embodiment from the isolated naturally occurring polynucleotide. A protein produced in a bacterial cell is provided as a separate embodiment from the naturally occurring protein isolated from a eukaryotic cell in which it is produced in nature. An isolated mammalian cell is separated from where it is normally found in the body, or is removed from the body. For example, leukocytes collected by leukophereis are “isolated”, and dendritic cells differentiated from monocytes in vitro are “isolated”.
- The terms “major histocompatibility complex” or “MHC” refers to a complex of genes encoding cell-surface molecules that are required for antigen presentation to T cells and for rapid graft rejection. In humans, the MHC is also known as the “human leukocyte antigen” or “HLA” complex. The proteins encoded by the MHC are known as “MHC molecules” and are classified into Class I and Class II MHC molecules. Class I MHC molecules include membrane heterodimeric proteins made up of an a chain encoded in the MHC noncovalently linked with the β2-microglobulin. Class I MHC molecules are expressed by nearly all nucleated cells and have been shown to function in antigen presentation to CD8+ T cells. Class I molecules include HLA-A, B, and C in humans. Class II MHC molecules also include membrane heterodimeric proteins consisting of noncovalently associated α and β chains. Class II MHC molecules are known to function in CD4+ T cells and, in humans, include HLA-DP, DQ, and DR.
- By monocytes is meant CD14+ peripheral blood mononuclear cells capable of differentiating into immature dendritic cells in response to GM-CSF and IL-4.
- “Pathogen”, as used herein, refers to any disease causing organism or virus, and also to attenuated derivatives thereof.
- A “pharmaceutical composition” is intended to include the combination of an active agent (such as an antigen-loaded DC) with a carrier, inert or active, making the composition suitable for diagnostic or therapeutic use in vitro, in vivo or ex vivo.
- As used herein, the term “pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutical carriers, such as heat-inactivated serum plus 10% DMSO plus 5% dextrose, phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents. The compositions also can include adjuvants, stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see Remington's Pharm. Sci. 18th Ed. (Mack Publ. Co., Easton (1990)).
- The terms “polynucleotide” and “nucleic acid molecule” are used interchangeably to refer to polymeric forms of nucleotides of any length. The polynucleotides may contain deoxyribonucleotides, ribonucleotides, and/or their analogs. Nucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The term “polynucleotide” includes, for example, single-stranded, double-stranded and triple helical molecules, a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. In addition to a native nucleic acid molecule, a nucleic acid molecule of the present invention may also comprise modified nucleic acid molecules.
- The term “peptide” is used in its broadest sense to refer to a compound of two or more subunit amino acids, amino acid analogs, or peptidomimetics. The subunits may be linked by peptide bonds. In another embodiment, the subunit may be linked by other bonds, e.g., ester, ether, etc. As used herein the term “amino acid” refers to either natural and/or unnatural or synthetic amino acids, including glycine and both the D and L optical isomers, amino acid analogs and peptidomimetics. A peptide of three or more amino acids is commonly called an oligopeptide if the peptide chain is short. If the peptide chain is long, the peptide is commonly called a polypeptide or a protein.
- As used herein “subject” refers to a mammal, including, but not limited to, humans and other primates, rodents, dogs and cats. Preferably, the subject is a human.
- The inventors have discovered that immature dendritic cells, mature dendritic cells and antigen loaded dendritic cells can be produced from monocytes stored at 1° C.-34° C. for approximately 6 to 96 hours following collection of the monocytes from a patient. These results are surprising, as it was commonly believed critical to prepare dendritic cells from freshly isolated monocytes, rather than from monocytes that had been stored at ambient temperatures for a significant length of time. Moreover, monocyte-derived DC vaccines used in clinical trials performed prior to the instant invention have been prepared by culturing monocytes within less than 6 hours following collection from a patient, or by freezing PBMCs shortly after collection, and storing the PBMCs for subsequent thawing and culturing of monocytes.
- Not only have the inventors found that it is possible to make dendritic cells and dendritic cell vaccines from monocytes that have been stored at 1° C.-34° C. for approximately 6 to 96 hours, they have also surprisingly discovered that dendritic cells made by this method are phenotypically superior to the dendritic cells made from fresh monocytes. The method of manufacture and the characteristics of dendritic cell vaccines produced by these methods are particularly relevant to vaccine potency, successful commercialization over a widespread area, and ease of administration. First, the mature dendritic cells manufactured using the methods of the invention, when compared to DCs produced by prior art methods, express increased levels CD80, CD83 and CD86 costimulatory molecules, as well as increased levels of MHC class I and MHC class II molecules, all of which are indicative of DC maturity and potency. In addition, mature DCs of the invention are able to induce IL-2 production from memory T cells in an antigen specific fashion.
- Second, it would not be commercially feasible to establish dendritic cell manufacturing capabilities nearby each site where patient PBMCs will be collected. Therefore, successful widespread commercialization of an autologous dendritic cell vaccine will depend on the ability to ship PBMCs, or monocytes isolated from PBMCs to centralized manufacturing facilities for differentiation into immature and mature dendritic cells and preparation of vaccines. However, prior to the instant invention, it was widely thought that PBMCs must be frozen or cultured shortly after removal from a patient. The methods of the invention solve this problem by allowing the processing of PBMCs or monocytes isolated from PBMCs which have been shipped by overnight or longer delivery.
- Third, antigen-loaded dendritic cells are typically frozen in DMSO and stored until thawing, washing and resuspending in a DMSO-free pharmaceutically acceptable carrier prior to administration to a patient. The washing step was included in prior DC vaccine clinical trials because it was thought that DMSO has detrimental effects on unfrozen or thawed DCs. Surprisingly, the inventors have discovered that DMSO has no noticeable detrimental effect on dendritic cells. Thus, there is no need to wash and resuspend the thawed DC vaccine prior to administration. Omitting this step increases the ease of administration and decreases both the risk of contamination and of adverse effects to the DCs due to additional manipulations.
- Accordingly, in one aspect, the invention provides a method for producing dendritic cells from monocytes, comprising:
- a. providing monocytes that have been incubated at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours from the time they are removed from a subject; and
- b. inducing the differentiation of the incubated monocytes into dendritic cells.
- As used herein, “monocyte” refers to a CD14+ leukocyte having the capacity to differentiate into a dendritic cell. The monocyte may be from any mammal, and preferably is a human monocyte. The monocytes can be provided and incubated in compositions such as, but not limited to, blood, blood fractions (e.g., white blood cells (WBCs), buffy coats, peripheral blood mononuclear cells (PBMCs), etc, and as well as in compositions further enriched for monocytes. In a preferred embodiment, the monocytes are provided together with other peripheral blood mononuclear cells (PBMCs), for example, as a leukapheresis product. In another embodiment, the monocytes are enriched from PBMCs, or isolated directly from peripheral blood. Methods of isolating monocytes or PBMCs containing monocytes are known to those of skill in the art. In preferred embodiments, the monocytes are collected together with other PBMCs by leukapheresis. Methods of leukapheresis are known in the art. In a preferred embodiment of the invention, PBMCs comprising monocytes are collected from a subject by leukapheresis at a hospital, clinic, doctor's office, etc. Leukapheresis is a procedure by which the white blood cells are removed from a subject's blood, the remainder of which is then transfused back into the subject. The leukapheresis product is typically a blood fraction enriched for PBMCs, with low levels of contaminating red blood cells, granulocytes and platelets. Methods and equipment for performing leukapheresis are well known in the art. See, for example gambrobct.com/Products_&_Services/ for detailed information on leukapheresis. Examples of leukapheresis apparatuses include the COBESpectra™ manufactured by GAMBRO BCT, and the CS3000 Plus Blood Cell Separator manufactured by Baxter Fenwal.
- Monocytes can be enriched from blood or blood fractions (e.g., PBMCs), during or after the 1° C.-34° C. incubation period. As used herein, “enriching monocytes” means a method which increases the proportion of monocytes with respect to other cell types that were present at the start of the method. Methods for enriching monocytes from PBMCs, blood or other blood fractions are known to those of skill in the art and include, but are not limited to elutriation, FACS, panning, magnetic sorting, low density Ficoll gradient centrifugation, and the like. Preferably, monocytes are enriched from PBMCs by elutriation. In one alternative embodiment, monocytes are enriched from PBMCs following the 6-96 hour incubation period by selection for monocytes which adhere to plastic during cell culture. In another embodiment, monocytes are enriched by immunomagnetic selection. The immunomagnetic selection may be positive selection to bind monocytes, or may be negative selection, to bind cells which are not monocytes (e.g., T cells, B cells, etc.)
- Once isolated from a subject, monocytes (e.g., purified monocytes, enriched monocytes, PBMCs comprising monocytes, etc.) are incubated at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. As used herein, the time at which monocytes or PBMCs containing monocytes are isolated from a subject refers to the time at the completion of the process of removing the cells from the subject. For example, where PBMCs are isolated from a patient over the course of a four hour leukapheresis procedure, the time of isolation would be the time at which collection of PBMCs by leukapheresis ends.
- Preferably, the monocytes are incubated for 6 to 96 hours at a temperature of 3° C.-34° C., or 4° C.-32° C. or 5° C.-30° C., more preferably at a temperature of 6° C.-28° C., even more preferably at a temperature of 6° C.-27° C., 8° C.-26° C. or about 14° C.-24° C. Preferred lower temperature ranges are 6° C., 7° C., 8° C., 9° C., 10° C., 11° C., 12° C., 13° C. and 14° C. Preferred upper temperature ranges are 20° C., 21° C., 22° C., 23° C., 24° C., 25° C., 26° C., 27° C., 28° C., 29° C., 30° C., 31° C., 32° C., 33° C. and 34° C. Preferably, the period of incubation is 8 to 72 hours, more preferably 10 to 48 hours, even more preferably 12 to 24 hours, and most preferably, 15 to 22 hours. Other preferred ranges of incubation times include 8 to 48 hours, 10 to 30 hours, 26 to 72 hours and 48 to 80 hours. Preferred lower limits of incubation times can be selected from 6, 7, 8, 10, 12, 14, 16, 20, 22, 24, 26, 28, 30, 36 and 48 hours. Preferred upper limits of incubation times can be selected from 24, 26, 28, 30, 36, 48, 60, 72, 84 and 96 hours.
- Monocytes in any form (e.g., monocytes in blood, blood fractions, PBMCs, purified monocytes, etc.) may be shipped from a clinical site to a dendritic cell manufacturing site during the 1° C.-34° C. incubation period. Preferably, the monocytes are shipped in a temperature controlled container. Methods of maintaining the temperature of the monocytes between 1° C.-34° C. during the incubation period are known to those of skill in the art. For example, the monocytes can be incubated in an incubator or a room at 1° C.-34° C. Preferably, the monocytes are subjected to some motion (either occasional or continuous) during the incubation period. The motion can be the motion associated with shipping. In another embodiment, the cells can be gently rocked or rotated during incubation. While not wishing to be bound by theory, it is thought that the motion may prevent cell damage associated with compaction during settling.
- During the 6-96 hour incubation period at 1° C.-34° C., the monocytes are incubated without culturing. By “without culturing”, is meant that during the 6 to 96 hour incubation period, the monocytes are not cultured in a mammalian cell culture medium (including, but not limited to, physiologically appropriate concentrations (e.g., about 1×) of culture mediums such as RPMI, DMEM, X-VIVO 15, AIM-V, StemSpan H2000, and the like) at a temperature of about 36-38° C. Rather, monocytes processed by the methods of the invention are incubated at 1° C.-34° C., preferably in blood or blood fractions (e.g., serum, plasma, leukapheresis product (e.g., PBMCs), buffy coat, etc.) saline or biological buffers such as phosphate buffer saline (PBS). Most preferably, the leukapheresis product containing monocytes is incubated at 1° C.-34° C. in the leukapheresis collection container (e.g., a blood collection bag). While the leukapheresis product may be transferred to another container at the beginning or during the incubation period, it is preferable to avoid unnecessary transfers, which could increase the likelihood of contamination.
- During or after the 6-96 hour incubation at 1° C.-34° C., the monocytes can be enriched prior to differentiation step. Manipulations may be performed on the monocytes or PBMCs, etc., during the period of incubation, so long as the manipulations are performed at 1° C.-34° C. In particular, PBMCs may be further purified, or monocytes may be enriched from PBMCs during this period of incubation. Such manipulations include, but are not limited to, centrifugation, elutriation, tangential flow filtration, Ficoll density gradient, dilute Ficoll density gradient centrifugation, dilute Percoll density gradient centrifugation, antibody panning, magnetic cell sorting, positive or negative immunomagnetic selection, and the like. In one embodiment, monocytes can be enriched from PBMCs after the incubation period by culture in a container (preferably a plastic container) and selection for adherent monocytes.
- Following incubation at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours, and an optional step of further enrichment of the monocytes, the monocytes are induced to differentiate into dendritic cells. Typically, monocytes are differentiated into immature dendritic cells and then the immature dendritic cells then can be matured into mature dendritic cells. A variety of methods for differentiating monocytes into dendritic cells, and for maturing the dendritic cells are known to those of skill in the art.
- In one embodiment, monocytes are cultured in a medium comprising a composition that induces the differentiation of monocytes into immature or mature dendritic cells. Compositions which induce the differentiation of monocytes into immature dendritic cells are known to those of skill in the art. Such compositions include, but are not limited to, GM-CSF+IL-4; GM-CSF+IL-13; GM-CSF+IL-15; IFNα; and GM-CSF+TNFα. Preferably the composition which induces differentiation is GM-CSF+IL-4. The concentrations of GM-CSF and IL-4 may range from about 400 to 2000 U/ml of each cytokine Preferably, the concentration of GM-CSF and IL-4 is 500 to 1000 units/ml of each cytokine. In one embodiment, the monocytes are contacted with GM-CSF and IL-4 for about 4-7 days, most preferably for about 5-6 days, during which time the monocytes differentiate into immature dendritic cells.
- Following differentiation of monocytes into immature dendritic cells, the immature dendritic cells can be matured into mature dendritic cells. Methods for maturing dendritic cells are known to those of skill in the art. In one embodiment, the immature dendritic cell are matured by contact with a medium comprising GM-CSF, IL-4 and a maturation cocktail (PGE2, TNFα, IL-6 and IL-1β). See for example, Jonuliet et al. (1997) Eur J Immunol 27:3135-3142, the contents of which are incorporated by reference.
- In an alternative maturation method, immature dendritic cells are signaled with a first signal, comprising IFN-γ, followed by a second signal comprising CD40L. For example, in one embodiment, immature dendritic cells are contacted with PGE2, IFN-γ and CD40L, preferably in the presence of GM-CSF and IL-4. In a preferred embodiment, the contacting with CD40L is effected upon translation of a recombinant CD40L mRNA within the dendritic cells. Preferably, the dendritic cell is transiently transfected with an mRNA encoding CD40L or an active fragment thereof.
- Most preferably, immature dendritic cells are contacted with PGE2, TNFα, and IFNγ, preferably in the presence of GM-CSF and IL-4, to produce mature dendritic cells. The maturity of the dendritic cells can be further increased by transfection, preferably transient transfection, with an RNA encoding CD40L. Preferably, the dendritic cells are transfected with an RNA encoding CD40L and/or RNA encoding one or more antigens or epitopes of interest. The above maturation methods are described in U.S. application Ser. No. 11/246,387 the contents of which are incorporated by reference.
- In preferred embodiments of the invention, the dendritic cells are loaded with one or more antigens. Antigen loaded dendritic cells are useful as vaccines and for the in vitro stimulation of T cells. Antigens can be loaded into immature or mature dendritic cells. If antigens are loaded into immature dendritic cells, the immature dendritic cells can then be matured by the process of loading itself, or by other maturation methods described herein or alternative maturation methods known to those of skill in the art. The antigen(s) can be loaded as the antigen itself (e.g., proteins, peptides, epitopes, cell lysates, viral particles, etc.) or can be loaded as a nucleic acid(s) encoding antigen(s). Preferably, the antigen is loaded as a nucleic acid encoding the antigen. More preferably, the nucleic acid is an RNA, most preferably an mRNA. In a preferred embodiment mRNA encoding one or more antigens is cotransfected with mRNA encoding CD40L. Preferably, the antigen is autologous to the subject, and is used to prepare an antigen loaded autologous DC vaccine for administration to the subject. Methods for loading dendritic cells with peptide and protein antigens, cells, cell or tissue lysates, viruses or viral particles, nucleic acids and the like are known to those of skill in the art.
- In a preferred embodiment, the antigen is loaded by electroporation of a dendritic cell (mature or immature) with a nucleic acid, preferably an mRNA. Preferably, the dendritic cells are transfected with approximately 0.25 to 4 micrograms RNA per 106 dendritic cells, most preferably with about 2 μg RNA per 106 dendritic cells. In one embodiment, 1 microgram tumor RNA per million DC is used per transfection. In another embodiment, 0.25 to 1.0 μg each of four RNAs encoding four separate antigens from a pathogen (e.g., HIV) is used per 106 dendritic cells.
- The antigen can be from any source. However, in preferred embodiments, the antigen or antigen(s) are autologous to the subject. By autologous to the subject is meant that the antigen is obtained or derived from the subject. As non-limiting examples, the antigens may be from cancer cells or tumor tissue obtained from a subject. The cancer antigens could be loaded into dendritic cells as cancer cells, cancer cell or tissue lysates, extracts from cancer cells or tissues, purified or cloned components of cancer cells or tissues, total RNA or total mRNA, or selected RNA or mRNA from such cells or tissues, whether present in extracts, purified, amplified, in vitro translated and the like. Alternatively, the antigen may be obtained or derived from a pathogen or pathogen-infected cells present in a subject.
- The methods of the invention are particularly useful for the treatment or prevention of cancer and pathogen infection. In preferred embodiments, the cancer is renal cell carcinoma, melanoma, breast cancer, chronic lymphocytic leukemia, multiple myeloma, lung cancer, colon cancer, pancreatic cancer, stomach cancer or prostate cancer.
- The term pathogen refers to any virus or organism which is involved in the etiology of a disease and also to attenuated derivatives thereof. Such pathogens include, but are not limited to, bacterial, protozoan, fungal and viral pathogens such as Helicobacter, such as Helicobacter pylori, Salmonella, Shigella, Enterobacter, Campylobacter, various mycobacteria, such as Mycobacterium leprae, Bacillus anthracis, Yersinia pestis, Francisella tularensis, Brucella species, Leptospira interrogans, Staphyloccus, (e.g., S. aureus), Streptococcus, Clostridum, Candida albicans, Plasmodium, Leishmania, Trypanosoma, human immunodeficiency virus (HIV), hepatitis C virus (HCV), human papilloma virus (HPV), cytomegalovirus (CMV), human T-lymphotrophic virus (HTLV), herpesvirus (e.g., herpes
simplex virus type 1, herpessimplex virus type 2, coronavirus, varicella-zoster virus, and Epstein-Barr virus (EBV)), papilloma virus, influenza virus, hepatitis B virus, poliomyelitis virus, measles virus, mumps virus, and rubella virus. Preferably the pathogen is a viral pathogen, more preferably a retroviral pathogen, and most preferably HIV or HCV. - Dendritic cells, whether mature or immature, antigen loaded or not, can be frozen in a composition comprising a cryoprotectant. Numerous cryoprotectants are known to those of skill in the art. Examples of cryoprotectants include, but are not limited to, dimethylsulfoxide (DMSO), glycerol, ethanol, methanol, acetamide, glycerol monoacetate, propane-diol, polyethylene glycol, ethylene glycol, i-erythritol, D-ribitol, D-mannitol, D-sorbitol, D-lactose, i-inositol, choline chloride, amino acids, albumin (preferably human serum albumin), polyvinyl pyrrolidone, dextran, sucrose, Ficoll, inorganic salts, and hydroxyethyl starch. In a preferred embodiment, the cryoprotectant is DMSO. Preferably, the concentration of DMSO is 2-20%, more preferably 5-15%, and most preferably approximately 10%. Also, the freezing medium may contain one or more polyol compounds derived from carbohydrates, such as glucose, dextrose, sucrose, etc., preferably in a concentration of from 2-30%, more preferably from 5-10%, most preferably 5% dextrose. Methods for freezing dendritic cells are known to those of skill in the art. See, for example U.S. patent application 20040253574, the contents of which are incorporated by reference. Preferably, the cryoprotectant is dimethylsulfoxide (DMSO). In preferred embodiments, the concentration of DMSO is 5% to 20%. Most preferably, the concentration of DMSO in the composition is approximately 10%.
- Surprisingly, dendritic cells and dendritic cell vaccines made by the methods of the invention are capable of surviving in vitro for at least 24 hours post-thaw following freezing in the presence of 5%-20% DMSO and thawing. Because the antigen-loaded dendritic cells of the invention are resistant to DMSO, it is not necessary to wash the cell prior to administering the dendritic cell vaccine. Accordingly, the thawed dendritic cell vaccines of the invention are ready for administration to a subject at any time after thawing. Eliminating the washing step reduces the risk of contamination and avoids further manipulations that may damage the dendritic cells. Thus, in one embodiment, the invention provides a method for the administration of an antigen loaded dendritic cell vaccine, comprising thawing a frozen dendritic cell vaccine comprising at least 2% to 20% DMSO, and administering the vaccine to a subject without altering the ratio of dendritic cells to DMSO prior to administration. Preferably, the concentration of DMSO in the vaccine is approximately 5-20%, and more preferably 10%.
- In another embodiment, the invention provides the use of an antigen-loaded dendritic cell for the preparation of a frozen medicament for the treatment or prevention of cancer or pathogen infection, wherein the medicament comprises at least 2% DMSO and is ready for administration upon thawing.
- The methods of the invention allow the production of novel dendritic cells with increased functionality and increased levels of maturity markers. For example, in one aspect the invention provides mature monocyte derived dendritic cells, wherein the mature dendritic cells have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from fresh monocytes.
- In yet another embodiment, the invention provides a mature monocyte derived dendritic cell, wherein the dendritic cell can elicit antigen-specific IL-2 production from a memory T cell. Methods for measuring IL-2 are known in the art. Cell surface markers and expression of other molecules which are characteristic of memory T cells, and which distinguish them from other types of T cells, are disclosed in FIG. 10.35 of Immunobiology, 6th Edition, Eds. Janeway et al., Garland Science Publishing, New York, N.Y., 2005; the content of which is incorporated by reference. For example, memory T cells express high levels of CD44, CD45RO, CD45RA, Bcl-2, IFNγ, CD127 and Ly6C; moderate levels of CD122, and CXCR4; low levels of FasL, and are CD69 and CD25 negative.
- As disclosed herein, microarray analysis of steady state RNA levels shows altered gene expression between dendritic cells produced from day old monocytes as compared to dendritic cells produced from fresh monocytes. Thus, in one embodiment, the invention provides a mature monocyte-derived dendritic cell, wherein the steady state ratio of ALOX15 RNA to either β-actin RNA or GAPDH RNA in the cell is less that 1.0. Preferably, the ratio is between 0.2 to 0.7, more preferably between 0.4 to 0.5, and most preferably about 0.45.
- In another embodiment, the invention provides a mature monocyte derived dendritic cell, wherein the steady state ratio of CD52 RNA to β-actin RNA or GAPDH in the cell is greater than 1.0. Preferably, the ratio is between 1.2 to 5.0, more preferably between 1.5 to 2.2, or between 1.8 to 1.9, and most preferably the ratio is 1.86.
- In still another embodiment, the invention provides a mature monocyte derived dendritic cell, wherein the steady state ratio of TLR1 RNA, TLR2 RNA, IL-1β RNA or CD69 RNA to β-actin RNA or GAPDH RNA in the cell is less than 1.0. Preferably the ratio is between 0.2 to 0.9, and more preferably between 0.5 to 0.8.
- The human ALOX15 mRNA (SEQ ID NO:1) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:2-12. The human IL-1β mRNA (SEQ ID NO:13) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:14-24. The human TLR1 mRNA (SEQ ID NO:25) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:26-36. The human TLR2 mRNA (SEQ ID NO:37) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:38-48. The human CD69 mRNA (SEQ ID NO:49) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:50-60. The human CD52 mRNA (SEQ ID NO:61) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:62-77. The human GAPDH mRNA (SEQ ID NO:78) and allelic variants thereof can be detected using the Affymetrix probes of SEQ ID NOs:79-98. The human β-actin mRNA (SEQ ID NO: 99) and allelic variants thereof can be detected using Affymetrix probes of SEQ ID NOs:100-119.
- RNA steady state expression levels can be detected by microarray, preferably using the Affymetrix Human Genome U133 Plus 2.0 Array. Alternatively, hybridization can be performed using the gene specific probes listed in the paragraph above. Preferably, RNA samples extracted from dendritic cells can be applied to the Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, Calif.) according to the manufacture's instruction (Genechip® Expression Analysis Technical Manual, 2004). Briefly, three micrograms of total RNA spiked with Genechip® Poly-A RNA Control Kit (Affymetrix, Santa Clara, Calif.) are converted to first-strand cDNA using SuperScript™ II reverse transcriptase. Second-strand cDNA synthesis is followed by in vitro transcription for linear amplification of each transcript and incorporation of biotinylated CTP and UTP. The cRNA products are fragmented to around 100 nucleotides, and hybridized for 16 hours to the microarrays. The microarrays are then washed at low (6× SSPE) and high (100 mM MES, 0.1M NaCl) stringency and stained with streptavidin-phycoerythrin.
- Fluorescence is amplified by adding biotinylated anti-streptavidin and an additional aliquot of streptavidin-phycoerythrin stain. The GeneChip® Scanner 3000 (Affymetrix, Santa Clara, Calif.) is used to collect fluorescence signal at 3 μm resolution after excitation at 570 nm. The average signal from two sequential scans is calculated for each microarray feature of interest. Scanned images were analyzed with Genechip® Operating Software v1.1 (Affymetrix, Santa Clara, Calif.). Preferably, high linear correlation (R2>0.95) of 4 control RNAs included in Poly-A RNA Control Kit (Affymetrix, Santa Clara, Calif.) is confirmed as a control for the success of the labeling process.
- Profile data for all genes, or just the genes of interest (e.g., ALOX15, IL-1β, TLR1, TLR2, CD69 and/or CD52, as well as β-actin and/or GAPDH) are imported into the computer program GeneSpring™ and normalized. Three steps are performed in the normalization step according to the standard method suggested by GeneSpring™ for Affymetrix arrays.
- 1) data transformation (all values less than 0.01 were set to 0.01)
- 2) Normalization to the 50th percentile.
- 3) Normalization to the median.
- The ratio of steady state mRNA of interest (ALOX15, IL-1β, TLR1, TLR2, CD69 or CD52 mRNA) to steady state GAPDH or β-Actin mRNA can then be determined by dividing the normalized expression of the mRNA of interest by the normalized expression of GAPDH or β-actin mRNA.
- The antigen-loaded dendritic cells of the invention are useful as vaccines in the treatment or prevention of disease or for the activation of T cells, which can then be used in therapy. For example, antigen loaded dendritic cells can be used to elicit an immune response against an antigen. They may be used as vaccines to prevent future infection or disease, or to activate the immune system to treat ongoing disease, such as, but not limited to pathogen infection or cancer. The antigen loaded dendritic cells may be formulated for use as vaccines or pharmaceutical compositions with suitable carriers such as physiological buffers or other injectable liquids. The vaccines or pharmaceutical compositions would be administered in therapeutically effective amounts sufficient to elicit an immune response.
- Preferably, the dendritic cells are loaded with an antigen autologous to the subject from which the dendritic cell is derived, and administered to the same subject. See for example, U.S. Pat. No. 5,853,719 (the contents of which is incorporated by reference), which describes the preparation and uses of antigen loaded dendritic cells and particularly RNA loaded dendritic cells. Alternatively the dendritic cell may be loaded with an antigen that is not autologous to the intended recipient of the DC therapy. Examples of such antigens include, but are not limited to antigens that are known therapeutic targets, such as telomerase, prostate specific antigen, and other tumor markers, or known antigens from a pathogen.
- A variety of methods for collecting monocytes and PBMCs comprising monocytes from a subject are known to those of ordinary skill in the art. See for example, gambrobct.com/Products_&_Services/ for detailed information on leukapheresis for the collection PBMCs and elutriation for the purification of monocytes. In a preferred embodiment, a leukapheresis product and plasma are collected in separate sterile, disposable, single-use cytopheresis bags is collected using the AutoPBSC (Automated Peripheral Blood Stem Cell) procedure on a Gambro BCT COBE Spectra (Gambro BCT, Lakewood, Colo.).
- In one alternative method to leukapheresis, PBMCs are obtained by collecting blood in a heparinized syringe, dilution in PBS, layering over Histopaque 1077 (Sigma), centrifugation and recovery of PBMCs at the interface. See Woodhead et al. (2000) International Immunol 12:1051-1061. Additional methods of collecting, purifying or fractionating PBMCs are known to those of ordinary skill in the art.
- Following collection of the leukapheresis product or other blood product, monocytes contained therein are incubated at 1-34° C. for 6-96 hours. In one embodiment, the leukapheresis product is collected in a bag and then transported to the vaccine manufacturing facility in a temperature-monitored shipping container maintained at 1-34° C., preferably at about 6-28° C., and most preferably at 8-26° C. Gel packs, such as those disclosed in U.S. Pat. No. 4,102807, which aid in the prevention of temperature changes, can be included in the shipping container. For example, the monocytes can be shipped in an insulated container (e.g., ThermoSafe™ model E65 polyurethane foam insulated container), and packed with ThermoSafe™ U-tek gel packs and gel mats as shown in
FIG. 1 . For example, in the packing procedure shown inFIG. 1 , a 16 oz U-tek gel mat adjusted to a temperature of −1° C. is laid flat in the bottom of the E65 container. Two 16 oz U-tek gel mats (−1° C.) are folded and placed between the first gel mat and the short wall of the E65 container. Two 16 oz U-tek gel (adjusted to +18° C.) are then placed vertically next to the previous gel mats. A ThermoSafe™ INF3000 transplant container is placed between the gels. The leukapheresis bags are placed in a sealed inner bag (STP711). A device which records the temperature of the inner bag can be used to monitor the temperature during shipment. One such device is the ThermoSafe™ DataLogger. The inner bag is placed in a sealed outer bag (STP710) and then the bags are placed in the INF3000 container. A 16 oz U-tek gel (+18° C.) is placed on top of the closed INF300 container, topped with Kraft paper and then a 4″ foam plug. The box is then sealed with tape and ready for shipment. - During or after the incubation period at 1-34° C., the leukapheresis product can be further processed or purified, for example by Ficoll density gradient centrifugation at room temperature in 50 ml conical tubes to separate and concentrate the mononuclear cell fraction that includes dendritic cell precursors (monocytes). Preferably, after multiple washing steps with phosphate buffered saline (PBS), the cell concentration and cell viability can be determined.
- Methods of enriching for monocytes are know to those of ordinary skill in the art, and include, but are not limited to, density gradient centrifugation (e.g, dilute Ficoll density gradient centrifugation, dilute Percoll density gradient centrifugation, etc.), elutriation, adherence to plastic, tangential flow filtration, fluorescence activated cell sorting (FACS), immunological cell separation techniques (antibody panning to select monocytes or to remove non-monocytes (e.g., leukocytes, macrophages, granulocytes, etc), differential lysis, magnetic cell sorting, etc.), culture in plastic culture bags coated with plastic microcarrier beads, etc. See, for example, O'Doherty et al. (1993) J Exp Med 178:1067-1076; Young et al. (1990) J Exp Med 171:1315-1332; Freudenthal et al. (1990) PNAS 87:7698-7702; Bernhard et al. (1995) Cancer Res 55:1099-1104; Caux et al. (1992) Nature 360:258-261; Read et al. (2003) “Evaluation of a Closed Automated System to Isolate Peripheral Blood Monocytes for Dendritic Dell (DC) Immunotherapy”, Ninth annual meeting of the ISCT; Mu et al. (2003) Scand J Immunol 58:578-586; Maffei et al. (2000) Transfusion 40:1419-1420; mitenyibiotec.com; Meyer-Wentrup et al. (2003) J Hematother Stem Cell Res 12:289-299; and WO 2004/000444, the contents of which are incorporated by reference. For example, magnetic cell sorting can be used to enrich form monocytes by positive selection (CD14+ cells) or by negative selection (i.e., removal of cells that are not monocytes; e.g., CD3+, CD19+ and CD2+ cells).
- Preferably, monocytes are enriched from the leukapheresis product by elutriation, an automated method to isolate monocytes from the subject leukapheresis. Methods of leukapheresis are known in the art. For example, elutriation can be performed on the Gambro BCT Elutra™ Cell Separation System (Gambro BCT, Lakewood, Colo.). Elutriation buffer can be prepared by adding 1000 mL of 5% Human Albumin Serum (HSA) to a 4 L bag of Hank's Balanced Salt Solution (HBSS). The cells can be fractionated by elutriation according to the manufacturer's protocol. In a preferred embodiment, a modified version of the manufacturer's (Gambro) protocol is used for elutriation, where the final rotor off fraction is the fourth fraction instead of the fifth fraction. CBC with differential analysis can performed on the monocyte fraction to verify purity and recovery. Alternatively, monocyte purity can be assessed by immunophenotyping with CD14. The enriched monocytes can then be differentiated into dendritic cells, or can be frozen and stored for later use. In one embodiment, the cells are frozen in 25 ml or 50 mL freezing bags. Examples of freezing bags include Cryocyte™ freezing bags, Origen™ freezing bags (Cryostore) and Pall™ freezing bags. Preferably, each freezing bag contains 15 mL of up to 3×109 cells in culture medium (e.g., AIM V, X-VIVO, RPMI, etc.) with approximately 10-12% DMSO and 10-20% heat inactivated, filtered plasma, about 107 to 507 mg/L final concentration of CaCl2 and about 44 to 241 mg/L final concentration of MgSO4. The cells can be frozen using a controlled rate freezer, then stored cryogenically.
- In an alternative embodiment, after incubation of PBMCs and purification by Ficoll density gradient, the PBMCs are resuspended in AIM-V® medium and seeded in T150 cm2 flasks at 2.0×108 cells per flask. In the event that an insufficient number of PBMCs are obtained, the PBMCs may be frozen and combined with a second leukapheresis. Monocytes are selected from the mononuclear cell population of PBMCs by adhesion to sterile tissue culture plastic flasks for one to two hours at 37° C., 5% CO2, ≧75% humidity. Non-adherent and semi adherent cells are removed. PBS is added to the flasks to remove the remaining non-adherent cells, semi-adherent cells and residual medium. The remaining adherent cells are predominantly monocytes, and represent a population of enriched monocytes.
- Methods for Differentiating Monocytes into Dendritic Cells
- A variety of methods for differentiating monocytes into dendritic cells are known to those of ordinary skill in the art. See U.S. Pat. No. 6,607,722, WO 97/29182, Romani, et al. (1994) J. Exp. Med. 180:83-93; Sallusto and Lanzavecchia (1994) J. Exp. Med. 179:1109 and on, and Reddy et al. (1997) Blood 90:3640-3646; the contents of which are incorporated by reference. Most of these methods involve culturing monocytes in the presence of cytokines which induce the differentiation of monocytes into dendritic cells. Examples of alternative methods for differentiating monocytes into dendritic cells include, but are not limited to exposure to physical perturbation (e.g., shearing), irradiation in the presence of a photo-activatable agent capable of forming photoadducts with cellular DNA components, and/or treatment with a DNA binding agent, followed by incubation with disease effector agents, such as microbes, fungi, viruses, and malignant cells. See U.S. Pat. No. 6,607,722, the contents of which are incorporated by reference.
- In one embodiment, monocytes are differentiated into dendritic cells by culture in medium comprising a composition that induces differentiation of monocytes into dendritic cells. Suitable media for the culture of monocytes, immature and mature dendritic cells includes, but is not limited to, AIM-V, X-VIVO-15, RPMI, DMEM, and the like. Compositions that induce the differentiation of monocytes into dendritic cells are known in the art, and include, but are not limited to, GM-CSF plus IL-4; GM-CSF plus IL-13; and IFNα.
- In a preferred embodiment, enriched monocytes are differentiated into dendritic cells by culture in the presence of GM-CSF and IL-4 (see, e.g., WO 97/29182; Sallusto and Lanzavecchia (1994) J. Exp. Med. 179:1109; and Romani et al. (1994) J. Exp. Med. 180:83-93). Briefly, enriched monocytes, preferably at a concentration of 1×106 cells/ml are cultured in AIM V medium, X-VIVO 15 medium, or other suitable medium in the presence 800 U/ml GM-CSF and 500 U/ml IL-4 for approximately 4-7 days, preferably 6 days at 37° C., 5% CO2, ≧75% humidity to allow the differentiation of monocytes into immature dendritic cells. Cytokine concentrations can be varied. For example, preferred concentrations of GM-CSF are 500 to 1500 U/ml, more preferably 700 to 1000 U/ml, most preferably 800 U/ml. Preferred concentrations of IL-4 are 400-1500 U/ml, more preferably 450 to 1000 U/ml, most preferably 500 U/ml. IL-13 or IL-15 can be used in place of or in addition to IL-4. IFNα can be used in place of GM-CSF plus IL-4, IL-13 or IL-15. As the monocytes differentiate into dendritic cells, they progressively lose expression of CD14 and acquire CD80 expression consistent with the phenotype of dendritic cells in the immature state.
- Methods for the Maturation of Immature Dendritic Cells into Mature Dendritic Cells
- Methods of maturing immature dendritic cells into mature dendritic cells are known to those of ordinary skill in the art, and include, but are not limited to, antigen uptake and/or contact with compositions that induce maturation. Compositions that induce maturation of immature dendritic cells include, but are not limited to, monocyte conditioned medium; PBMC conditioned medium; fixed Staphylococcus aureus (Pansorbin™); lipopolysacharrides (LPS); other bacterial cell products, such as monophosphoryllipid A (MPL), lipoteichoic acid, etc.; phosphorylcholine; calcium ionophores; phorbol esters such as PMA; heat-shock proteins; nucleotides, such as ATP, etc.; lipopeptides; Toll-
like receptor 4; artificial ligands for Toll-like receptors; double stranded RNA, such as poly-I:C, etc.; immunostimulant DNA sequences; maturation cocktail (TNF-α, IL-6, IL-1β and PGE2); GM-CSF, IL-4 and maturation cocktail (TNFα, IL-6, IL-1β and PGE2), GM-CSF, IL-4, PGE2 and sequential signaling of IFNγ followed by signaling with CD40L; and the like. See, for example, Cisco et al. (2004) J Immunol 172:7162-7168; Jonluit et al. (1997) Eur J Immunol 27:3135-3142; U.S. patent application 20040203143; PCT application PCT/US2005/036304 and U.S. patent application Ser. No. 11/246,387, the contents of which are incorporated by reference. - In one embodiment, a maturation cocktail containing TNFα, IL-6, IL-1β and PGE2 is added to a culture of immature dendritic cells. The cells are then cultured overnight (approximately 12 hours or more) to produce mature dendritic cells.
- In one alternative embodiment, immature dendritic cells are transfected, preferably by electroporation, with mRNA encoding CD40L, and optionally with mRNA encoding one or more antigens, and then cultured overnight (approximately 12 hours or more) in the presence of IFNγ and optionally PGE2 to produce mature dendritic cells. A human CD40L cDNA and protein are shown in SEQ ID NO:120 and SEQ ID NO:121, respectively. Other CD40L mRNAs are known to those of skill in the art.
- In a preferred embodiment, a maturation formulation in AIM V medium is added directly to the immature DC to give a final concentration of TNF-α (10 ng/ml), IFN-γ (1000 U/ml), and PGE2 (1 μg/ml). The cells can then cultured overnight (approximately 12 hours or more) to produce mature dendritic cells. Maturation can optionally be further increased by exposure of the cells to CD40 Ligand (CD40L), either added to the culture media, or more preferably expressed within the cell. CD40L can be expressed constitutively or transiently. Preferably, the mature dendritic cells are transfected with an mRNA encoding CD40L, and optionally with mRNA encoding one or more antigens of interest.
- Any antigen can be loaded into immature or mature dendritic cells. The antigen will then be processed and presented by the mature DCs. Examples of antigens include, but are not limited to, viral particles, bacteria, or other pathogens, proteins, and fragments thereof, polypeptides, pathogen lysates, pathogen extracts, pathogen nucleic acids, cancer cells, cancer cell proteins and fragments thereof, cancer cell lysates, cancer cell extracts and cancer cell nucleic acids. Antigens can be naturally occurring, chemically processed or recombinantly produced. The antigens can be delivered to the cells as polypeptides, proteins or as nucleic acids using methods known in the art.
- An antigen may be delivered in its “natural” form in that no human intervention was involved in preparing the antigen or inducing it to enter the environment in which it encounters the dendritic cell. Alternatively or additionally, the antigen may comprise a crude preparation, for example of the type that is commonly administered in a conventional allergy shot or in a tumor lysate. The antigen may alternatively be substantially purified, e.g., at least about 90% pure.
- Where the antigen is a peptide, it may be generated, for example, by proteolytic cleavage of isolated proteins. Any of a variety of cleavage agents may be utilized including, but not limited to, pepsin, cyanogen bromide, trypsin, chymotrypsin, etc. Alternatively, peptides may be chemically synthesized, preferably on an automated synthesizer such as is available in the art, or recombinantly expressed. In addition, recombinant techniques may be employed to create a nucleic acid encoding the peptide of interest, and to express that peptide under desired conditions. Alternatively, antigen encoding nucleic acids may be purified or derived from a cell, tissue or virus.
- The antigen can have a structure that is distinct from any naturally-occurring compound. In certain embodiments of the invention, the antigen is a “modified antigen” in that the antigen has a structure that is substantially identical to that of a naturally-occurring antigen but that includes one or more deviations from the precise structure of the naturally-occurring compound.
- For instance, where the naturally-occurring antigen is a protein or polypeptide antigen, a modified antigen as compared with that protein or polypeptide antigen would have an amino acid sequence that differs from that of the naturally-occurring antigen in the addition, substitution, or deletion of one or more amino acids, and/or would include one or more amino acids that differ from the corresponding amino acid in the naturally-occurring antigen by the addition, substitution, or deletion of one or more chemical moieties covalently linked to the amino acid. In one aspect, the naturally-occurring and modified antigens share at least one region of at least 5 amino acids that are at least 75% identical. Those of ordinary skill in the art will appreciate that, in comparing two amino acid sequences to determine the extent of their identity, the spacing between stretches (i.e., regions of at least two) of identical amino acids need not always be precisely preserved. Naturally-occurring and modified protein or polypeptide antigens can show at least approximately 80% identity, more alternatively 85%, 90%, 95%, or greater than 99% identity in amino acid sequence for at least one region of at least 5 amino acids. Often, it may be useful for a much longer region (e.g., 10, 20, 50, or 100 or more amino acids) of amino acid sequence to show the designated degree of identity.
- In preferred embodiments, the antigen is delivered as a polynucleotide or gene encoding the antigen, so that expression of the gene results in antigen production either in the individual being treated (when delivered in vivo) or the cell culture system (when delivered in vitro). Techniques for generating nucleic acids including an expressible gene or mRNA, and for introducing such nucleic acids into an expression system in which any protein encoded by the expressible gene will be produced are known in the art and briefly described infra. Preferably, the antigen is delivered as an mRNA. RNA or mRNA obtained from a cell (for example a cancer cell, pathogen cell or pathogen-infected cell) can be loaded directly into dendritic cells. Alternatively, RNA or mRNA can be amplified prior to loading. In one embodiment, total or targeted mRNA is amplified by RT-PCR using a primer containing a sense promoter to make a cDNA expression construct. RNA transcribed in vitro from the expression construct can then be used to load the cells. Methods for isolating, amplifying, in vitro transcribing the RNA and loading RNA or other nucleic acids into dendritic cells are known to those of skill in the art. See, for example, PCT/US04/39539 and U.S.
provisional application 60/522,310, the contents of which are incorporated by reference. - In one embodiment of the invention, the antigen is one or more HIV proteins or fragments thereof. As a non-limiting example, plasma from an HIV infected patient can serve as a source for isolation of HIV RNA. In one embodiment, a portion of the plasma is centrifuged, and the supernatant is collected and filtered using 0.22 μm filters and stored at −20° C. until use in formulation of the dendritic cell vaccine. The HIV RNA present in plasma is amplified by RT-PCR and in vitro transcription reactions to provide a sufficient quantity of amplified HIV RNA for loading into dendritic cells. Briefly, viral RNA is reverse transcribed in to single-stranded (ss) DNA using a reverse transcriptase, appropriate reaction buffers and random hexamers or targeted reverse primers. The single-stranded cDNA is then amplified by PCR into double-stranded DNA in a primary PCR reaction using multiplex primers. The identity of region(s) amplified in the primary PCR reaction is determined by the selection of specific primers complimentary to target sequences which flank those regions. The product of the primary PCR reaction is purified using a QIAquick® PCR Purification Kit and then serves as the template in a second round or nested PCR amplification. In this round of amplification, the 5′ primers(s) contains an overhang with an RNA polymerase binding site (e.g., a T7 promoter), and the 3′ primer contains an overhang with poly T stretches. The modifications introduced by the overhanging regions in a nested round of PCR enable transcription of the PCR product in vitro and successful translation upon delivery into dendritic cells. Purification of the in vitro transcribed RNA is performed using the Qiagen RNeasy® Kit, and the RNA is eluted in nuclease-free water. If necessary, ethanol precipitation is performed to concentrate the RNA. The RNA is re-suspended in nuclease-free water and passed through a 0.8/0.2 μm polyethersulfone (PES) filter, then dispensed into 0.5 ml safe-lock polypropylene tubes and loaded into DC or cryopreserved at ≦−150° C. for until thawing prior to transfection.
- In another preferred embodiment, RNA or mRNA is extracted from one or more cancer cells. The RNA or mRNA can be loaded directly into dendritic cells, or it can first be amplified by RT-PCR and in vitro transcription using the methods described in PCT/US04/39539.
- Dendritic cells may be loaded with one or more antigens as immature dendritic cells, mature dendritic cells, or during differentiation from immature to mature dendritic cells. Dendritic cells are capable of ingesting antigens, such as proteins, peptides, viruses, cells, cell lysates, and the like. Accordingly, antigen loading can be performed simply by contacting the dendritic cell with the antigen or nucleic acid encoding the antigen. Other methods for loading dendritic cells are known to those of skill in the art, including, but not limited to nucleic acid transfection, exosomes, viral vectors, microparticle delivery, etc. See for example, Mitchell et al. (2000) Curr Opin Mol Ther 2:176-181; Zitovogel et al. (1998) Nature 4:594-600; Jenne et al., (2001) Trends Immunol 22:102-106, and U.S. patent publication 2005/0158856 the contents of which are incorporated by reference. One or more antigens may be loaded directly into the dendritic cells, or nucleic acids encoding one or more antigens may be loaded (transfected) into the dendritic cells. In a preferred embodiment, the dendritic cells are loaded with nucleic acids encoding one or more antigens. Preferably, the nucleic acid is an mRNA.
- Method of transfecting nucleic acids into dendritic cells are known to those of ordinary skill in the art and include, but are not limited to, passive transfection, lipid-mediated transfection, cationic lipid-mediated transfection (e.g., DOTAP), cationic peptide mediated transfection, electroporation. See Nair et al. (1998) Nat Biotechnology 16:364-369; Van Tendeloo et al. (2001) Blood 98:49-56; Saeboe-Larssen et al. (2002) J Immunol Methods 259:191-203; Boczkowski et al (2000) Cancer Res 60:1028-1034; Gilboa et al. Immunol Rev (2004) 199:251-263; U.S.
provisional application 60/583,579; and U.S. patent application Ser. No. 10/177,390, the contents of which are incorporated by reference. - Methods for loading dendritic cells with proteins, polypeptides, peptides, cell or tissue extracts and other types of antigens are known to those of ordinary skill in the art. In a preferred embodiment, immature dendritic cells are loaded with one or more antigens. In one embodiment of the invention, peptides, polypeptides and/or cell or tissue extracts are loaded simply by incubation with immature dendritic cells in culture medium.
- Antigen Loading by Electroporation Followed by Maturation of Immature Dendritic Cells using a Cytokine Cocktail
- In one embodiment of the invention, immature dendritic cells are harvested by tapping the culture flask to dislodge the cells. Cells in suspension are then transferred to conical tubes. PBS is added to the culture flask to remove the remaining floating cells and residual medium, which is added to the conical flask. Some immature dendritic cells may remain adherent to the flask. Detachment of these cells is promoted by adding PBS and incubating the flasks at anywhere from 2° C. up to room temperature. At the end of the incubation period, the flasks are tapped and the dislodged cells are added to the conical tubes. The total cell suspension is then pelleted, washed in PBS and re-suspended in chilled ViaSpan® at 4×107/ml in 0.5 ml and placed on ice. DCs are mixed with mRNA at 2 μg/106 cells for mRNA encoding antigen(s) and placed in a 4 mm gap electroporation cuvette and electroporated at a pulse of 275-350V, 100-300Ω and 150 μF, and preferably at 325V, 200Ω. Immediately after electroporation, DCs are washed in X-VIVO 15 medium and re-suspended at 1×106/ml in X-VIVO 15 supplemented with GM-CSF (800 U/ml), IL-4 (500 U/ml) and PGE2 (1 μg/ml), TNF-α (10 ng/ml), IL-1β (10 ng/ml) and IL-6 (100 ng/ml). The immature dendritic cells are then incubated overnight at 37° C., 5% CO2, ≧75% humidity to produce stably mature dendritic cells. Mature dendritic cells are then washed in PBS.
- Antigen Loading by Electroporation and Maturation using CD40L
- In one embodiment of the invention, immature dendritic cells are matured using CD40L and IFN-γ. Preferably, immature DCs are transfected with 4 μg CD40L mRNA per 106 and mRNA (2 μg/106 cells) encoding one or more antigens by electroporation as described above, and then are cultured overnight in X-VIVO 15 supplemented with GM-CSF (800-1000 U/ml), IL-4 (500-1000 U/ml), IFN-γ (500-1000 U/ml) or TNF-α (10 ng/ml) and PGE2 (1 μg/ml) to generate stable mature dendritic cells. Dendritic cells matured by this process secrete higher levels of IL-12 (a T cell growth factor), and minimal IL-10, as compared to dendritic cell matured by the cytokine cocktail process described above.
- Mature Dendritic cells can be loaded with antigen by methods known to those of skill in the art. In one non-limiting embodiment of the invention, on the sixth day after initiating differentiation of monocytes into immature dendritic cells, a maturation formulation in AIM V medium is added directly to the immature DC to give a final concentration of TNF-α (10 ng/ml), IFN-γ (1000 U/ml), and PGE2 (1 μg/ml). The cells are then cultured overnight to produce mature dendritic cells. The DC are then harvested and co-electroporated with 1 μg of antigen encoding RNA and optionally with 4 μg of CD40L RNA per 106 cells. Post-electroporation, the cells are cultured for 4 hours at 1×106 cells AIM V medium supplemented with GM-CSF (800 U/mL), and IL-4 (500 U/mL). The cells can then be formulated for administration to a subject without freezing, or formulated for freezing. For freezing, the cells are preferably formulated in heat inactivated autologous plasma, 10% DMSO, and 5% dextrose at 2×107 cells/mL. Cryogenic vials are filled with 0.7 mL for a total number of 1.4×107 cells per vial. Vials are then frozen in alcohol boxes at −85° C. for a minimum of 4 hours and transferred to the cryogenic freezer for storage. The frozen dendritic cell vaccine can then be thawed and administered to a subject without washing or reformulation.
- In a preferred method, 106 DCs are harvested and re-suspended in chilled PBS/1% FCS. Phycoerythrin (PE) or FITC conjugated antibodies specific for MHC molecules (HLA-ABC, HLA-DR), co-stimulatory molecules (CD80, CD86), maturation markers (CD83) and monocyte markers (CD14) are mixed with 1×105 DCs per well in a 96 well plates (BD Biosciences) and incubated at 4° C. for a minimum of 15 minutes. Isotype matched antibodies were used as controls. After thorough washing, fluorescence analysis was performed with a FACScalibur flow cytometer (BD Biosciences) using CellQuest software (BD Biosciences).
- Methods for formulating dendritic cell vaccines are known to those of skill in the art. In a preferred embodiment, the mature dendritic cells are washed and resuspended in heat-inactivated plasma (preferably autologous plasma) and 10% dextrose at a concentration of 4×107 cells/ml. The cells can then be diluted 1:1 with a mixture of heat-inactivated plasma and 20% DMSO to give a final concentration of 5% dextrose, 10% DMSO in heat-inactivated plasma. The target final filled formulation is 1.4×107 cells/0.7 ml in a container suitable for cyropreservation. The dendritic cells can then be administered to a patient or frozen, preferably at −85° C., and stored in cryogenic freezer (preferably in a dry liquid nitrogen freezer designed to prevent contamination), preferably at a temperature of ≦−150° C. The frozen vaccine can then be shipped to a clinical site for patient administration (preferably by intradermal injection). Upon thawing, the vaccine can be administered directly to the patient without further processing.
- Other suitable formulations for administration can include aqueous isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, preservatives, immunostimulants, cytokines and adjuvants.
- In a preferred embodiment, mature dendritic cells are suspended in heat-inactivated autologous plasma and 10% dextrose, at a final concentration of 4×107 cells/ml. These cells are then diluted 1:1 with a mixture of heat-inactivated autologous plasma and 20% DMSO to give a final concentration of 2×107 cells/ml in heat inactivated autologous plasma which contains 5% dextrose and 10% DMSO. The final filled formulation is 1.4×107 cells/0.7 ml in a container suitable for cyropreservation. The vaccine is then frozen and stored at ≦−150° C. in a dry liquid nitrogen freezer. The vaccine is ready for administration after thawing, without the need for washing and resuspending.
- The dendritic cell vaccine can be administered by a variety of methods, such as, but not limited to, injection (e.g., subcutaneous, intradermal, intravenous, intralymphatic, intraarticular, intramuscular, intraperitoneal), by continuous infusion, sustained release from implants, etc. DC vaccines have typically been administered at two to four week intervals. The dendritic cell vaccine can be administered with physiologically acceptable carriers, buffers, dilutents, adjuvants, immunomodulaters, etc. Preferably, the dendritic cell vaccine is autologous to the patient it is administered to, or is HLA matched.
- The dose of cells (e.g., activated T cells, or dendritic cells) administered to a subject is in an effective amount, effective to achieve the desired beneficial therapeutic response in the subject over time, or to inhibit growth of cancer cells, or to inhibit infection. A preferred dose is approximately 107 cells. Biological response modifiers are optionally added for treatment by the DCs or activated T cells of the invention. For example, the cells are optionally administered with an adjuvant, or cytokine such as GM-CSF, IL-12 or IL-2.
- The immunogenicity of the antigen-loaded dendritic cells or educated T cells produced by the methods of the invention can be determined by well known methodologies including, but not limited to the following:
- 51Cr-release lysis assay. Lysis of peptide-pulsed 51Cr-labeled targets by antigen-specific T cells can be compared. “More active” compositions will show greater lysis of targets as a function of time. The kinetics of lysis as well as overall target lysis at a fixed timepoint (e.g., 4 hours) may be used to evaluate performance. Ware, C. F. et al. (1983) J. Immunol. 131:1312.
- Cytokine-release assay. Analysis of the types and quantities of cytokines secreted by T cells upon contacting modified APCs can be a measure of functional activity. Cytokines can be measured by ELISA or ELISPOT assays to determine the rate and total amount of cytokine production. Fujihashi, K. et al. (1993) J. Immunol. Meth. 160:181; Tanquay, S. and Killion, J. J. (1994) Lymphokine Cytokine Res. 13:259.
- In vitro T cell education. The compositions of the invention can be assayed for the ability to elicit reactive T cell populations from normal donor or patient-derived PBMC. In this system, elicited T cells can be tested for lytic activity, cytokine-release, polyclonality, and cross-reactivity to the antigenic epitope. Parkhurst, M. R. et al. (1996) J. Immunol. 157:2539.
- Proliferation Assays. T cells will proliferate in response to reactive compositions. Proliferation can be monitored quantitatively by measuring, for example, 3H-thymidine uptake. Caruso, A. et al. (1997) Cytometry 27:71.
- Transgenic animal models. Immunogenicity can be assessed in vivo by vaccinating HLA transgenic mice with the compositions of the invention and determining the nature and magnitude of the induced immune response. Alternatively, the hu-PBL-SCID mouse model allows reconstitution of a human immune system in a mouse by adoptive transfer of human PBL. These animals may be vaccinated with the compositions and analyzed for immune response as previously mentioned in Shirai, M. et al. (1995) J. Immunol. 154:2733; Mosier, D. E. et al. (1993) Proc. Natl. Acad. Sci. USA 90:2443.
- Primate models. A non-human primate (chimpanzee) model system can be utilized to monitor in vivo immunogenicities of HLA-restricted ligands. It has been demonstrated that chimpanzees share overlapping MHC-ligand specificities with human MHC molecules thus allowing one to test HLA-restricted ligands for relative in vivo immunogenicity. Bertoni, R. et al. (1998) J. Immunol. 161:4447.
- Monitoring TCR Signal Transduction Events. Several intracellular signal transduction events (e.g., phosphorylation) are associated with successful TCR engagement by MHC-ligand complexes. The qualitative and quantitative analysis of these events have been correlated with the relative abilities of compositions to activate effector cells through TCR engagement. Salazar, E. et al. (2000) Int. J. Cancer 85:829; Isakov, N. et al. (1995) J. Exp. Med. 181:375).
- Cell isolation or immunoassays for detection of cells during cell purification can be performed in any of several configurations, e.g., those reviewed in Maggio (ed.) (1980) Enzyme Immunoassay CRC Press, Boca Raton, Fla.; Tijan (1985) “Practice and Theory of Enzyme Immunoassays,” Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers B.V., Amsterdam; Harlow and Lane, supra; Chan (ed.) (1987) Immunoassay: A Practical Guide Academic Press, Orlando, Fla.; Price and Newman (eds.) (1991) Principles and Practice of Immunoassays Stockton Press, NY; and Ngo (ed.) (1988) Non-isotopic Immunoassays Plenum Press, NY.
- Cells can be isolated and characterized by flow cytometry methods such a FACS analysis. A wide variety of flow-cytometry methods are known. For a general overview of fluorescence activated flow cytometry see, for example, Abbas et al. (1991) Cellular and Molecular immunology W.B. Saunders Company, particularly
chapter 3, and Kuby (1992) Immunology W.H. Freeman and Company, particularlychapter 6. FACS machines are available, e.g., from Becton Dickinson. - Labeling agents which can be used to label cell antigen include, but are not limited to monoclonal antibodies, polyclonal antibodies, proteins, or other polymers such as affinity matrices, carbohydrates or lipids. Detection proceeds by any known method, such as immunoblotting, western blot analysis, tracking of radioactive or bioluminescent markers, capillary electrophoresis, or other methods which track a molecule based upon size, charge or affinity.
- The following examples are intended to illustrate, rather than to limit the invention.
- Peripheral blood mononuclear cells (PBMCs) were collected from 4 human donors by leukapheresis and transported by overnight delivery to a dendritic cell manufacturing facility in temperature-monitored shipping containers maintained at a temperature of 8° C.-26° C. The day of delivery, the leukapheresis product underwent Ficoll density gradient centrifugation in 50 ml conical tubes (800×g) for 20 minutes at room temperature (approximately 19-22° C.) to separate and concentrate the mononuclear cell fraction that includes the dendritic cell precursors (monocytes). After two washing steps with phosphate buffered saline (PBS), cell concentration and cell viability were determined. After the third centrifugation/washing step with PBS, mononuclear cells were resuspended in StemSpan™ H2000 medium (StemCell Technologies, Inc.) and seeded in T150 cm2 flasks at 2.0×108 cells per flask. Monocytes were then selected from the mononuclear cell population by adhesion to the sterile tissue culture plastic flask for 1-2 hours at 37° C., 5% CO2, ≧75% humidity. Non-adherent and semi-adherent cells (primarily lymphocytes) were discarded. The remaining adherent cells, which were predominantly monocytes, were cultured in StemSpan™ H2000 medium containing GM-CSF (800 U/ml) and IL-4 (500 U/ml). These cells were incubated for 6 days at 37° C., 5% CO2, ≧75% humidity to allow the differentiation of monocytes into immature dendritic cells.
- The immature dendritic cell-rich population was harvested by gently tapping the flasks to dislodge the cells. Cells in suspension were transferred to conical tubes. Additional PBS was added to the flasks to remove the remaining floating cells and residual media and added to the cell suspension in the conical tubes. Detachment of the remaining adherent cells was completed by adding PBS and incubating the flasks at 2-8° C. for approximately 10 minutes. While these cells were incubating, the cell suspension in the conical tubes was centrifuged, and the cell pellet was resuspended in PBS. At the end of the incubation period, the flasks were gently tapped and the contents added to the cell suspension in the conical tubes. The total cell suspension was pelleted and resuspended in PBS, and a sample was removed for cell concentration, cell viability and immunophenotyping. The following four sets of cell markers were examined by flow cytometry: monocyte lineage markers (CD3, CD14, CD19, and CD56), indication of presence of dendritic cells (CD11c), an antigen presenting cell marker (HLA-DR), and a mature dendritic cell marker (CD83). The immature dendritic cell-enriched preparation expressed insignificant levels of lineage markers and CD83, and high levels of CD11c and HLA-DR.
- Immature dendritic cells were washed once with OPTI-MEM® I reduced serum medium (GIBCO™) with HEPES buffer, L-glutamine, without phenol red. The dendritic cells were then transfected with amplified tumor RNA by electroporation at a ratio of approximately 2 μg of RNA per 106 dendritic cells. Electroporation was performed in 4 mm gap cuvettes containing 600 μL of a cell suspension containing 5×107 cells/ml, at a pulse of 500 V for 500 μs. After electroporation, transfected cells were transferred into T150 flasks (one cuvette per flask) containing StemSpan H2000™ medium (serum free culture medium), supplemented with IL-4 (500 U/ml) and GM-CSF (800 U/ml). Transfected cells were incubated at for 2-3 hours at 37° C., 5% CO2, ≧75% humidity to allow the cells to recover from electroporation.
- The immature electroporated dendritic cells were matured in StemSpan H2000™ medium, supplemented with IL-4 (500 U/ml) and GM-CSF (800 U/ml) and a maturation cocktail (IL-1β at 5 ng/ml, IL-6 at 150 ng/ml, TNF-α at 5 ng/ml and PGE2 at 1 μg/ml) at 37° C., 5% CO2, ≧75% humidity for 20-24 hours. All cytokines, as well as PGE2, were reconstituted or diluted (in the case of PGE2) in PBS with 1% HSA. Prior to the dilution step, PGE2 was reconstituted in ethanol. Mature dendritic cells were then rinsed with PBS prior to adding cell dissociation buffer (trypsin free) and then washed three times with PBS to remove the cell dissociation buffer. Samples were collected for cell concentration, viability and immunophenotyping. A comparison of the immunophenotyping of immature and mature dendritic cells is shown in Table 1.
-
TABLE 1 Donor 39 Donor 40Donor 41 Donor 42 Average S.D. Immature DCs % viability (Trypan) 96.0 95.0 96.0 97.0 96.0 0.8 % yield (PBMC) 6.1 2.3 1.9 6.0 4.1 2.3 IMMUNOPHENOTYPE Gated on small + large cells % CD3+ 1.2 1.4 0.8 0.9 1.1 0.3 % CD19+ 1.9 11.7 3.5 4.8 5.5 4.3 % CD14+ 1.4 0.3 0.3 0.0 0.5 0.6 % CD56+ 1.0 1.1 0.8 1.0 1.0 0.1 CD3+CD19+CD14+CD56+ 5.5 14.5 5.4 6.7 8.0 4.4 Gated on large cells % CD11c+ 99.6 97.8 99.7 99.7 99.2 0.9 % CD80+ 26.6 77.3 37.0 46.6 46.9 21.9 % CD83+ 2.2 2.5 2.3 8.2 3.8 2.9 % CD86+ 92.1 42.4 66.2 82.0 70.7 21.7 % HLA-DR+ 90.8 74.9 72.4 42.7 70.2 20.1 Mature DCs Tumor Source Melanoma Renal CC Renal CC Melanoma % viability (Trypan) 93.0 83.0 88.0 91.0 88.8 4.3 % yield (PBMC) 73.0 72.0 61.0 57.3 65.8 7.9 IMMUNOPHENOTYPE Gated on small + large cells % CD3+ 1.2 1.2 0.9 1.0 1.1 0.2 % CD19+ 2.3 11.3 2.2 5.3 5.3 4.3 % CD14+ 1.4 0.4 0.9 0.1 0.7 0.6 % CD56+ 1.0 1.4 2.0 0.9 1.3 0.5 CD3+CD19+CD14+CD56+ 5.9 14.3 6.0 7.3 8.4 4.0 Gated on large cells % CD11c+ 99.6 98.9 99.4 99.6 99.4 0.3 % CD80+ 90.8 92.8 92.9 91.8 92.1 1.0 % CD83+ 75.0 50.8 79.2 72.9 69.5 12.7 % CD86+ 99.4 94.2 98.8 99.1 97.9 2.5 % HLA-DR+ (MHC class II) 97.5 97.2 98.1 93.9 96.7 1.9 - Transfected mature dendritic cells were suspended in autologous plasma at a final concentration of 2×107 cells/ml. The cells were then diluted 1:1 with a mixture of 80% plasma and 20% DMSO to give a final concentrations of 3×106 or 1×107 cells/ml in 90% plasma with 10% DMSO, then frozen in cryovials using controlled-rate freezing, and stored at ≦−150° C.
- A frozen dendritic cell vaccine prepared as described in Example 1 was thawed at 37° C., and kept at 20-25° C. or at 2-8° C. for 2 hours. Viability was determined immediately post-thaw and at 30 minute intervals for up to two hours. Viability immediately post-thaw at 37° C. was 92%. The results are shown in Table 2, and confirm that the vaccine can be thawed and stored in 10% DMSO for at least two hours.
-
TABLE 2 Viability (%) Post-thaw 20-25° C. 2-8° C. time (minutes) Post-thaw Post-thaw 30 91 88 60 89 86 90 89 80 120 87 83 - Peripheral blood mononuclear cells and plasma were collected from a patient or volunteer by leukapheresis at room temperature at a clinical site. The leukapheresis product (PBMCs) and serum were shipped overnight in a temperature controlled container maintained in a temperature range of 6-28° C. The day following leukapheresis, the PBMCs were purified by Ficoll density gradient centrifugation in 50 ml conical tubes at room temperature to separate and concentrate the mononuclear cell fraction that includes monocytes (the dendritic cell precursors) and leukocytes. The mononuclear cells were washed several times in phosphate buffered saline (PBS), and the cell concentration was determined. After the final centrifugation/washing step with PBS, mononuclear cells were resuspended in AIM-V medium and seeded in T150 cm2 flasks at 2.0×108 cells per flask. Monocytes were then selected from the mononuclear cell population by adhesion to sterile tissue culture flasks for one to two hours at 37° C., 5% CO2, ≧75% humidity. Nonadherent and semi-adherent cells were removed by gentle washing with PBS. The remaining adherent cells, which were predominantly monocytes, were cultured in X-VIVO 15 culture medium containing 1000 U/ml GM-CSF and 1000 U/ml IL-4. The cells were incubated for 6 days at 37° C., 5% CO2, ≧75% humidity to allow differentiation of monocytes into immature dendritic cells.
- Following in vitro culture, the immature dendritic cell-rich population was harvested by tapping the flasks to dislodge the cells. Cells in suspension were transferred to conical tubes. PBS was added to the flasks to remove the remaining floating cells and residual medium, and then added to the cell suspension in the same conical tubes. Detachment of remaining adherent immature dendritic cells was promoted by incubation in PBS at 2-8° C. At the end of the incubation period, the flasks were tapped and the contents added to the cell suspension in the same conical tubes. The total cell suspension was then pelleted and resuspended in PBS, and a sample was removed to determine the cell concentration.
- Immature dendritic cells were washed and resuspended in ViaSpan and transfected with 2 μg antigen-encoding mRNA per 106 dendritic cells. Electroporation was performed in 4 mm gap cuvettes containing 0.4 ml of the cell suspension (4×107 cells/ml) at a pulse of 300V, 100Ω and 150 μF. After electroporation, transfected cells were diluted with X-VIVO 15 medium, centrifuged and resuspended in X-VIVO 15 medium (serum free) supplemented with GM-CSF (800 U/ml), IL-4 (500 U/ml), IL-1β (10 ng/ml), IL-6 (150 ng/ml), TNF-α (10 ng/ml) and PGE2 (1 μg/ml). The cells were incubated at 37° C., 5% CO2, ≧75% humidity overnight to mature.
- Transfected mature dendritic cells were suspended in heat-inactivated autologous plasma and 10% dextrose, at a final concentration of 4×107 cells/ml. The cells were then diluted 1:1 with a mixture of 20% DMSO to give a final concentration of 2×107 cells/ml in heat-inactivated autologous plasma which contains 10% DMSO and 5% dextrose, and then frozen in sterile cryovials at ≦−150° C.
- The data in this example supports the functionality and feasibility of producing RNA transfected dendritic cells from day-old apheresis product. Dendritic cells were prepared by the method described in Example 3. The data below shows that dendritic cells can be reproducibly manufactured at the appropriate yield from a single day-old apheresis product and that the resulting cells (1) exhibit a classical mature phenotype, (2) can be efficiently transfected with RNA, and (3) can be cryopreserved with high post-thaw viability.
- Immunophenotype of DCs. The mature DCs were extensively characterized by FACS staining for molecular markers that should be present or absent from the final cell preparation. HLA-DR, CD83, CD86, CD80, CD1a, and CD209 should show high expression and CD14, CD56, CD19, and CD3 should show low expression. Table 3 (below) shows the results (mean and standard deviation for percent positive cells) compiled from 11 consecutive runs of producing dendritic cell vaccines from PBMCS obtained from different healthy donors.
-
TABLE 3 Expression of Cell Surface Markers in DCs produced from Day Old Monocytes % positive cells % positive cells Marker (Mean) Standard Dev. HLA-DR 99.08 1.21 CD83 91.46 4.97 CD14 0.87 0.89 CD56 6.45 6.85 CD19 1.57 0.71 CD3 2.33 0.66 CD86 98.87 1.66 CD80 83.73 25.50 CD1a 56.15 19.45 CD209 95.73 4.81 - These data, along with photomicrographs (not shown) demonstrate that the DCs produced by the methods of the invention conditions exhibit the classical DC phenotype and morphology. Furthermore, the relatively low standard deviations are indicative of the reproducibility of the process.
- Yield, phenotype and viability. The dendritic cell methods have been thoroughly tested and shown to reproducibly generate high-quality RNA-transfected mature dendritic cells. Table 4 shows the outcome of 11 vaccine runs using total amplified tumor cell line RNA as the antigen payload and normal donor dendritic cells as the vehicle.
-
TABLE 4 Summary of release test results for DC vaccine product generated in 11 consistency runs Consistency MatDC Phenotype Post Thaw Run CD14 CD83 HLA-DR Viability Doses 1 1.5% 86.6% 99.7% 81% 5 2 0.7% 95.0% 100.0% N/ A 2 3 2.9% 94.8% 99.9% 93% 22 4 0.3% 89.6% 96.1% 88% 15 5 2.0% 81.2% 97.7% 64% 17 6 0.5% 92.7% 100.0% 88% 34 7 0.1% 85.8% 98.7% 84% 20 8 0.6% 95.2% 99.5% 85% 12 9 0.5% 93.0% 99.8% 83% 18 10 0.3% 96.4% 99.8% 90% 38 11 0.2% 95.6% 98.6% 88% 12 Mean ± SD 0.9% ± 0.9% 91.4% ± 5.0% 99.0% ± 1.2% 84% ± 8% 17.7 ± 10.8 For 11 Runs - Matured RNA-transfected DCs express CCR7 and are migratory. In addition to the mature DC markers described above, CCR7 expression, which is critical for lymph node migration of the DCs in vivo, was evaluated. In this study FACS analysis with a CCR7-specific antibody was used to examine thawed RNA-transfected DCs produced using the full-scale GMP process (consistency runs 3, 4, 6, 7, 8, and 10). The results are shown in Table 5 below:
-
TABLE 5 Percentage of CCR7+ Dendritic Cells IgG isotype CCR7 control antibody Run # 3 0.37* 41.9 Run # 40.12 44.6 Run # 60.14 42.42 Run # 70.65 42.96 Run #8 0.17 26.94 Run # 100.13 32.76 *% positive cells - In addition to demonstrating the physical presence of CCR7 on the DCs after maturation, it was demonstrated that DCs also have migratory capacity using the collagen gel matrix spontaneous migration assay, which indicates that the expressed CCR7 is also functional (data not shown).
- RNA-transfected DCs provide functional costimulatory support. The experiments described above show that the manufactured DCs express all of the critical costimulatory markers, while the experiments below demonstrate that these molecules are functional. To this end, the ability of the DCs to stimulate interferon gamma (IFN-γ) production from PBMCs in an allo mixed lymphocyte (MLR) assay was determined using thawed DCs manufactured from 3 different donors along with previously frozen PBMCs from each donor. The expectation was that DCs would not stimulate INF-γ production from their HLA-matched autologous PBMCs but would do so when mixed with non-autologous PBMCs. All pair wise combinations were tested using ELISPOT (INF-γ) as the readout. The data is presented in
FIG. 2 . The result of this experiment demonstrates that, as anticipated, only mismatched DC/PBMC combinations elicit INF-γ production, a property which requires expression of functional MHC and costimulatory molecules. - Matured DCs have added functionality. In this experiment, the cytokine cocktail used to mature the DCs post-transfection and pre-freeze contains TNF-α, IL-1β, IL-6, and PGE2. To demonstrate that matured DCs are superior to the immature DCs, the ability of these two populations (from the same donor) to stimulate
T H1 cytokine production from autologous T cells. Both populations of DCs were transfected with RNA encoding Flu matrix protein and used to stimulate Flu-specific memory CTL from autologous PBMCs.FIG. 3 below shows the results of the ELISPOT analyses (# spots/well as a function of input PBMC). No statistical difference between immature and mature DCs to elicit INF-γ production from Flu-specific memory T cells was observed. However, only the mature DCs could also elicit IL-2 production from these cells. IL-2 induction is considered to be an important because (1) induced IL-2 secretion sustains autocrine antigen-specific CTL proliferation and (2) low production of INF-γ and IL-2 has recently been shown to correlate with increased mortality risk in HIV patients and in a recent study, lack of secretion of INF-γ or IL-2 has resulted in impaired T cell function and an inability to maintain central memory responses. For simplicity, the negative controls were not graphed. The average number of spots observed from the PBMC alone (i.e., no DCs) was 9.7 (INF-γ) and 1.3 (IL-2). This experiment was repeated with vaccines made from the PBMCs of 3 independent donors and the results were qualitatively identical. Accordingly, the mature DCs have added and superior functionality compared to the immature DCs. - Post-thaw RNA-transfected DCs are stable. While clinical protocols may specify immediate injection of the dendritic cell vaccine upon thawing, unforeseen circumstances could arise that might delay administration. To demonstrate that the DCs would remain viable and functional if thawed but not immediately injected, the following experiment was performed. Two vials each of 2 dendritic cell preparations corresponding to 2 different healthy donors were thawed. One vial from each donor was immediately tested in an allo MLR assay while the second vial from each preparation was allowed remain at room temperature for 40 minutes before being assayed by the same method. The PBMCs used in this experiment included autologous cells from each donor as well as a third sample of PBMCs from a donor unrelated to either. The readout for this assay was ELISPOT (INF-γ). The result of this experiment is shown in
FIG. 4 and indicates that there is no appreciable difference in function between the DCs assayed immediately upon thawing and those that remained at room temperature for 40 minutes. In addition to this functional assay, cell viability post-thaw and 40 minutes post-thaw by trypan dye exclusion was determined and identical results were obtained (data not shown). - Freeze-thaw does not affect DC function. To assess whether DC function is adversely affected by the freeze-thaw process, the functionality of DCs pre-freeze and post-thaw was compared. Functionality was assessed by the ability of the DCs to stimulate a memory Flu-specific response from autologous PBMC as a function of decreasing Flu mRNA concentration used for transfection. The assay readout was ELISPOT (INF-γ). Results are shown in
FIG. 5 below and indicate that the freeze-thaw process has no effect on the functionality of the DCs in this assay. A constant amount of GFP mRNA (0.5 μg) was mixed in to monitor transfection efficiencies. Post-thaw samples were thawed after being frozen for 24 hours. - Protein expression after electroporation of DCs with mRNA. As a first step, we assessed whether transfection of DCs with mRNA leads to the proper expression of the mRNA-encoded protein. For preparation of DCs, PBMCs (either fresh or frozen) obtained by leukapheresis from healthy volunteers were enriched for monocytes by adherence to plastic flask following a 2-hour incubation in vitro. After washing, adherent cells were cultured for six days in X-VIVO 15 medium supplemented with recombinant granulocyte/macrophage-colony stimulating factor (rGM-CSF) and interleukin-4 (rIL-4) to generate immature DCs (iDCs). iDCs were then electroporated (300V, 150 μF, 100Ω) with RNA encoding viral or control proteins and induced to mature for 24 hours in X-VIVO 15 medium supplemented with IL-1β, IL-4, IL-6, GM-CSF, TNF-α and prostaglandin E2 (PGE2). To test the expression of protein following transfection, DCs were electroporated with RNA encoding the Green Fluorescent Protein (GFP) and expression was measured by flow cytometry. As shown in
FIG. 6 , a large fraction of mature DCs produced from day-old monocytes expresses high levels of GFP up to four days after transfection, confirming that this method is efficient at promoting long-term protein expression in DCs. - Next, the ability of autologous DCs transfected by electroporation with mRNA encoding the CMV pp65 protein to induce CD4 and CD8 T cell responses in PBMCs from CMV-infected individuals was determined. CMV-infected subjects were identified by stimulating PBMCs from several blood donors with well-defined immunodominant peptides derived from the pp65 protein and measuring IL-2/IFN-γ secretion as well as cell proliferation in both CD4 and CD8 T cells. Individuals in which positive CMV-specific T cell responses were detected and who agreed to undergo leukapheresis after informed consent were selected for further studies.
- DCs from these individuals were prepared as described above. Mature DCs transfected with RNA encoding the CMV pp65 protein were then incubated for 16 hours (ICS) or 6 days (proliferation) with autologous PBMCs at a 1/40 ratio. After stimulation, IL-2 and IFN-γ secretion (
FIG. 7 ) and proliferation (FIG. 8 ) of CMV-specific CD4 and CD8 T cells was assessed by flow cytometry. DCs electroporated with CMV pp65 RNA selectively induced high IFN-γ and IL-2 expression as well as proliferation of CD8 T cells from CMV-infected subjects. However, this protocol induces minimal CD4 T cell activation, as shown by the low level of cytokine secretion and proliferation detected in CD4 T cells (FIGS. 7 and 8 , lower panels). - PBMC's from day-old leukapheresis maintained at a temperature of 6-28° C. were washed and seeded @˜2×108/flask in AIM-V media for a 2 hour adherence step. After 2 hours, non-adherent cells were removed, and adherent cells were washed and resuspended in X-VIVO 15 supplemented with 1000 U/ml GM-CSF and either 500 U/ml or 1000 U/ml IL-4; incubated @ 37° C. for 6 days. In addition, for culture in X-VIVO 15 supplemented with 1000 U/ml GM-CSF and 500 U/ml IL-4, the effect of changing the medium on
day 3 was compared to culture for 6 days without a change in medium. Specifically, onday 3, media was removed along with cells in suspension; the flask was gently washed with X-VIVO media to harvest loosely adherent cells; and the media and wash were centrifuged @ 1300 rpm for 8 minutes to pellet cells. The cells were resuspended in fresh X-VIVO 15 medium supplemented with 1000 U/ml GM-CSF and 500 U/ml IL-4; the media and cells added back into flasks still containing the adherent cells; and the flasks were incubated @ 37° C. for a further three days. - All flasks were harvested individually for electroporation.
Day 6 DCs were transfected with 2 μg GFP mRNA per 106 cells (20 μg GFP mRNA per 5×106 cells), resuspended in X-VIVO 15 and seeded at 1×106/ml; supplemented with 800 U/ml GM-CSF and 500 U/ml IL-4 and matured with cytokine cocktail (TNFα—10 ng/ml; IL-1β—10 ng/ml; IL-6—100 ng/ml; PGE2—1 μg/ml). The DC's were incubated overnight @ 37° C.; 5% CO2. Phenotyping was undertaken on immature DC's on day 6 (immature DC;FIG. 9 ) and 24 hours post transfection (mature DC;FIG. 10 ). The yield (% Rec) and viability (% V) for each culture condition immediately post transfection and at 24 hour post transfection is shown in Tables 6A-C. -
TABLE 6A 1000 U/ml IL-4 DC DC yield % DC per DC @0 hr % @24 hr % day 6 Rec % V Tn post Tn Rec % V post Tn Rec % V F1 3.76 × 107 21 97 5 × 106 2.08 × 106 42 81 1.03 × 106 21 84 F2 3.88 × 107 22 94 5 × 106 2.41 × 106 48 84 8.80 × 105 18 91 F3 4.44 × 107 25 96 5 × 106 2.06 × 106 41 83 8.10 × 105 16 84 pooled 2 × 107 1.04 × 107 52 80 7.40 × 106 37 94 pooled 2 × 107 1.11 × 107 56 93 7.50 × 106 38 93 -
TABLE 6B 500 U/ml IL-4 DC DC yield % DC per DC @0 hr % @24 hr % day 6 Rec % V Tn post Tn Rec % V post Tn Rec % V F1 4.16 × 107 23 97 5 × 106 2.81 × 106 56 77 1.19 × 106 24 87 F2 4.23 × 107 24 97 5 × 106 2.43 × 106 49 84 1.32 × 106 26 85 F3 3.87 × 107 22 96 5 × 106 3.26 × 106 65 84 1.52 × 106 30 89 -
TABLE 6C 500 U/ml IL-4, change medium on day 3DC DC yield % DC per DC @0 hr % @24 hr % day 6 Rec % V Tn post Tn Rec % V post Tn Rec % V F1 2.81 × 107 16 94 5 × 106 1.79 × 106 36 62 9.6 × 105 19 82 F2 2.82 × 107 16 93 5 × 106 2.37 × 106 47 69 9.0 × 105 18 83 F3 2.06 × 107 11 85 5 × 106 2.15 × 106 43 71 1.07 × 106 21 84 - Elutriation, also known as counter-flow centrifugation, was performed on the Elutra™ Cell Separation System (Gambro BCT, Lakewood, Colo.) as an automated method to isolate monocytes from a day old leukapheresis, which had been shipped to the manufacturing facility from a collection site by overnight delivery in a temperature controlled (6-28° C.) container. Elutriation buffer was prepared by adding 1000 mL of 5% Human Albumin Serum (HSA, Baxter Healthcare, Westlake, Calif.) to a 4 L bag of Hank's Balanced Salts Solution (HBSS, Cambrex Bio Science, Walkersville, Md.). This elutriation buffer was added to the day old pheresis product in a volume equal to that of the pheresis. The Elutra™ Cell Separation System (Gambro BCT, Lakewood, Colo.) was primed with elutriation buffer and the pheresis product was loaded. After the elutriation procedure was performed, monocytes were collected from the rotor off fraction. The monocytes were stored frozen.
- Frozen elutriated monocytes were thawed, and then differentiated at 1 million cells/mL in X-VIVO 15 (Cambrex Bioscience, Walkersville, Md.) with 800 U/mL GM-CSF (Berlex Laboratories, Richmond, Calif.) and 500 U/mL IL-4 (R&D Systems, Minneapolis, Minn.) in flasks for 5 days to produce immature dendritic cells (iDC). The iDC were harvested, and antigen loaded with amplified RCC tumor RNA using electroporation. Cells were cultured with 800 U/ml GM-CSF, 500 U/ml IL-4 and maturation cytokines (TNF-α, IL-1β, IL-6, and PGE2) and harvested after 24 hours of culture. Cell count and viability for the mature dendritic cells (mDC) were determined using Trypan blue exclusion by the ViCell (Beckman Coulter Inc., Fullerton, Calif.). The resulting mDC were phenotyped. The cells cultured in flasks were 99% CD83+ and 0.2% CD14+. The yield of mDC was 34% of the CD14+ cells cultured in flasks.
- Peripheral blood was collected from 3 healthy human donors on three separate days by leukapheresis and transported to the University of Montreal within 30 minutes post collection. Twenty mL of the leukapheresis was removed and autologous plasma was prepared by centrifugation. The leukapheresis volume was divided into two equal parts. One part was processed immediately to generate “fresh” monocytes while the second part was stored as 20 mL aliquots in five 50 mL conical tubes to generate cells from a “day old pheresis”. The tubes were placed in a plastic container within a box that was stored tilted on a rocking platform between 16-20° C. for 24 hours. Following the incubation period, the PBMCs were separated using Ficoll density gradient.
- A mononuclear cell fraction that includes the dendritic cell precursors (monocytes) was separated from both fresh and day old pheresis using a Ficoll density gradient. The Leukapheresis was layered onto Ficoll in 50 mL conical tubes and tubes were centrifuged (800×g) for 20 minutes at room temperature. Cells were washed four times with phosphate buffered saline (PBS), and counted to determine cell concentration and cell viability. To obtain a highly purified monocyte population, the mononuclear fraction was further purified using CD14 microbeads (Miltenyi). 1×109 cells were resuspended in 8 mL of buffer containing PBS, 0.5% BSA, and 2 mM EDTA (Miltenyi buffer). 2 mL of CD14 microbeads were added to each 50 mL tube containing the 1×109 cells and incubated at 4° C. for 15 minutes. The cells were washed in 100 mL of the same buffer, centrifuged at 300×g and resuspended in 20 mL of Miltenyi buffer. The cell suspension was applied to four LS columns situated under magnetic field (Miltenyi Quadromax™). Following application of the cells using gravity flow, the columns were washed three times with 3 mL of Miltenyi buffer. The monocytes were eluted twice in the absence of a magnetic field with 5 mL of Miltenyi buffer and centrifuged at 300×g for 10 minutes. Purity of both the eluate and flow through fractions were determined with flow cytometry using antibodies specific for CD3, CD19, CD16, CD56, CD14, and CD209. The eluate fraction contained 88-98% monocytes and less than 2% small cells. The nonadherent fractions contained only a small percentage (2%) of monocytes. Total RNA was extracted from a portion of the purified monocytes (50 million) at this time.
- To prepare mature differentiated DCs, 50 million monocytes were seeded into T150 cm2 flasks in X-VIVO medium containing IL-4 and GM-CSF at 37° C. for five days. A cytokine cocktail (TIP) containing tumour necrosis factor, interferon gamma, and prostaglandin E2 was added to the cells on day five. Cells were harvested on day six of culture and at this time were termed “TIP-DCs”. The dendritic cell-rich population was harvested by gently tapping the flasks to dislodge the cells, additional phosphate buffered saline (PBS) washes and detachment of the remaining adherent cells by incubating in PBS and at 2-8° C. for approximately 10 minutes. The total cell suspension was pelleted and resuspended in PBS, and analyzed for cell concentration, cell viability and immunophenotyping. The following sets of cell markers were examined by flow cytometry: monocyte lineage markers (CD3, CD14, CD19, CD16, and CD56), indication of presence of dendritic cells (CD11c, CD1a, and CD209), an antigen presenting cell marker (HLA-II), markers of migration (CD38 and CCR7) and markers for mature dendritic cells (CD83 and CD86).
- 20 million TIP-DCs were resuspended in 600 μl of ViaSpan™ and electroporated with CD40L RNA at a ratio of 4 μg of RNA per one million dendritic cells. Electroporation was performed in 4 mm gap cuvettes, at a pulse of 300V for 300 μs. After electroporation, cells were transferred into T75 flasks (one cuvette per flask) containing X-VIVO medium (serum free culture medium), supplemented with IL-4 and GM-CSF. Transfected cells were incubated at for 4 hours at 37° C., 5% CO2, ≧75% humidity to allow the cells to recover from electroporation. After this cells were further matured and termed “PME-CD40L DCs”. RNA was isolated from a portion of the PME-CD40L DCs generated.
- PME-CD40L DCs were frozen in 90% autologous plasma with 10% DMSO, in cryovials using controlled-rate freezing, and stored at ≦−85° C. A frozen dendritic cell vaccine prepared as described above was thawed at 37° C., and kept at 20-25° C. for 30 minutes. Viability was determined immediately post-thaw and at 10 minute intervals up to 30 minutes. Post Thaw PME-CD40L DCs were analyzed by flow cytometry using antibodies specific for monocyte lineage markers (CD14), dendritic cell markers (CD11c, CD1a, and CD209), an antigen presenting cell marker (HLA-II), markers of migration (CD38 and CCR7) and markers for mature dendritic cells (CD80, CD83 and CD86).
- The data from the three donors demonstrates that positive selection using CD14 bead results in 88-98% pure population of monocytes (Table 7). The maximum amount of small cell contamination is 2% (Table 7). The nonadherent (flow through) fraction contained up to 2% of monocytes (large cells) in all three donors (data not shown). Therefore, there is no significant loss of monocytes in the nonadherent fraction. The small cell population contamination present in the eluate is composed primarily of T cells as evident from high CD3 expression and lower CD19, 16 or 56 markers expression (data not shown). There were no visible differences in expression of CD83, CD86, CD11C, HLA-I, or HLA-II markers in the eluate fraction between fresh and day old leukapheresis.
-
TABLE 7 Monocyte Summary % Large % Small Donor Monocytes Fraction cells cells % CD14 + 1 Fresh Eluate 97-98 <1-1.5 99 1 Day old Eluate 88-89 0.8-1.5 99 2 Fresh Eluate 98-99 0.9-1.4 99 2 Day old Eluate 94-98 1-2 98 3 Fresh Eluate 97-98 <1 99 3 Day old Eluate 89-90 <1 97 - Monocytes were very pure initially (90%), and the purity was further improved during the differentiation process as the percentage of large cells in the TIP-DCs from all three donors was 98-99% and, thus, the percentage of small cells was less than 2% (data not shown). Analysis of the phenotype of TIP-DCs with flow cytometry revealed there was a difference in the expression of CD83 between TIP-DCs generated from fresh and day old leukapheresis. The percentage of positive cells refers to the number of cells positive for a marker under investigation. The percentage of DCs expressing the surface maturation marker CD83 was lower in TIP-DCs from all 3 donors prepared from fresh leukapheresis than those prepared from day old leukapheresis (Table 8). There were no other differences in any other markers from the TIP-DCs generated from fresh and day old leukapheresis.
-
TABLE 8 TIP-DC summary Donor Leukapheresis % CD83+ % CD86+ 1 Fresh 26 90 Day old 59 81 2 Fresh 40 74 Day old 51 85 3 Fresh 57 98 Day old 87 98 - The DCs post-transfection (PME-CD40L DCs) were analyzed for expression of CD154 (CD40L) four hours after transfection. PME-CD40L DCs from day old leukapheresis expressed more CD40L in
donors - PME-CD40L DCs were analyzed for expression of a variety of DC markers after thawing. There were differences in the phenotype of the post thaw PME-CD40L DCs generated from fresh versus day old leukapheresis. The mean fluorescence intensity of CD40L expression in PME-CD40L DCs prepared from fresh leukapheresis was lower than DCs prepared from day old Leukapheresis (Table 9).
- There was also a trend suggesting that, in two donors the transfection efficiency (of percent positive of CD40L expression) is lower in DCs generated from fresh leukapheresis (Table 9).
-
TABLE 9 Summary of CD154 Expression in PME-CD40L DC Donor Leukapheresis PME-CD40L DC % CD154+ CD154 MFI 1 Fresh 4 hrs post 35 26 electroporation Day Old 4 hrs post 63 51 electroporation 2 Fresh 4 hrs post 40 41 electroporation Day Old 4 hrs post 50 60 electroporation 3 Fresh 4 hrs post 58 61 electroporation Day Old 4 hrs post 52 35 electroporation 1 Fresh Post Thaw 21 31 Day Old Post Thaw 38 50 2 Fresh Post-Thaw 16 39 Day Old Post-Thaw 30 44 3 Fresh Post-Thaw 60 56 Day Old Post-Thaw 56 64 - Percent positive cells measured by flow cytometry revealed that, in two out of three cases, more cells are stained positive with CD83 antibodies in dendritic cells generated from the day old portion of the leukapheresis (Table 10).
-
TABLE 10 Phenotype of Post Thaw PME-CD40L DC Donor Leukapheresis % CD83+ % CD86+ % CD80+ 1 Fresh 50 97 95 Day old 86 99 99 2 Fresh 57 97 98 Day old 71 99 94 3 Fresh 90 98 97 Day old 89 99 97 - While the difference in percent positive cells for CD80, CD83, and CD86 is not always higher in the DC generated from day old leukapheresis (
Donor 3, Table 10), the mean fluorescent intensity of cells generated from day old leukapheresis stained with specific antibodies is higher in all donors (Table 11). In addition to CD80, CD86, and CD83, HLA-I and HLA-II exhibited the same result (Table 11). The mean fluorescent intensity signal correlates with a higher protein level expression per cell and expression of CD80, CD83, CD86, HLA-I and HLA-II molecules is upregulated in a mature DC. Therefore the phenotype of these cells reflects a more mature status of dendritic cells obtained from day old portion in all three donors. These changes reflect the maturation status of the DC. Taken together data obtained with measure of percent positive cells as well as mean fluorescent intensity allows us to conclude that cells generated from day old portion of a leukapheresis exhibit a more mature phenotype. -
TABLE 11 MFI of Post Thaw PME-CD40L DCs CD83 CD86 CD80 HLA-I HLA-II Donor Leukapheresis MFI MFI MFI MFI MFI 1 Fresh 55 97 48 330 145 Day old 73 282 71 904 338 2 Fresh 43 66 47 249 115 Day old 55 123 55 383 214 3 Fresh 27 104 38 630 175 Day old 53 219 57 974 182 - The RNA samples from fresh monocytes and day old monocytes (monocytes which had been incubated at 16-20° C. for 24 hours following leukapheresis), and RNA from DCs prepared from fresh and day old monocytes, as described in Example 8, were applied to the Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, Calif.) according to the manufacture's instruction (Genechip® Expression Analysis Technical Manual, 2004). Briefly, three micrograms of total RNA spiked with Genechip® Poly-A RNA Control Kit (Affymetrix, Santa Clara, Calif.) was converted to first-strand cDNA using SuperScript™ II reverse transcriptase. Second-strand cDNA synthesis was followed by in vitro transcription for linear amplification of each transcript and incorporation of biotinylated CTP and UTP. The cRNA products were fragmented to around 100 nucleotides, and hybridized for 16 hours to the microarrays. The microarrays were then washed at low (6× SSPE) and high (100 mM MES, 0.1M NaCl) stringency and stained with streptavidin-phycoerythrin.
- Fluorescence was amplified by adding biotinylated anti-streptavidin and an additional aliquot of streptavidin-phycoerythrin stain. The GeneChip® Scanner 3000 (Affymetrix, Santa Clara, Calif.) was used to collect fluorescence signal at 3 um resolution after excitation at 570 nm. The average signal from two sequential scans was calculated for each microarray feature. Scanned images were analyzed with Genechip® Operating Software v1.1 (Affymetrix, Santa Clara, Calif.). High linear correlation (R2>0.95) of 4 control RNAs included in Poly-A RNA Control Kit (Affymetrix, Santa Clara, Calif.) was confirmed to guarantee the success of the labeling process.
- All profile data were imported into the computer program Genespring and was normalized according to sample type (ie monocyte samples to monocyte and dendritic samples to dendritic). Three steps were performed in the normalization step and were according to the standard method suggested by Genespring for Affymetrix arrays.
- 4) data transformation (all values less than 0.01 were set to 0.01)
- 5) Normalization to the 50th percentile.
- 6) Normalization to the median.
- The data was first filtered for flags with missing spots. The data was then analyzed with a one way anova without random prediction models with a confidence level ranging from p.05 or p.1. The list of filtered genes generated was then analyzed for either fold changes, level of expression, or confidence. This was performed using the samples as averages or as individual samples. Level of expression between fresh and day monocytes or dendritic cells were compared prior to or after an anova. The lists of genes were compared to one another and those overlapping in several lists were chosen for their reliability. Genes with altered steady state RNA levels in dendritic cells prepared from day old monocytes versus dendritic cell prepared from fresh monocytes are listed in Table 12A. Descriptions of these genes are listed in Table 12B. Genes with altered steady state RNA levels in day old monocytes versus fresh monocytes are listed in Table 13A. Descriptions of these genes are listed in Table 13B. These results demonstrate that fresh monocytes are phenotypically different from day old monocytes, and that dendritic cells prepared from fresh monocytes are phenotypically different from dendritic cells prepared from day old monocytes.
-
TABLE 12A Genes with Altered Steady State RNA Levels in Dendritic Cells prepared from Day Old Monocytes as compared to Dendritic Cells Prepared from Fresh Monocytes Gene Affymetrix Change in Symbol Identifier NCBI Unigene Fold P value Day Old ALOX15 207328_at NM_001140 Hs.73809 5.8 0.0699 Decrease 1558517_s_at AK094804 Hs.24181 5.5 0.0957 Decrease KRT17; 212236_x_at NM_000422 Hs.2785 5 0.0759 Decrease PC; K17; PC2; PCHC1 KCNJ2 231513_at, NM_000891 Hs.1547 4.5 0.0507 Decrease 206765_at YWHAZ 214848_at NM_003406, Hs.492407 4.3 0.0581 Decrease NM_145690 IL1B 205067_at, NM_000576 Hs.126256 3.7 0.0752 Decrease 39402_at PTX3 206157_at NM_002852 Hs.127657 3.5 0.0408 Decrease FYN 216033_s_at, NM_002037, Hs.390567 3.5 0.0724 Decrease 210105_s_at NM_153047, NM_153048 GALNT3 203397_s_at NM_004482 Hs.170986 3.3 0.0295 Decrease FLJ20073 219691_at NM_017654 Hs.65641 3 0.0262 Decrease CDK6 243808_at NM_001259 Hs.119882 3 0.00634 Decrease CD69 209795_at NM_001781 Hs.208854 2.6 0.0145 Decrease TLR1 210176_at NM_003263 Hs.111805 2.193 0.456 Decrease TLR2 204924_at NM_003264 Hs.519033 2 0.089 Decrease ENO3 204483_at NM_001976 Hs.224171 6 0.0588 Increase NM_053013 CD52 34210_at NM_001803 Hs.276770 5 0.0925 Increase TRPS1 234351_x_at NM_014112 Hs.253594 4 0.067 Increase FLJ21069 226425_at NM_024692 Hs.122927 3.7 0.0806 Increase (RSNL2) TNS 218864_at NM_022648 Hs.471381 3.5 0.019 Increase CPEB1 219578_s_at NM_030594 Hs.459132 3.2 0.0779 Increase RAB9P40 203150_at NM_005833 Hs.19012 3 0.0357 Increase PIR 207469_s_at NM Hs.495728 3 0.0559 Increase 001018109 NM_003662 CALM2 235190_at NM_001743 Hs.468442 3 0.0913 Increase ABCG2 209735_at NM_004827 Hs.480218 3 0.0985 Increase A2M 217757_at NM_000014 Hs.212838 3 0.0384 Increase 232750_at Hs.550958 3 0.0207 Increase APEX2 204408_at NM_014481 Hs.555936 4.3038 0.027 Increase THBD 203888_at NM_000361 Hs.2030 6.5432 0.122 Decrease DNASE1L3 205554_s_at NM_004944 Hs.476453 3.9148 0.108 Decrease PKIB 223551_at NM_032471 Hs.486354 3.6986 0.130 Decrease PTGER3 210375_at NM_000957 Hs.445000 28.2 0.0979 Decrease CAMTA1 213268_at NM_015215 Hs.397705 6.4 0.0897 Decrease PLS3 201215_at NM_005032 Hs.496622 6.4 0.0436 Decrease TREM1 219434_at NM_018643 Hs.283022 5.2 0.031 Decrease TMEPAI 217875_at NM_020182 Hs.517155 5.5 0.0784 Decrease CHI3L1 209396_at NM_001276 Hs.382202 6.5 0.0367 Increase -
TABLE 12B Description of Genes Listed in Table 12A Gene Symbol Go Description ALOX15 Arachidonate 15-lipoxygenase Electron transport, lipid metabolism, inflammatory response, leukotriene biosynthesis, leukotriene metabolism CDNA FLJ37485 fis Clone BRAWH2014379 KRT17; PC; Keratin 17 Epidermis development K17; PC2; PCHC1 KCNJ2 Potassium inwardly-rectifying Ion transport channel, subfamily J, member 2 YWHAZ Tyrosine 3- Protein domain specific binding monooxygenase/tryptophan 5- monooxygenase activation protein, zeta polypeptide IL1B Interlukin 1, beta immune response, inflammatory response PTX3 Pentraxin-related gene, rapidly Inflammatory response induced by IL-1 beta FYN FYN oncogene related to SRC, Protein amino acid phosphorylation, FGR, YES protein amino acid phosphorylation intracellular signaling cascade protein kinase cascade protein amino acid phosphorylation calcium ion transport GALNT3 UDP-N-acetyl-alpha-D- Carbohydrate metabolism galactosamine-polypeptide N- acetylgalactosaminyltransferase 3 (GalNAc-T3) FLJ20073 Sterile alpha motif domain Binding containing 9 CDK6 Cyclin-dependent kinase 6 Regulation of progression through cell cycle G1 phase of mitotic cell cycle protein amino acid phosphorylation cell proliferation CD69 CD69 antigen (p60, early T-cell Defense response, cell surface receptor activation antigen) linked signal transduction TRL1 Toll-like receptor 1 inflammatory response, immune response TRL2 Toll-like receptor 2 Induction of apoptosis, inflammatory response, signal transduction, immune response ENO3 Enolase 3 (beta, muscle) Glycolysis CD52 CD52 antigen (CAMPATH-1 integral to plasma membrane antigen) TRPS1 Trichorhinophalangeal Skeletal development transcription syndrome 1 regulation of transcription, DNA- dependent transcription from RNA polymerase II promoter NLS-bearing substrate import into nucleus FLJ21069, Restin-line 2 RSNL2 TNS Tensin1 Intracellular signaling cascade CPEB1 Cytoplasmic polyadenylation mRNA processing element binding protein 1 RAB9P40 Rab9 effector protein with Receptor mediated endocytosis, vesicle kelch motifs docking during exocytosis PIR Pirin (iron-binding nuclear Transcription cofactor activity iron ion protein) binding metal ion binding CALM2 Calmodulin 2 (phosphorylase G-protein coupled receptor protein kinase, delta) signaling pathway ABCG2 ATP-binding cassett, sub- Transport response to drug transport family G (WHITE), member 2 A2M Alpha-2 macroglobulin Intracellular protein transport protein homooligomerization CDNA FLJ13750 fis, clone PLACE 3000331 APEX2 APEX nuclease DNA repair response to DNA damage (apurinic/apyrimidinic stimulus endonuclease) 2 THBD Thrombomodulin Transmembrane receptor activity, calcium ion binding, sugar binding, receptor activity, calcium ion binding receptor activity DNASE1L3 DNASE1L3 DNA catabolism, apoptosis, DNA metabolism PKIB Protein kinase (cAMP- Negative regulation of protein kinase dependent, catalytic) inhibitor activity beta PTGER3 Prostaglandin E receptor 3 Transcription, DNA-dependant, signal (subtype EP3) transduction, cell death, G-protein coupled receptor protein signaling pathway CAMTA1 Calmodulin binding WNT receptor signaling pathway transcription activator 1 PLS3 Plastin 3 (T isoform) Actin binding calcium ion binding actin binding TREM1 Triggering receptor expressed Humoral immune response intracellular on myeloid cells 1 signaling cascade TMEPAI Transmembrane, prostate Integral to membrane androgen induced RNA CHI3L1 Chitinase-3-like 1 (cartilage Carbohydrate metabolism chitin glycoprotein-39) catabolism -
TABLE 13A Genes with Altered Steady State RNA Levels in Day Old Monocytes as compared to Fresh Monocytes Gene Affymetrix Change in Symbol Identifier NCBI Unigene Fold P value Day Old ADM 202912_at NM_001124 Hs.440147 6.67 0.020 Increase Est 230127_at AW044663 Hs.232417 5.29 0.017 Increase PPARD 242218_at NM_006238 Hs.485196 5.29 0.040 Increase CIAS1 216016_at NM_004895, NM_183395 Hs.159483 4.60 0.030 Increase SLC6A6 211030_s_at NM_003043 Hs.529488 3.30 0.020 Increase Est 243423_at AF150368 Hs.205098 3.40 0.015 Increase WTAP 1560274_at NM_004906, NM_152857, Hs.446091 3.30 0.008 Increase NM_152858 1556072_at AK097861 Hs.517397 3.90 0.010 Increase APAF1 204859_s_at NM_013229 Hs.552567 3.00 0.020 Decrease CCR2 206978_at NM_000647, NM_000648 Hs.511794 4.05 0.004 Decrease SLC35A5 218519_at NM_017945 Hs.237480 4.12 0.030 Decrease RPE 225039_at NM_006916, Hs.282260 4.12 0.040 Decrease NM_199229 TRPS1 222651_s_at NM_014112 Hs.253594 4.17 0.020 Decrease OXR1 222553_x_at NM_181354 Hs.148778 4.22 0.006 Decrease TRIM14 203148_s_at NM_014788 Hs.555909 4.22 0.040 Decrease NM_033219 NM_033220 NM_033221 MRF2 212614_at NM_032199 Hs.535297 4.22 0.040 Decrease TNFSF10 214329_x_at NM_003810 Hs.478275 4.37 0.040 Decrease DKFZp434L142 219872_at NM_001031700 Hs.535739 4.42 0.030 Decrease NM_016613 LOC115294 232382_s_at NM_052937 Hs.308480 4.15 0.030 Decrease (PCMTD1) LOC201895 227052_at NM_174921 Hs.205952 4.88 0.040 Decrease PAG1 227354_at NM_018440 Hs.266175 5.03 0.046 Decrease DMXL1 203791_at NM_005509 Hs.181042 5.46 0.002 Decrease CX3CR1 205898_at NM_001337 Hs.78913 10.88 0.030 Decrease -
TABLE 13B Description of Genes Listed in Table 13A Gene Symbol Go description ADM Adrenomedullin cAMP biosynthesis, progesterone biosynthesis, Signal transuction, cell-cell signaling, pregnancy, excretion Est Transcribed locus PPARD Peroxisome proliferative Transcription regulator activated receptor, delta CIAS1 Cold autoinflammatory Apoptosis, induction of apoptosis, inflammatory syndrome 1 response, signal transduction SLC6A6 Solute carrier family 6 Amino acid metabolism, integral to plasma member 6 membrane Est Transcribed locus WTAP Wilms tumor 1 associated protein Hypothetical protein APAF1 apoptotic peptidase activating regulation of apoptosis factor CCR2 Chemokine (C-C motif) Chemotaxis, inflammatory response, cellular defense receptor 2 response, signal transduction SLC35A5 Solute carrier family 35, Carbohydrate transport, nucleotide-sugar transport member A5 RPE Ribulose-5-phosphate-3- Carbohydrate metabolism epimerase TRPS1 Trichorhinophalangeal Transcription factor activity syndrome I OXR1 Oxidation resistance 1 Response to oxidative stress TRIM14 Tripartite motif-containing 14 Compartment specification MRF2 AT rich interactive domain SB Transcription, negative regulation of transcription, (MRF1-like) DNA-dependent, regulation of transcription, DNA- dependent TNFSF10 Tumor necrosis factor (ligand) Apoptosis, induction of apoptosis, inflammatory superfamily, member 10 response, signal transduction, cell-cell signaling DKFZp434L142 Hypothetical protein DKFZp434L142 LOC115294 Protein-L-isoaspartate (D- Protein modification (PCMTD1) aspartate) O-methyltransferase domain containing 1 LOC201895 Hypothetical protein Protein binding LOC201895 PAG1 Phosphoprotein associated Negative regulation of T cell activation, intracellular with glycosphingolipid signaling cascade, regulation of T cell activation microdomains 1 DMXL1 Protein binding CX3CR1 Chemokine (C-X3-C motif) Chemotaxis, cellular defense response, cell adhesion, receptor 1 signal transduction - The dendritic cell genes were further normalized to expression of two housekeeping genes shown to remain constant between DCs produced from fresh and day old monocytes. The average expression of each gene (normalized) was divided by the average expression (normalized) of GAPDH (glyceraldehyde-3-phosphate dehydrogenase) or β-actin to produce a ratio of expression relative to the housekeeping gene. The results for six genes are shown in Table 14. “DCdo” refers to DCs prepared from day old monocytes. “DCf” refers to DCs prepared from fresh monocytes.
-
TABLE 14 Steady State RNA Expression Ratios of Certain RNAs to GAPDH or β-Actin in DCs prepared from Day Old or Fresh Monocytes Gene: GAPDH Gene: GAPDH Gene: Actin Gene: Actin Gene DCdo DCf DCdo DCf ALOX15 0.45 1.5 0.45 1.52 IL1β 0.58 1.38 0.57 1.37 TLR1 0.68 1.49 0.68 1.48 TLR2 0.67 1.34 0.66 1.33 CD69 0.66 1.61 0.65 1.60 CD52 1.86 0.74 1.85 0.74 - Additional verification, to date, of differential expression in monocytes of two of the candidate genes was performed by Quantitative Real-Time PCR (QPCR) using the primers shown in Table 15. First strand cDNA was generated from each total RNA (identical to that used in the GeneChip analysis) using oligo(dT) primers and SuperScript™ III First-Strand Synthesis System for RT-PCR according to the manufacturer's instructions (Invitrogen, Carlsbad, Calif.). QPCR was performed using an ABI Prism® 7900HT Sequence Detection System (Applied Biosystems, Foster City, Calif.) according to the manufacturer's instruction (ABI Prism® 7900HT Sequence Detection System User Guide). TaqMan® Gene Expression Assays or Custom TaqMan® Gene Expression Assays (Applied Biosystems, Foster City, Calif.) were used as TaqMan® probes. PCR reactions were performed in triplicate using ABsolute™ QPCR ROX Mix (ABgene, Surrey, UK). Quantitation of relative cDNA concentrations was done using the relative standard curve method as described in ABI Prism® 7700 Sequence Detection System User Bulletin #2 (Applied Biosystems, Foster City, Calif.). One cDNA with the most expression of each gene in the GeneChip analysis was used for generating the relative standard curve. All data are shown as expression relative to internal GAPDH expression. APAF-1 and
CDCA2 effector protein 2 were demonstrated to decrease, relative to GAPDH, at least 2.5 fold and 3 fold, respectively between fresh and day old monocytes. -
TABLE 15 Primers Gene TaqMan ® Gene Expression Assays ID GAPDH Hs99999905_m1 CDC42 effector protein 2Hs00198943_m1 APAF1 Hs00185508_m1 - ‘Healthy donor’ leukapheresis products from two donors were received after overnight shipping. Approximately one third of each product was processed for DC generation at the specified times post apheresis collection as follows. The leukopheresis product (i.e., PBMCs) was incubated at room temperature for 23, 48 or 71 hours prior to ficoll-histopaque density gradient centrifugation and the adherence step described below. After the room temperature incubation period, the viability of the PBMCs and the percentages of B cells, T cells, monocytes and NK cells were determined. The results are shown in Table 16.
-
TABLE 16 Characterization of cellular product on Day 0 ofculture Donor 1 Donor 223 hrs 48 hrs 71 hrs 23 hrs 48 hrs 71 hrs PBMC viability 97 99 97 98 99 97 (%) % B- cells 4 3.8 4.4 5.15 4.55 5.45 % T-cells 38.9 35.5 27.4 49.3 42.7 46.4 % Monocytes 41.9 37.7 41.2 29.5 24.4 28.7 % NK-cells 6.4 11.3 10.9 4.7 2.54 5.7 - PBMCs were prepared by ficoll-histopaque density centrifugation, and washed four times in PBS at room temperature. 2×108 PBMCs were re-suspended in 30 ml AIM-V medium (Invitrogen) and allowed to adhere to 150 cm3 plastic flasks for 2 hours at 37° C. Non-adherent cells were removed and remaining cells cultured in X-VIVO 15 medium, supplemented with 1000 U/ml GM-CSF (Leukine) and 1000 U/ml IL-4 (R&D systems), for 5 days at 37° C., 5% CO2. Immature DCs were initially matured by addition of TNF-α (10 ng/ml), IFN-γ (1000 U/ml) and PGE2 (1 μg/ml). After overnight culture, the TIP-DC intermediate products were harvested by removal of media, and a cold PBS wash. TIP-DC were phenotyped to confirm the generation of a mature population of cells. To generate antigen-loaded, fully mature DC, the TIP-DC were electroporated: Cells were re-suspended in chilled Viaspan at 4×107/ml in 0.5 ml and placed on ice. DCs were mixed with amplified total tumor renal cell carcinoma mRNA at 1 μg/106 cells, as a model antigen-encoding payload, plus 4 μg/106 CD40L mRNA, and placed in a 4 mm gap electroporation cuvette, followed by electroporation using a Biorad GenePulsar Xcell system. Immediately after electroporation, DCs were washed in X-VIVO 15 medium and finally re-suspended in 20 ml of X-VIVO 15 supplemented with GM-CSF (800 U/ml) and IL-4 (500 U/ml) at 1×106/ml, and cultured for 4 hours at 37° C. in low adherence T75 flasks. Cell counts and viability determinations were made using propidium iodide and CalTag counting beads as described by the manufacturer. Post-ficoll PBMC samples,
day 6 TIP-DC, DCs recovered 4 hrs after electroporation and culture (PME-CD40L DC), and post thaw of the final product, were all subjected to cell count and viability analysis. The results are shown in Table 17. -
TABLE 17 Recovery and Yield of DC during the generation of PME-CD40L DC Percent of input 4 hr post Freeze/thaw % No. of seeded PBMC recovered electroporation % Recovery/viability PBMCs/ flask Day 6/viability Recovery/viability of final product Donor 1 23 hrs 2 × 108 27%/96% viable 60%/93% viable 78%/86% viable 48 hrs 2 × 108 17%/98% viable 58%/95% viable 85%/94% viable 72 hrs 2 × 108 9%/97% viable 50%/96% viable 71%/93% viable Donor 2 19 hrs 2 × 108 6.6%/95% viable 68%/95% viable 68.9%/91% viable 41 hrs 2 × 108 12%/96% viable 62%/93% viable 78.5%/89% viable 66 hrs 2 × 108 3.1%/97% viable 41%/91% viable 86.3%/90% viable - All antibodies were sourced from BD Biosciences and used at dilutions recommended by the manufacturer. PBMCs: 3×105 cells were each stained with CD19-PE, CD14-PE and CD3-PE, or matched isotype conjugated controls by incubation in antibody for 30 minutes at 4 C. After incubation, the stained cells were washed 3 times in cold 1% FBS/PBS and resuspended in PBS for fluorescence analysis using a FACScalibur flow cytometer (BD Biosciences) using CellQuest software (BD Biosciences). 3 minutes prior to acquisition, propidium iodide (1 ug/ml) was added to each sample as a viability dye for gating purposes. DCs: 1×106 cells (TIP-DC and PME-CD40L DC) were re-suspended in chilled PBS/1% FBS. PE or FITC conjugated antibodies specific for MHC molecules (HLA-ABC, HLA-DR), or co-stimulatory molecules (CD80, CD86), or maturation markers (CD83) or monocyte/DC lineage markers (CD14, CD209) were mixed with 1×105 DCs per and incubated at 4° C. for 30 minutes. Isotype matched antibodies were used as controls. After thorough washing cells were subjected to flow cytometry as described above. Intracellular CD40L was determined as follows: 2×105 PME-CD40L DCs re-suspended in 250 μL of Cytofix/Cytoperm solution (BD Biosciences) for a minimum of 10 minutes up to 2 hours at 4° C. Cells were washed twice with 2 ml staining buffer (PBS, BSA, NaN3, and EDTA), re-suspended in 0.5 ml staining buffer and stored over night at 4° C. Cells were re-suspended in 2.0 ml Perm/Wash solution (BD Biosciences) for 15 minutes, centrifuged and re-suspended in 100 μl Perm/Wash solution. 20 μL of mouse anti-human CD40L APC or mouse IgG1 APC was added to each DC preparation and incubated at 4° C. for 30 minutes in the dark. Cells were washed twice with 1 ml Perm/Wash solution and re-suspended in staining buffer prior to flow cytometric analysis. The results are shown in Table 18.
-
TABLE 18 Phenotype of intermediate TIP-DC and final PME-CD40L DC product Donor 1 Donor 223 hrs 48 hrs 71 hrs 23 hrs 48 hrs 71 hrs Day 6 TIP-DC (%) CD14 4.1 1.23 .62 .16 1.38 .89 CD80 96.92 97.9 98.3 99.4 99.5 87.8 CD83 84.19 88 93 92.2 88.5 62.1 CD86 99.31 99.6 98.4 99.8 99.9 99.4 HLA-I 95.65 94.6 96.1 95.6 97.4 82.6 HLA-II 99.55 99.7 98.5 99.8 99.8 96.9 Final PME- CD40L product (%) CD14 1.19 1.36 1.3 .43 .66 1.08 CD209 97.98 97.60 98.23 89.9 98.2 96.3 - It will be understood that particular embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the claims.
- All publications and patent applications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications, and in particular relevant portions thereof, are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
- All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
- Data in Table 16, from two independent experiments, show that apheresis products that are held for up to 72 hrs post collection from the patient can yield highly viable PBMC populations, without significant bias in the recovered leukocyte subsets. Seeding of flasks with PBMCs from each time point, and culture for the generation of mature DCs (TIP-DCs) results in a high frequency of viable cells, although the total recovery of DCs using apheresis products held for extended time periods does decline (Table 17). Nevertheless, sufficient DCs can be generated for further processing by electroporation with total amplified tumor RNA, and CD40L RNA. Most importantly, Tables 17 and 18 show that TIP-DCs generated from the various starting products are equally amenable to electroporation, and recovery, with full maturation into the final product, PME-CD40L DC. PME-CD40L DC generated from this study can be formulated as ‘vaccine’ and frozen and thawed without any deterioration of the DC preparations. In conclusion, apheresis products held for up to 72 hrs post collection are a viable raw material for centralized manufacturing of DC vaccines for application in the clinic.
Claims (20)
1. A method for producing dendritic cells from monocytes, comprising:
b. providing monocytes that have been incubated at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject; and
c. inducing the differentiation of said monocytes into dendritic cells.
2. The method of claim 1 , wherein the monocytes are human monocytes.
3. The method of claim 1 , wherein the incubation temperature is 6° C.-28° C.
4. The method of claim 4 , wherein the incubation temperature is 8° C.-26° C.
5. The method of claim 1 , wherein the period of incubation is 8 to 48 hours.
6. The method of claim 5 , wherein the period of incubation is 10 to 30 hours.
7. The method of claim 1 , wherein the period of incubation is 26 to 72 hours.
8. The method of claim 1 , wherein the period of incubation is 48 to 80 hours
9. The method of claim 1 , wherein the differentiation is induced by contacting the monocytes with a culture medium comprising an effective amount of a composition that induces the differentiation of monocytes into immature dendritic cells.
10. The method of claim 9 , wherein the composition is GM-CSF and IL-4; GM-CSF and IL-13; GM-CSF and IL-15; or IFNα.
11. The method of claim 1 , wherein the monocytes are present together with peripheral blood mononuclear cells (PBMCs) during all or a portion of the incubation period.
12. The method of claim 11 , wherein the PBMCs are isolated from the subject by leukapheresis.
13. The method of claim 11 , wherein the monocytes are enriched from the PBMCs during or following the incubation period.
14. The method of claim 13 , wherein the monocytes are enriched from said PBMCs by elutriation, dilute Ficoll gradient centrifugation, dilute Percoll density gradient centrifugation or magnetic bead sorting.
15. The method of claim 13 , wherein the monocytes are enriched from the PBMCs following the incubation period by allowing the monocytes to adhere to plastic.
16. The method of claim 9 , further comprising a step of maturing the immature dendritic cells into mature dendritic cells.
17. The method of claim 16 , further comprising loading one or more antigens into said mature dendritic cells.
18. The method of claim 16 , wherein the step comprises contacting the immature dendritic cells with PGE2, TNFα, IL-6 and IL-1β.
19. The method of claim 16 , wherein said step comprises signaling said immature dendritic cells with IFN-γ, followed by signaling the dendritic cells with CD40L.
20. The method of claim 19 , wherein said signaling with CD40L is effected upon translation of a recombinant CD40L mRNA within the dendritic cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/879,336 US20160102291A1 (en) | 2005-04-08 | 2015-10-09 | Dendritic Cell Compositions and Methods |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66946805P | 2005-04-08 | 2005-04-08 | |
PCT/US2006/013159 WO2006127150A2 (en) | 2005-04-08 | 2006-04-07 | Dendritic cell compositions and methods |
US91807607A | 2007-10-09 | 2007-10-09 | |
US13/351,510 US8501470B2 (en) | 2005-04-08 | 2012-01-17 | Dendritic cell compositions and methods |
US13/929,889 US20130280805A1 (en) | 2005-04-08 | 2013-06-28 | Dendritic Cell Compositions and Methods |
US14/307,991 US20150132844A1 (en) | 2005-04-08 | 2014-06-18 | Dendritic Cell Compositions and Methods |
US14/879,336 US20160102291A1 (en) | 2005-04-08 | 2015-10-09 | Dendritic Cell Compositions and Methods |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/307,991 Continuation US20150132844A1 (en) | 2005-04-08 | 2014-06-18 | Dendritic Cell Compositions and Methods |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160102291A1 true US20160102291A1 (en) | 2016-04-14 |
Family
ID=36992670
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/450,092 Expired - Fee Related USRE46152E1 (en) | 2005-04-08 | 2006-04-07 | Dendritic cell compositions and methods |
US11/918,076 Ceased US8153425B2 (en) | 2005-04-08 | 2006-04-07 | Dendritic cell compositions and methods |
US13/351,510 Active US8501470B2 (en) | 2005-04-08 | 2012-01-17 | Dendritic cell compositions and methods |
US13/929,889 Abandoned US20130280805A1 (en) | 2005-04-08 | 2013-06-28 | Dendritic Cell Compositions and Methods |
US14/307,991 Abandoned US20150132844A1 (en) | 2005-04-08 | 2014-06-18 | Dendritic Cell Compositions and Methods |
US14/879,336 Abandoned US20160102291A1 (en) | 2005-04-08 | 2015-10-09 | Dendritic Cell Compositions and Methods |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/450,092 Expired - Fee Related USRE46152E1 (en) | 2005-04-08 | 2006-04-07 | Dendritic cell compositions and methods |
US11/918,076 Ceased US8153425B2 (en) | 2005-04-08 | 2006-04-07 | Dendritic cell compositions and methods |
US13/351,510 Active US8501470B2 (en) | 2005-04-08 | 2012-01-17 | Dendritic cell compositions and methods |
US13/929,889 Abandoned US20130280805A1 (en) | 2005-04-08 | 2013-06-28 | Dendritic Cell Compositions and Methods |
US14/307,991 Abandoned US20150132844A1 (en) | 2005-04-08 | 2014-06-18 | Dendritic Cell Compositions and Methods |
Country Status (12)
Country | Link |
---|---|
US (6) | USRE46152E1 (en) |
EP (1) | EP1882031B1 (en) |
JP (1) | JP5020935B2 (en) |
KR (6) | KR20160045151A (en) |
CN (1) | CN101155914B (en) |
AU (1) | AU2006249640C1 (en) |
CA (1) | CA2602434C (en) |
ES (1) | ES2650569T3 (en) |
IL (2) | IL185977A0 (en) |
MX (1) | MX2007012221A (en) |
NO (1) | NO345353B1 (en) |
WO (1) | WO2006127150A2 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
CA2640836C (en) * | 2005-12-08 | 2018-05-15 | Dandrit Biotech A/S | Method for generating dendritic cells employing decreased temperature |
KR20170102040A (en) | 2006-04-14 | 2017-09-06 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | Hemangio-colony forming cells |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US8524495B2 (en) | 2007-05-16 | 2013-09-03 | Yale University | Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
KR100935826B1 (en) | 2007-11-27 | 2010-01-08 | 주식회사 바이넥스 | The isolation method of monocytes from peripheral blood mononuclear cells by flotation density gradient centrifugation |
WO2009108341A1 (en) | 2008-02-28 | 2009-09-03 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
CA3123228A1 (en) * | 2008-03-27 | 2009-10-01 | Asterias Biotherapeutics, Inc. | Differentiation of primate pluripotent stem cells to hematopoietic lineage cells |
JP5971945B2 (en) | 2008-04-17 | 2016-08-17 | ピーディーエス バイオテクノロジー コーポレイションPds Biotechnology Corporation | Stimulation of immune responses by enantiomers of cationic lipids |
MX2011004670A (en) * | 2008-11-04 | 2011-05-25 | Idera Pharmaceuticals Inc | Modulation of toll-like receptor 2 expression by antisense oligonucleotides. |
CA2774140A1 (en) * | 2009-09-14 | 2011-03-17 | Baylor Research Institute | Vaccines directed to langerhans cells |
CA2781969A1 (en) * | 2009-12-04 | 2011-06-09 | Stem Cell & Regenerative Medicine International, Inc. | Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts |
RU2575978C2 (en) * | 2010-03-15 | 2016-02-27 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | System and method of obtaining and storage of activated mature dendritic cells |
JP5960120B2 (en) | 2010-03-31 | 2016-08-02 | スタビリテック リミテッド | Stabilization of virus particles |
CN102892409B (en) | 2010-03-31 | 2015-12-09 | 稳定性科技有限公司 | For preserving the method for Alum adjuvant and aluminum salt-adjuvanted vaccine |
AU2011234264B2 (en) | 2010-03-31 | 2016-02-04 | Stabilitech Ltd | Excipients for stabilising viral particles, polypeptides or biological material |
US20130011438A1 (en) * | 2011-07-05 | 2013-01-10 | SOTIO a.s. | Means And Methods For Active Cellular Immunotherapy Of Cancer By Using Tumor Cells Killed By High Hydrostatic Pressure and Dendritic Cells |
GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
CN109536446B (en) * | 2012-02-10 | 2022-08-02 | 医疗法人社团博心厚生会 | Monocyte growth promoting agent, monocyte growth promoting medium, and method for producing monocyte |
JP6134785B2 (en) | 2012-05-31 | 2017-05-24 | ジェイダブリュ クレアジェン インコーポレイテッド | Dendritic cell maturation composition and method for producing antigen-specific dendritic cells using the same |
WO2014047533A1 (en) | 2012-09-21 | 2014-03-27 | Frank Bedu-Addo | Improved vaccine compositions and methods of use |
DK2951208T3 (en) * | 2013-02-01 | 2020-01-13 | Kira Biotech Pty Ltd | ANTI-CD83 ANTIBODIES AND USE THEREOF |
DK2970843T3 (en) * | 2013-03-15 | 2021-11-22 | Genzyme Corp | HIGH DENSITY CELL BANK PROCEDURES |
EP3107996B1 (en) * | 2014-02-21 | 2020-02-19 | Colmmune, Inc. | Tscm cells and methods for use |
CN103948917A (en) * | 2014-04-02 | 2014-07-30 | 江苏和泽生物科技有限公司 | Method for preparing dendritic cell vaccine |
GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
KR101518972B1 (en) | 2014-08-01 | 2015-05-18 | 제이더블유크레아젠 주식회사 | Method of Preparing Dendritic Cell, Dendritic Cell Prepared by the Same and Use Thereof |
EP3219320B1 (en) * | 2014-11-14 | 2019-05-01 | Japanese Red Cross Society | Method and solution for cryopreservation of umbilical cord blood and peripheral blood |
MX2018000052A (en) * | 2015-07-02 | 2018-05-11 | Primevax Immuno Oncology Inc | Compositions and methods for combination therapy with dengue virus and dendritic cells. |
WO2017083820A1 (en) * | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
JP6779616B2 (en) * | 2015-12-25 | 2020-11-04 | 富士ソフト株式会社 | NKT cell activating pharmaceutical composition, method for producing the same, and method for storing antigen-presenting cells. |
EP3468581A1 (en) | 2016-06-13 | 2019-04-17 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
AU2018328209A1 (en) | 2017-09-05 | 2020-04-23 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
KR20200085299A (en) | 2017-11-07 | 2020-07-14 | 코이뮨, 인크. | Methods and uses for dendritic cell therapy |
US20200330576A1 (en) * | 2018-01-08 | 2020-10-22 | The Regents Of The University Of Michigan | Aldh1 antigen-pulsed dendritic cells |
WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
JP7520806B2 (en) | 2018-07-15 | 2024-07-23 | レノヴァロ バイオファーマ インコーポレイテッド | Methods and compositions using recombinant dendritic cells for cancer treatment |
KR102159766B1 (en) * | 2018-11-12 | 2020-09-24 | 조선대학교산학협력단 | Medium Composition Containing Extract of Red Algae and the Method for Inducing of Immature Dendritic Cell |
IL286482B1 (en) * | 2019-03-21 | 2024-09-01 | Gamida Cell Ltd | Expanded nk cell fractions for transplantation in combination therapy |
CN114621921A (en) * | 2020-12-11 | 2022-06-14 | 深圳先进技术研究院 | Method for extracting neurite contact body |
CN113980901B (en) * | 2021-12-28 | 2022-06-17 | 上海惠盾因泰生物科技有限公司 | Method for preparing high-purity mature human dendritic cells and application |
WO2023245609A1 (en) * | 2022-06-24 | 2023-12-28 | Lihpao Life Science Corp. | Method for producing mature dendritic cells |
US20240216101A1 (en) * | 2023-01-04 | 2024-07-04 | Sheridan O'Neal | Carriers for Collecting Biological Samples |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
AU705647B2 (en) | 1996-07-10 | 1999-05-27 | Immunex Corporation | Method of activating dendritic cells |
US20050158856A1 (en) | 1999-04-20 | 2005-07-21 | Edelson Richard L. | Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials |
CA2368855C (en) | 1999-04-20 | 2012-05-29 | Richard Leslie Edelson | Differentiation of monocytes into functional dendritic cells |
US20050084966A1 (en) * | 1999-04-20 | 2005-04-21 | Edelson Richard L. | Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
IT1312570B1 (en) * | 1999-05-28 | 2002-04-22 | Genera Spa | METHOD FOR TRANSFER OF DENDRITIC CELL ANTIGENS. |
DE10041515A1 (en) * | 2000-08-24 | 2002-03-14 | Gerold Schuler | Process for the production of ready-to-use, antigen-loaded or unloaded, cryopreserved mature dendritic cells |
EP1270732A1 (en) | 2001-06-21 | 2003-01-02 | Schuler, Gerold | Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
FR2833271B1 (en) | 2001-12-10 | 2004-09-17 | Coletica | PRODUCTION OF IN VITRO DENDRITIC CELLS FROM CD14 + MONOCYTES, IN PARTICULAR FOR THE PRODUCTION OF CELLULAR AND / OR TISSUE MODELS IN SUSPENSION, IN MONOLAYERS AND THREE-DIMENSIONAL; USE OF THESE MODELS |
EP3173141B1 (en) | 2002-06-19 | 2019-09-04 | NorthWest Biotherapeutics, Inc. | Tangential flow filtration device and methods for leukocyte enrichment |
EP1389480A1 (en) * | 2002-08-14 | 2004-02-18 | Mondobiotech Interferon SA | Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation |
US20060239962A1 (en) | 2002-12-04 | 2006-10-26 | Banchereau Jacques F | Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors |
CN1264974C (en) * | 2003-01-17 | 2006-07-19 | 江西医学院 | Culture media for leukemia cell inducel production of dendrite cell and its culturing method and application |
MXPA05009178A (en) | 2003-02-27 | 2006-03-08 | Northwest Biotherapeutics Inc | Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines. |
KR101450497B1 (en) | 2004-09-14 | 2014-10-13 | 아고스 쎄라퓨틱스, 인코포레이티드 | Strain independent amplification of pathogens and vaccines thereto |
US8513008B2 (en) * | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
JP5269412B2 (en) * | 2004-10-07 | 2013-08-21 | アルゴス セラピューティクス,インコーポレイティド | Mature dendritic cell composition and culture method thereof |
-
2006
- 2006-04-07 KR KR1020167009557A patent/KR20160045151A/en active Search and Examination
- 2006-04-07 EP EP06749566.3A patent/EP1882031B1/en active Active
- 2006-04-07 KR KR1020137010879A patent/KR20130061753A/en not_active Application Discontinuation
- 2006-04-07 KR KR1020177020072A patent/KR20170086700A/en active Search and Examination
- 2006-04-07 AU AU2006249640A patent/AU2006249640C1/en active Active
- 2006-04-07 WO PCT/US2006/013159 patent/WO2006127150A2/en active Application Filing
- 2006-04-07 KR KR1020207016974A patent/KR20200072566A/en not_active Application Discontinuation
- 2006-04-07 KR KR20157005703A patent/KR20150032915A/en not_active Application Discontinuation
- 2006-04-07 KR KR1020077025609A patent/KR101368035B1/en active IP Right Grant
- 2006-04-07 ES ES06749566.3T patent/ES2650569T3/en active Active
- 2006-04-07 MX MX2007012221A patent/MX2007012221A/en active IP Right Grant
- 2006-04-07 CN CN2006800113802A patent/CN101155914B/en active Active
- 2006-04-07 CA CA2602434A patent/CA2602434C/en active Active
- 2006-04-07 US US14/450,092 patent/USRE46152E1/en not_active Expired - Fee Related
- 2006-04-07 JP JP2008505602A patent/JP5020935B2/en active Active
- 2006-04-07 US US11/918,076 patent/US8153425B2/en not_active Ceased
-
2007
- 2007-09-17 IL IL185977A patent/IL185977A0/en unknown
- 2007-10-10 NO NO20075166A patent/NO345353B1/en unknown
-
2012
- 2012-01-17 US US13/351,510 patent/US8501470B2/en active Active
-
2013
- 2013-06-28 US US13/929,889 patent/US20130280805A1/en not_active Abandoned
-
2014
- 2014-04-03 IL IL231889A patent/IL231889A/en active IP Right Grant
- 2014-06-18 US US14/307,991 patent/US20150132844A1/en not_active Abandoned
-
2015
- 2015-10-09 US US14/879,336 patent/US20160102291A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8501470B2 (en) | Dendritic cell compositions and methods | |
US11248209B2 (en) | Mature dendritic cell compositions and methods for culturing same | |
Thurner et al. | Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application | |
JP4610847B2 (en) | Preparation of ready-to-use, antigen-loaded or unloaded cryopreserved mature dendritic cells | |
US20120244620A1 (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells | |
WO2008055354A1 (en) | Rna-loaded dendritic cell compositions for eliciting cd4+ t cell help and related methods | |
WO2009149539A1 (en) | Enhancing antigen-specific cd8+ t cell response using irf-7 mrna | |
US20040197903A1 (en) | Method for induction of proliferation of natural killer cells by dendritic cells cultured with GM-CSF and IL-15 | |
Sato et al. | Generation of dendritic cells from fresh and frozen cord blood CD34+ cells | |
Enomoto et al. | In vitro generation of dendritic cells derived from cryopreserved CD34+ cells mobilized into peripheral blood in lymphoma patients | |
Morse et al. | Isolation and Culture of Dendritic Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: COIMMUNE, INC., NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ARGOS THERAPEUTICS, INC.;REEL/FRAME:048645/0673 Effective date: 20190122 |